Unnamed: 0 int64 0 2.34M | titles stringlengths 5 21.5M | abst stringlengths 1 21.5M |
|---|---|---|
2,329,200 | Pericytes in the infarcted heart. | The adult mammalian heart lacks regenerative capacity and heals through activation of an inflammatory cascade that leads to the formation of a collagen-based scar. Although scar formation is important to preserve the structural integrity of the ventricle, unrestrained inflammation and excessive fibrosis have been implicated in the pathogenesis of adverse post-infarction remodeling and heart failure. Interstitial cells play a crucial role in the regulation of cardiac repair. Although recent studies have explored the role of fibroblasts and immune cells, the cardiac pericytes have been largely ignored by investigators interested in myocardial biology. This review manuscript discusses the role of pericytes in the regulation of inflammation, fibrosis and angiogenesis following myocardial infarction. During the inflammatory phase of infarct healing, pericytes may regulate microvascular permeability and may play an important role in leukocyte trafficking. Moreover, pericyte activation through Toll-like receptor-mediated pathways may stimulate cytokine and chemokine synthesis. During the proliferative phase, pericytes may be involved in angiogenesis and fibrosis. To what extent pericyte to fibroblast conversion and pericyte-mediated growth factor synthesis contribute to the myocardial fibrotic response remains unknown. During the maturation phase of infarct healing, coating of infarct neovessels with pericytes plays an important role in scar stabilization. Implementation of therapeutic approaches targeting pericytes in the infarcted and remodeling heart remains challenging, due to the lack of systematic characterization of myocardial pericytes, their phenotypic heterogeneity and the limited knowledge on their functional role. |
2,329,201 | Detectability of the choroid plexus of the third ventricle with magnetic resonance ventriculography. | To clarify the detectability of the choroid plexus of the third ventricle (ChPl3V) with magnetic resonance ventriculography (MRVn) employing a steady-state free precession (SSFP) sequence in comparison to surgical endoscopic movies as a golden standard, as we encountered some clinical cases of total agenesis of corpus callosum (ACC) where we could not recognize the choroid plexus of the third ventricle and found no previous article addressing this problem.</AbstractText>This retrospective study included consecutive patients from 2010 to 2016 for whom endoscopic evaluation of the third ventricle was conducted. The anterior portion of the right and left streaks of ChPl3V was evaluated in 8 patients on 16 sites, while the posterior portion of both streaks of ChPl3V was evaluated in 13 patients on 26 sites. Sensitivity of MRVn to visualize ChPl3V with endoscopic movies as the golden standard was calculated.</AbstractText>Sensitivity of MRVn in visualizing the anterior portion of ChPl3V was 0.813, and that for the posterior portion 0.692. The anterior portion of ChPl3V was visualized in all cases where no tumor contacted the foramen of Monro.</AbstractText>MRVn visualizes the anterior portion of ChPl3V with significant sensitivity and the posterior portion with lower one.</AbstractText> |
2,329,202 | Iodine Dose of Administered Contrast Media Affects the Level of Radiation-Induced DNA Damage During Cardiac CT Scans. | <b>OBJECTIVE.</b> The purpose of this study is to investigate the contributing effect of contrast media (CM) iodine dose on radiation-induced DNA damage in blood lymphocytes during a cardiac CT scan. <b>MATERIALS AND METHODS.</b> The minipigs were exposed 12 times in total to a fixed cardiac CT scan protocol. An unenhanced and two CM injection protocols were considered, the latter with 50% saline diluted (160 mg I/mL) and standard iodixanol. Blood samples were collected before and after CT, and radiation-induced DNA double-strand breaks were assessed using γ-H2AX (H2A histone family member X) immunofluorescent staining of the blood lymphocytes. Significant differences in foci numbers were investigated with an independent sample <i>t</i> test. In addition, a numeric dosimetry model was applied that simulates the cardiac CT scan, with the heart represented by a blood volume containing a mixture of six iodine concentrations (0, 10, 20, 30, 40, and 50 mg I/mL). <b>RESULTS.</b> Compared with the unenhanced (0 mg I/mL) protocol, the number of γ-H2AX foci per cell increased significantly (<i>p</i> < 0.038), by 56.1% for the reduced iodine dose (160 mg I/mL) and by 141.1% for the standard iodine dose (320 mg I/mL) protocols. These in vivo results are confirmed by the dosimetry simulation model, in which 78.8% and 133.7% increases in locally absorbed blood dose in the left ventricle were observed for the reduced and standard iodine dose protocols, respectively. <b>CONCLUSION.</b> Administration of CM during a cardiac CT examination significantly increases radiation-induced DNA damage in blood lymphocytes. Moreover, a lower CM iodine dose results in a reduced level of DNA damage, at constant radiation exposure. |
2,329,203 | Which source and level of dietary sodium is appropriate for broiler chickens reared in a high-altitude area? | This study investigated effect of increasing level of dietary sodium using sodium bicarbonate or sodium chloride on growth performance, mortality, characteristics of carcass, organs and tibia, calcium and phosphorus of serum in broilers reared in a high-altitude area (1,700 m above sea level). A total of 588 Ross 308 male broiler chicks were used in seven treatments, six replicates per treatment of 14 birds per each from 1 to 38 d of age. Seven dietary treatments consisted of a basal diet (with 0.16% sodium and 0.23% chloride), top-dressed for six diets to give three supplementary levels of sodium (0.07%, 0.14% and 0.21%) from sodium bicarbonate (respectively by 0.26%, 0.52% and 0.78%) or sodium chloride (respectively by 0.18%, 0.36% and 0.54%), resulting in seven diets with total sodium and chloride levels of 0.16% and 0.23%, 0.23% and 0.23%, 0.30% and 0.23%, 0.37% and 0.23%, 0.23% and 0.33%, 0.30% and 0.44%, 0.37% and 0.55% respectively. Increasing sodium level improved feed conversion ratio (FCR) linearly and quadratically. However, when FCR was calculated without adjusting for feed intake of mortalities, the enhanced sodium level did not improve this parameter. Increasing sodium level via sodium chloride enhanced ascites mortality, total mortality, relative weight of heart and right ventricle linearly. Increasing sodium level reduced serum calcium and enhanced serum phosphorus linearly; however, there was a linear tendency to increase tibia ash when sodium level was enhanced by sodium bicarbonate (p = 0.08) or sodium chloride (p = 0.07). Increasing sodium level via sodium bicarbonate tended (p = 0.08) to reduce tibia strength linearly. In conclusion, a diet with 0.16% sodium and 0.23% chloride is enough for broiler chicken reared in a high-altitude area, and increasing dietary sodium level via sodium chloride has detrimental effect on survivability of broiler in such condition. |
2,329,204 | Two cases of penetrating left ventricular cardiac trauma: Pre-hospital ultrasound and direct to theatre. | Left ventricular (LV) Cardiac penetrating trauma is a rare and grave injury. In cases of penetrating cardiac trauma, pre-hospital Ultrasound by flight doctors can assist identify specific pathology. This pre-hospital triage has now been linked to a change in both pre-hospital and in-hospital management. There are minimal cases reported where Pre-Hospital ultrasound provided definitive diagnosis and, while providing Pre-Hospital blood transfusion, informed a direct to theatre approach. In 2017 in New South Wales, Australia, a new protocol "Code Crimson" has been introduced to formalise a system wide process where Pre-Hospital medical teams can expedite a straight to Theatre approach. |
2,329,205 | Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. | Echocardiography is the most commonly applied technique for non-invasive assessment of cardiac function in small animals. Manual tracing of endocardial borders is time consuming and varies with operator experience. Therefore, we aimed to evaluate a novel automated two-dimensional software algorithm (Auto2DE) for small animals and compare it to the standard use of manual 2D-echocardiographic assessment (2DE). We hypothesized that novel Auto2DE will provide rapid and robust data sets, which are in agreement with manually assessed data of animals.2DE and Auto2DE were carried out using a high-resolution imaging-system for small animals. First, validation cohorts of mouse and rat cine loops were used to compare Auto2DE against 2DE. These data were stratified for image quality by a blinded expert in small animal imaging. Second, we evaluated 2DE and Auto2DE in four mouse models and four rat models with different cardiac pathologies.Automated assessment of LV function by 2DE was faster than conventional 2DE analysis and independent of operator experience levels. The accuracy of Auto2DE-assessed data in healthy mice was dependent on cine loop quality, with excellent agreement between Auto2DE and 2DE in cine loops with adequate quality. Auto2DE allowed for valid detection of impaired cardiac function in animal models with pronounced cardiac phenotypes, but yielded poor performance in diabetic animal models independent of image quality.Auto2DE represents a novel automated analysis tool for rapid assessment of LV function, which is suitable for data acquisition in studies with good and very good echocardiographic image quality, but presents systematic problems in specific pathologies. |
2,329,206 | Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. | Impaired diurnal blood pressure (BP) variability is related to higher cardiovascular risk.</AbstractText>To assess diurnal variability of BP and its relation to target organ damage (TOD) and catecholamine phenotype in a consecutive sample of pheochromocytoma/paraganglioma (PPGL).</AbstractText>We included 179 patients with PPGL All patients underwent 24 hours of ambulatory BP monitoring to determine dipping status. Differences in plasma metanephrine or urine adrenaline were used to distinguish catecholamine biochemical phenotype. To evaluate TOD, renal functions, presence of left ventricle hypertrophy (LVH), and the subgroup (n = 111) carotid-femoral pulse wave velocity (PWV) were assessed. Structural equation modeling was used to find the relationship among nocturnal dipping, catecholamine phenotype, and TOD parameters.</AbstractText>According to the nocturnal dipping, patients were divided into the three groups: dippers (28%), nondippers (40%), and reverse dippers (32%). Reverse dippers were older (P < 0.05), with a higher proportion of noradrenergic (NA) phenotype (P < 0.05), a higher prevalence of diabetes mellitus (P < 0.05), and sustained arterial hypertension (P < 0.01) and its duration (P < 0.05), as opposed to the other groups. All parameters of TOD were more pronounced only in reverse dippers compared with nondippers and dippers. The presence of NA phenotype (=absence of adrenaline production) was associated with reverse dipping and TOD (LVH and PWV).</AbstractText>Patients with reverse dipping had more substantial TOD compared with other groups. The NA phenotype plays an important role, not only in impaired diurnal BP variability but also independently from dipping status in more pronounced TOD of heart and vessels.</AbstractText>Copyright © 2019 Endocrine Society.</CopyrightInformation> |
2,329,207 | Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. | Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking.</AbstractText>To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018.</AbstractText>Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores.</AbstractText>The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures.</AbstractText>Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose-positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P < .001), A+T-N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A-T+N- (P = .009), A-T+N+ (P = .02), A+T-N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia).</AbstractText>The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.</AbstractText> |
2,329,208 | Echinococcosis in left ventricle: a case report. | Echinococcosis, also called hydatid disease, is a common parasitic infection of the liver. However, echinococcus lesions rarely involve the heart, especially in children.</AbstractText>An 8-year-old child from grazing areas of northwest China was referred to our hospital for the complaint of inpersistent precordial chest pain and left upper quadrant pain for 3 years. Palpation showed hepatomegaly, abdominal palpable mass while inspection abdominal distension. Routine blood tests were within the normal ranges.</AbstractText>Combining the life history in pasture area, imaging features and serology results, it was consistent with the diagnosis of cardiac echinococcosis.</AbstractText>Surgery was performed to evacuate cyst liquid and remove the internal capsule of the cyst.</AbstractText>There was no cystic lesion in heart on ultrasound and her physical condition improved significantly after the surgery. The patient died of hepatic hydatid cyst rupture due to refusing high-risk surgical treatment and other treatment.</AbstractText>We presented a rare case of cystic echinococcosis involving left ventricle in a child, and surgery is an alternative and effective therapy for this lesion due to the cyst rupture or leakage that can result in anaphylaxis. The typical imaging features of the cardiac echinococcosis on cardiac magnetic resonance are presented. Patient prognosis relies on proper treatment of all lesions.</AbstractText> |
2,329,209 | Neuronavigator-guided ventriculoscopic approach for symptomatic xanthogranuloma of the choroid plexus in the lateral ventricle. | Xanthogranuloma of choroid plexus is an extremely rare, benign, and mostly asymptomatic intracranial lesion. We report a case of symptomatic lateral ventricular xanthogranuloma resected via a neuronavigator-guided ventriculoscopic approach. Then we review recent English medical literature and notice that craniotomies have been the most popular treatment. But our choice of a ventriculoscopic approach possesses unique advantages such as minimized neural tissue damage, shortened operative time, less blood loss, and safer access to central structures over conventional open surgeries. Informed consent has been obtained from the patient and his immediate family regarding this case report. |
2,329,210 | Optimization of CRT programming using non-invasive electrocardiographic imaging to assess the acute electrical effects of multipoint pacing. | Quadripolar lead technology and multi-point pacing (MPP) are important clinical adjuncts in cardiac resynchronization therapy (CRT) pacing aimed at reducing the rate of non-response to therapy. Mixed results have been achieved using MPP and it is critical to identify which patients require this approach and how to configure their MPP stimulation, in order to achieve optimal electrical resynchronization.</AbstractText><AbstractText Label="METHODS & RESULTS" NlmCategory="RESULTS">We sought to investigate whether electrocardiographic imaging (ECGi), using the CARDIOINSIGHT ™</sup> inverse ECG mapping system, could identify alterations in electrical resynchronization during different methods of device optimization. In no patient did a single form of programming optimization provide the best electrical response. The effects of utilizing MPP were idiosyncratic and highly patient specific. ECGi activation maps were clearly able to discern changes in bulk LV activation during differing MPP programming. In two of the five subjects, MPP resulted in more rapid activation of the left ventricle compared to standard CRT; however, in the remaining three patients, the use of MPP did not appear to acutely improve electrical resynchronization. Crucially, this cohort showed evidence of extensive LV scarring which was well visualized using both CMR and ECGi voltage mapping.</AbstractText>Our work suggests a potential role for ECGi in the optimization of non-responders to CRT, as it allows the fusion of activation maps and scar analysis above and beyond interrogation of the 12 lead ECG.</AbstractText> |
2,329,211 | Low grade oligodendroglioma seeding around the 4th ventricle. | We report a 45 years old female patient with a left temporal grade II oligodendroglioma that recurred on the wall of the fourth ventricle at grade II oligodendroglioma. |
2,329,212 | Platelet microvesicles promote the recovery of neurological function in mouse model of cerebral infarction by inducing angiogenesis. | The aim of this study is to investigate the effect of PMVs on mice with ischemic cerebral infarction and its mechanism. Male C57BL/6 mice were selected, and the right focal cortical infarction model was established via cauterization under a microscope and randomly divided into sham operation (Sham) group, normal saline control (Saline) group and platelet microvesicles intervention (PMVs) group. At 1 h after modeling, 5 μL of PMVs (50 μg/mL) or normal saline was injected into the lateral ventricle. The neurological function of mice in each group was evaluated at 1, 3, 7, 14 and 28 d after modeling. After 28 d, the cerebral infarction area was detected via 2,3,5-triphenyltetrazolium chloride (TTC) staining. At 7 and 28 d after modeling, the blood vessel density, proliferation rate of new vessels and encapsulation rate of pericytes were detected via immunofluorescence staining. Moreover, the changes in cerebral cortical blood flow at the infarction side were detected before modeling and at 7 and 28 d after modeling, respectively. Finally, the expressions of proangiogenic factors vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and N-Cadherin were detected via Western blotting at 3, 7 and 28 d after modeling. PMVs could promote the improvement of neurological function and significantly reduce the cerebral infarction volume in mice with cerebral infarction. PMVs promoted proliferation of new vessels and increased blood vessel density at the infarction edge in mice with cerebral infarction. PMVs could increase the encapsulation rate of pericytes at the infarction edge and improve the permeability of blood-brain barrier in mice with cerebral infarction. PMVs could increase the cerebral cortical blood flow perfusion in mice with cerebral infarction. PMVs could increase proangiogenic factors in brain tissues in mice with cerebral infarction. PMVs could significantly improve the recovery of neurological function in mice with cerebral infarction, which is closely related to the ability of PMVs to promote angiogenesis at the infarction edge. The possible mechanism is that PMVs facilitate angiogenesis after cerebral infarction through promoting the expressions of VEGF, Ang-1 and N-Cadherin. More importantly, the new vessels promoted by PMVs have complete structure and perfect function, and can improve the cerebral blood flow perfusion at the infarction side. |
2,329,213 | Fourth Ventricular Meningiomas. | Fourth ventricular meningiomas (FVMs) are extremely rare. Here, we report a series of 11 patients at a single institution. A comprehensive literature analysis is conducted.</AbstractText>Information about 11 patient was extracted from the patient data. Reports of cases in English were obtained from the literature. Including our 11 patients, 71 patients were analyzed in this study.</AbstractText>The most common age of onset was from the third decade to sixth decade of life. The female/male ratio was about 1.16:1. The most frequent subtype of meningioma was fibrous meningioma. FVMs had specific imaging features, such as calcification (20%), peritumoral edema (30.3%), heterogeneous enhancement (22.5%), cystic formation (4.3%), and hydrocephalus (52.8%). The proportion of total tumor resection was about 94.9%, with 15.3% of postoperative complications. During follow-up, the recurrent rate of FVMs was about 6.8%. There was no significant difference in the analysis of correlation between hydrocephalus and the maximum diameter of tumors, correlation between hydrocephalus and the volume of tumor, or correlation between peritumoral edema and the volume of tumor, as well as correlation between heterogeneous enhancement and the grade of meningiomas.</AbstractText>FVMs have their own characteristics in age of onset, gender ratio, histologic types, and imaging features. The recommended treatment is surgical treatment via the telovelar approach with suboccipital craniotomy/craniectomy. Adjuvant therapy is needed in some high-grade meningiomas and in patients undergoing partial resection. The prognosis is relatively good, with fewer postoperative complications and a higher rate of total resection.</AbstractText>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,214 | Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats. | Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, disorientation and gradual deterioration of intellectual ability. In the pharmacotherapy of AD, the mitochondrial protective activity of Exendin-4 in experimental studies is yet to be established though its effectiveness is demonstrated in these patients. Therefore, the mitochondria protective activity of Exendin-4 (5 μg/kg, i.p.) was investigated in hippocampus and pre-frontal cortex (PFC) of AD-like animals. The amyloid beta (Aβ) was injected through bilateral intracerebroventricular route into lateral ventricles to induce AD-like manifestations in the male rats. Exendin-4 significantly attenuated Aβ-induced memory-deficits in the Morris water maze and Y-maze test protocols. Exendin-4 significantly decreased Aβ-induced increase in the level of Aβ in both brain regions. Exendin-4 significantly increased Aβ-induced decrease in acetylcholine level and activity of cholineacetyl transferase in all brain regions. Moreover, Exendin-4 significantly decreased Aβ-induced increase in the activity of acetylcholinestrase in both the brain regions. E4 significantly increased Aβ-induced decrease in mitochondrial function, integrity, respiratory control rate and ADP/O in all brain regions. Further, Exendin-4 significantly decreased Aβ-induced increase in the mitochondrial complex enzyme-I, IV and V activities in all brain regions. Furthermore, Exendin-4 significantly increased Aβ-induced decrease in the level of phosphorylated Akt and the ratio of phosphorylated Akt to Akt in both brain regions. However, LY294002 diminished the therapeutic effects of Exendin-4 on behavioral, biochemical and molecular observations in AD-like animals. Pearson's analysis showed that the attributes of mitochondrial dysfunction (MMP and RCR) exhibited significant correlation to the loss in memory formation, level of Aβ and cholinergic dysfunction in these animals. Thus, it can be speculated that Exendin-4 may mitigate AD-like manifestations including mitochondrial toxicity perhaps through PI3K/Akt-mediated pathway in the experimental animals. Hence, Exendin-4 could be a potential therapeutic alternative candidate in the management of AD. |
2,329,215 | Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. | Cardiac resynchronization therapy with defibrillator (CRT-D) implantation involves left ventricular (LV) lead placement for biventricular pacing and is more complex than implantable cardioverter-defibrillator (ICD)-only implantation. Differences in the prescription of CRT-D versus ICD may result from clinician biases based on patient body habitus, and body habitus may be associated with LV lead implantation failure.</AbstractText>We sought to evaluate whether patient body mass index (BMI) was associated with planned use and implantation failure of CRT-D therapy.</AbstractText>We studied all patients enrolled in the National Cardiovascular Data Registry ICD Registry who met standard CRT-D criteria and received either an ICD or CRT-D between 2010 and 2012. BMI was categorized based on World Health Organization classification. Using hierarchical logistic regression, two multivariate models adjusted for patient demographic and clinical characteristics were fit based on the following outcome variables: (1) planned implantation with CRT-D versus ICD and (2) failed versus successful LV lead placement.</AbstractText>Of 337,547 patients, 41,872 met inclusion criteria for the first analysis and 35,186 met criteria for the second analysis. After multivariable adjustment, patients with extreme (BMI > 40 kg/m2</sup>) obesity were less likely to receive guideline-concordant CRT-D compared with patients with normal weight (adjusted odds ratio (AOR), 0.86; 95% confidence interval (CI), 0.75-0.99; p = 0.04). Extreme (BMI > 40 kg/m2</sup>) obesity was associated with higher odds of failed LV lead placement (AOR, 1.35; 95% CI, 1.07-1.72, p = 0.01).</AbstractText>Compared with normal weight patients, extremely obese (BMI > 40 kg/m2</sup>) CRT-D eligible patients were less likely to be prescribed CRT-D and were at higher odds for failed LV lead placement.</AbstractText> |
2,329,216 | Neurological and neuropsychological outcome after resection of craniopharyngiomas. | Craniopharyngiomas are rare and benign tumors of the sellar and/or parasellar region. Primary treatment involves resection followed by adjuvant radiotherapy. While the grade of resection was frequently analyzed following surgery, the neurological outcome and especially neuropsychological deficits and quality of life have been neglected for many decades. Therefore, the authors retrospectively analyzed their patient series and prospectively assessed neuropsychological outcome and quality of life following resection of craniopharyngiomas in adults.</AbstractText>In total, 71 patients (39 men and 32 women) with a mean age of 49 years were enrolled in the retrospective analysis. In addition, 36 of the 71 patients were included in the prospective arm of the study and underwent neurological and neuropsychological testing as well as quality of life (36-Item Short-Form Health Survey; SF-36) assessment. Factors influencing outcome were identified and correlations calculated.</AbstractText>Resection was performed mostly using a pterional (41.6%, 47/113 surgical procedures) or bifrontal translamina terminalis (30.1%, 34/113 surgical procedures) approach. Following surgery, visual acuity was significantly improved (> 0.2 diopters) in 32.4% (23/71) of patients, or remained stable in 45.1% (32/71) of patients. During long-term follow up, 80.3% (57/71) of patients developed pituitary insufficiency, particularly involving the corticotropic and thyrotrophic axes. In total, 75% (27/36) of patients showed neuropsychological deviations in at least 1 test item. In particular, attentiveness, cognitive speed, and short-term memory were affected. Referring to the SF-36 score, quality of life was affected in both the mental and physical score in 19.4% (7/36) and 33.3% (12/36), respectively. The risk factors that were identified were a tumor volume larger than 9 cm3, tumor extension toward/into the third ventricle or the brainstem, and resection using a bifrontal translamina terminalis or left-sided approach.</AbstractText>This study demonstrated that resection of craniopharyngiomas is frequently associated with postoperative neuropsychological deficits and hence an impaired quality of life. In addition to tumor size and extension toward/into the third ventricle or the brainstem, selection of the surgical approach may play a crucial role in the patient's neuropsychological outcome and quality of life.</AbstractText> |
2,329,217 | Brain volumes and their ratios in Alzheimer´s disease on magnetic resonance imaging segmented using Freesurfer 6.0. | Ratios between opposing volumes from brain magnetic resonance imaging (MRI) can provide additional information to volumes in Alzheimer's disease (AD). Brain three-dimensional MPRAGE MRI at 3T were segmented into 44 regions using FreeSurfer v6 in 75 participants. The region's size in absolute volumes and relative proportions to the whole brain volume were compared between 39 AD patients and 36 age-, education- and sex-matched normal controls (NC). Volumes of the most atrophied parts were related to the opposing volumes of the most enlarged parts as ratios. The most atrophic structures in AD were both hippocampi. By contrast, the greatest enlargements in AD were inferior parts of both lateral ventricles. The best ratio for each side was the hippocampo-horn proportion calculated as ratio: the hippocampus / (the hippocampus + inferior lateral ventricle). Its optimal cut-off of 74% yielded sensitivity of 74% and specificity of 78% on the left and sensitivity of 74% and specificity of 78% on the right. The hippocampo-horn proportion is another measure to evaluate the degree of hippocampal atrophy on brain MRI in percentages. It has a potential to be simplified into a comparison of two-dimensional corresponding areas or a visual assessment. |
2,329,218 | Pediatric meningiomas: a report of 5 cases and review of literature. | The purpose of this paper is to provide novel insight into the rare pediatric meningiomas.</AbstractText>We retrospectively analyzed pediatric surgical cases of meningioma during 2002 to 2017 in our institution. The preoperative, intraoperative, and the postoperative status were collected to find any unique features that has not reported in the past.</AbstractText>Nine surgeries out of 5 patients were identified. The mean age was 7 years old (range 1-14 years old). Four patients were females. The mean tumor diameter was 52 mm (range 23-81 mm). The tumor locations were optic nerve sheath, Sylvian fissure, parasagittal, trigone of the lateral ventricle, and cerebellopontine angle. The Sylvian fissure meningioma without dural attachment (MWODA) was found in a 15-month-old female. A relapsed parasagittal meningioma showed regression in histological grade and residual tumor demonstrated spontaneous regression. In the initial surgeries, Simpson grade 1 resection was achieved in 2 cases. The pathological diagnoses were 1 meningothelial, 1 metaplastic, 2 atypical, and 1 clear cell meningiomas. The mean postoperative follow-up period was 71 months. Three patients experienced recurrence of the tumor. At the latest follow-up, all patients were free of radiological tumor recurrence or regrowth with a mean follow-up of 4 years (range 1-6.9 years). All patients were in the modified Rankin scale of 0-1.</AbstractText>MWODA is not considered to be rare in pediatric meningioma and should be included in the differential diagnosis. We presented a histologically regressed relapsed meningioma, which spontaneously regressed after subtotal resection. In the case of recurrent meningioma, surgical resection and adjuvant radiation therapy could be effective for long-term control of the tumor.</AbstractText> |
2,329,219 | Early signs of middle cerebral artery infarction on multidetector computed tomography: Review of 20 cases. | This study intended to assess the occurrence of early signs of middle cerebral artery (MCA) on multidetector computed tomography (MDCT) in correlation with duration of the clinical features of stroke.</AbstractText>This retrospective study analyzed the electronic records of 20 patients with MCA infarction. The detected signs studied according to the onset of the clinical features of stroke to the time of CT imaging.</AbstractText>Out of 20 patients with MCA infarction included in this study, the results revealed a significant relationship between the presence of insular ribbon sign and/or subtle hypodensity and hyperacute infarction (P</i> < 0.001 and 0.003, respectively). Results revealed significant relationship between the occurrence of hypodense area, effacement of the cortical sulci, and compression of the ipsilateral lateral ventricle with acute infarction (6-72 h), (P</i> = 0.006, 0.007, and 0.002) (odds ratio = 0.047, 0.050 and 0.028) and (95% confidence interval = 0.004-0.552, 0.004-0.597 and 0.002-0.367) respectively.</AbstractText>MDCT can detect nearly half of MCA infarctions in the first 6 h. Insular ribbon sign and subtle hypodensity were the most significant findings in the first 6 h of stroke. Hypodense area was a significant sign after 6 h. Diabetes mellitus and ischemic heart disease were the most common risk factors. Hemiparesis was the most common clinical finding in MCA infarction.</AbstractText> |
2,329,220 | Proliferation and Differentiation in the Adult Subventricular Zone Are Not Affected by CSF1R Inhibition. | Microglia are reported to have significant roles in regulating normal mammalian adult neurogenesis. There are two neurogenic niches in the adult mammal brain: the subgranular zone (SGZ) in the hippocampus, and the subventricular zone (SVZ), which makes up the lining of the lateral ventricles. While the microglia interactions on adult neurogenesis in the hippocampus have been characterized, the SVZ niche is not as well investigated. The SVZ niche is unique in that the newborn neurons migrate a much longer distance through multiple brain structures compared to newborn neurons in the hippocampus, making it more difficult to fully characterize how microglia influence this process. To examine the SVZ niche and migration pathway, we used the colony stimulating factor 1 receptor (CSF1R) antagonist PLX5622, which promotes brain wide microglia ablation. Microglia ablation resulted in no changes in the numbers of neural stem cells (NSCs), transient amplifying cells, and neuroblasts. Microglia ablation in the olfactory bulb (OB) was decreased compared to the SVZ. CSF1R inhibition had no effect on the ability of microglia to proliferate. Thus, our data suggest that microglia are not required for normal functioning SVZ adult neurogenesis. |
2,329,221 | Sorted Golden-step phase encoding: an improved Golden-step imaging technique for cardiac and respiratory self-gated cine cardiovascular magnetic resonance imaging. | Numerous self-gated cardiac imaging techniques have been reported in the literature. Most can track either cardiac or respiratory motion, and many incur some overhead to imaging data acquisition. We previously described a Cartesian cine imaging technique, pseudo-projection motion tracking with golden-step phase encoding, capable of tracking both cardiac and respiratory motion at no cost to imaging data acquisition. In this work, we describe improvements to the technique by dramatically reducing its vulnerability to eddy current and flow artifacts and demonstrating its effectiveness in expanded cardiovascular applications.</AbstractText>As with our previous golden-step technique, the Cartesian phase encodes over time were arranged based on the integer golden step, and readouts near ky</sub> = 0 (pseudo-projections) were used to derive motion. In this work, however, the readouts were divided into equal and consecutive temporal segments, within which the readouts were sorted according to ky</sub>. The sorting reduces the phase encode jump between consecutive readouts while maintaining the pseudo-randomness of ky</sub> to sample both cardiac and respiratory motion without comprising the ability to retrospectively set the temporal resolution of the original technique. On human volunteers, free-breathing, electrocardiographic (ECG)-free cine scans were acquired for all slices of the short axis stack and the 4-chamber view of the long axis. Retrospectively, cardiac motion and respiratory motion were automatically extracted from the pseudo-projections to guide cine reconstruction. The resultant image quality in terms of sharpness and cardiac functional metrics was compared against breath-hold ECG-gated reference cines.</AbstractText>With sorting, motion tracking of both cardiac and respiratory motion was effective for all slices orientations imaged, and artifact occurrence due to eddy current and flow was efficiently eliminated. The image sharpness derived from the self-gated cines was found to be comparable to the reference cines (mean difference less than 0.05 mm- 1</sup> for short-axis images and 0.075 mm- 1</sup> for long-axis images), and the functional metrics (mean difference < 4 ml) were found not to be statistically different from those from the reference.</AbstractText>This technique dramatically reduced the eddy current and flow artifacts while preserving the ability of cost-free motion tracking and the flexibility of choosing arbitrary navigator zone width, number of cardiac phases, and duration of scanning. With the restriction of the artifacts removed, the Cartesian golden-step cine imaging can now be applied to cardiac imaging slices of more diverse orientation and anatomy at greater reliability.</AbstractText> |
2,329,222 | Reference ranges for the left ventricle modified myocardial performance index, respective time periods, and atrioventricular peak velocities between 20 and 36 + 6 weeks of gestation. | <b>Objective:</b> To establish reference ranges for the fetal left ventricle (LV) modified myocardial performance index (Mod-MPI), respective time periods, and right and left atrioventricular peak velocities between 20 and 36 + 6 weeks of gestation.<b>Methods:</b> This cross-sectional study evaluated 360 low-risk singleton pregnancies between 20 and 36 + 6 weeks of gestation. The LV Mod-MPI was calculated as (isovolumetric contraction time + isovolumetric relaxation time)/ejection time. Polynomial regression was used to obtain the best-fit using Mod-MPI and atrioventricular peak velocity measurements and gestational age (GA) with adjustments using the coefficient of determination (<i>R</i><sup>2</sup>). The intra- and interobserver reliability was evaluated using the concordance correlation coefficient (CCC).<b>Results:</b> LV Mod-MPI (<i>R</i><sup>2</sup> = 0.026, <i>p</i> = .002) and isovolumetric relaxation time (IRT) (<i>R</i><sup>2</sup> = 0.036, <i>p</i> < .001) significantly increased with advancing GA. Isovolumetric contraction time (ICT) and ejection time (ET) did not significantly change with GA. RV and LV E wave, A wave, and E/A ratio significantly increased with GA (<i>p</i> < .001). The mean of each parameter ranged as follows: LV Mod-MPI (0.44-0.47 s), IRT (0.041-0.045 s), ICT (0.032-0.034 s), ET (0.167-0.167 s), RV E (30.2-46.91 cm/s), RV A (47.1-60.7 cm/s), RV E/A (0.65-0.78 cm/s), LV E (27.0-41.4 cm/s), LV A (43.2-53.8 cm/s), and LV E/A (0.63-0.78 cm/s). Only LV A wave measurements demonstrated an intraobserver CCC >0.80. The remaining intra- and interobserver reproducibility parameters demonstrated lower CCC.<b>Conclusions:</b> Reference values were replicated for the fetal LV Mod-MPI and LV and RV transvalvular peak velocities between 20 and 36 + 6 weeks of gestation. |
2,329,223 | Effects of Calorie Restriction and Voluntary Exercise on Doxorubicin-Induced Cardiotoxicity. | Doxorubicin (DOX) is a widely used chemotherapeutic agent with known cardiotoxic properties, while calorie restriction (CR) and exercise have well-documented cardioprotective effects. No studies have investigated the effects of CR alone or the combined effects of CR and exercise on DOX cardiotoxicity.</AbstractText>Rats were divided into 4 groups based on their food intake (ad libitum or CR) and activity (sedentary or voluntary wheel running [WR]). After completing a 16-week treatment, animals received either DOX (15 mg/kg) or saline (SAL) and cardiac function was measured 5 days after treatment. Chromatography was used to quantify left ventricular DOX accumulation.</AbstractText>Left ventricular developed pressure (LVDP), end systolic pressure (ESP), and left ventricular maximal rate of pressure development (dP/dtmax</sub>) were significantly higher in the CR + DOX group when compared with DOX. Fractional shortening, LVDP, ESP, dP/dtmax</sub>, and dP/dtmin</sub> were significantly higher in the CR + WR + DOX group compared with the DOX group. In addition, the CR + WR + DOX group showed significantly higher LVDP and ESP compared with the WR + DOX group. DOX accumulation in the heart was 5-fold lower ( P < .05) in the CR + WR + DOX group compared with the DOX group.</AbstractText>This is the first study to demonstrate that CR can reduce cardiac DOX accumulation, and confirms the protective role of CR against DOX-induced cardiac dysfunction. Our data also show that combining a known cardioprotective intervention, exercise training, with CR results in additive benefits in the protection against DOX cardiotoxicity.</AbstractText> |
2,329,224 | Sister, Sister: Ependymal Cells and Adult Neural Stem Cells Are Separated at Birth by Geminin Family Members. | The adult subventricular zone (SVZ) stem cell niche is comprised of multi-ciliated ependymal cells that line the brain ventricular system and adult stem cells. Papers in Neuron (Ortiz-Álvarez et al., 2019) and Cell Reports (Redmond et al., 2019) report that these cell types share a common precursor. Ortiz-Álvarez et al. further show that Geminin family members modulate the fate of daughter cells. |
2,329,225 | Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone. | Cardiac fibrosis contributes to the development of heart failure in pulmonary hypertension. We aimed to assess the development of fibrosis and the effects of treatment with the anti-fibrotic agent pirfenidone in pressure overload induced right ventricular (RV) failure. Wistar rat weanlings were randomized to pulmonary trunk banding (PTB) or sham surgery. One week after the procedure, PTB rats were randomized into two groups with either six weeks on standard chow or treatment with pirfenidone mixed in chow (700 mg/kg/day). RV hemodynamic effects were evaluated by echocardiography, cardiac magnetic resonance imaging (MRI), and pressure-volume measurements. Sections from the isolated RV, left ventricle, and septum were sampled systematically; stereological point grids and the nucleator were used to estimate volume of fibrosis and cardiac hypertrophy, respectively. PTB caused RV failure in all rats subjected to the procedure. The volume fraction of fibrosis in the RV increased threefold in PTB rats corresponding to a sixfold increase in total volume of RV fibrosis. Volume fraction of fibrosis and total volume of fibrosis also increased in the septum and in the left ventricle. Pirfenidone reduced body weight but did not improve RV hemodynamics or reduce cardiac fibrosis. RV cardiomyocyte profile area was increased twofold in PTB rats without any effect of pirfenidone. RV pressure overload after PTB induced not only RV but also septal and left ventricular fibrosis assessed by stereology. Treatment with pirfenidone reduced body weight but did not reduce the development of cardiac fibrosis or delay the progression of RV failure. |
2,329,226 | Optimized cultivation of porcine choroid plexus epithelial cells, a blood-cerebrospinal fluid barrier model, for studying granulocyte transmigration. | The blood-cerebrospinal fluid barrier (BCSFB) plays important roles during the transport of substances into the brain, the pathogenesis of central nervous system (CNS) diseases, and neuro-immunological processes. Along these lines, transmigration of granulocytes across the blood-cerebrospinal fluid (CSF) barrier (BCSFB) is a hallmark of inflammatory events in the CNS. Choroid plexus (CP) epithelial cells are an important tool to generate in vitro models of the BCSFB. A porcine CP epithelial cell line (PCP-R) has been shown to present properties of the BCSFB, including a strong barrier function, when cultivated on cell culture filter inserts containing a membrane with 0.4 µm pore size. For optimal analysis of pathogen and host immune cell interactions with the basolateral side of the CP epithelium, which presents the physiologically relevant "blood side", the CP epithelial cells need to be grown on the lower face of the filter in an inverted cell culture insert model, with the supporting membrane possessing a pore size of at least 3.0 µm. Here, we demonstrate that PCP-R cells cultivated in the inverted model on filter support membranes with a pore size of 3.0 µm following a "conventional" protocol grow through the pores and cross the membrane, forming a second layer on the upper face. Therefore, we developed a cell cultivation protocol, which strongly reduces crossing of the membrane by the cells. Under these conditions, PCP-R cells retain important properties of a BCSFB model, as was observed by the formation of continuous tight junctions and a strong barrier function demonstrated by a high transepithelial electrical resistance and a low permeability for macromolecules. Importantly, compared with the conventional cultivation conditions, our optimized model allows improved investigations of porcine granulocyte transmigration across the PCP-R cell layer. |
2,329,227 | Visualizing flow in an intact CSF network using optical coherence tomography: implications for human congenital hydrocephalus. | Cerebrospinal fluid (CSF) flow in the brain ventricles is critical for brain development. Altered CSF flow dynamics have been implicated in congenital hydrocephalus (CH) characterized by the potentially lethal expansion of cerebral ventricles if not treated. CH is the most common neurosurgical indication in children effecting 1 per 1000 infants. Current treatment modalities are limited to antiquated brain surgery techniques, mostly because of our poor understanding of the CH pathophysiology. We lack model systems where the interplay between ependymal cilia, embryonic CSF flow dynamics and brain development can be analyzed in depth. This is in part due to the poor accessibility of the vertebrate ventricular system to in vivo investigation. Here, we show that the genetically tractable frog Xenopus tropicalis, paired with optical coherence tomography imaging, provides new insights into CSF flow dynamics and role of ciliary dysfunction in hydrocephalus pathogenesis. We can visualize CSF flow within the multi-chambered ventricular system and detect multiple distinct polarized CSF flow fields. Using CRISPR/Cas9 gene editing, we modeled human L1CAM and CRB2 mediated aqueductal stenosis. We propose that our high-throughput platform can prove invaluable for testing candidate human CH genes to understand CH pathophysiology. |
2,329,228 | Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction. | The primary cause of heart failure is the loss of cardiomyocytes in the diseased adult heart. Previously, we reported that the miR-17-92 cluster plays a key role in cardiomyocyte proliferation. Here, we report that expression of miR-19a/19b, members of the miR-17-92 cluster, is induced in heart failure patients. We show that intra-cardiac injection of miR-19a/19b mimics enhances cardiomyocyte proliferation and stimulates cardiac regeneration in response to myocardial infarction (MI) injury. miR-19a/19b protected the adult heart in two distinctive phases: an early phase immediately after MI and long-term protection. Genome-wide transcriptome analysis demonstrates that genes related to the immune response are repressed by miR-19a/19b. Using an adeno-associated virus approach, we validate that miR-19a/19b reduces MI-induced cardiac damage and protects cardiac function. Finally, we confirm the therapeutic potential of miR-19a/19b in protecting cardiac function by systemically delivering miR-19a/19b into mice post-MI. Our study establishes miR-19a/19b as potential therapeutic targets to treat heart failure. |
2,329,229 | Position and size of massa intermedia in Serbian brains. | Massa intermedia, a midline bar-shaped structure, connects two thalami across the third ventricle in 70-80% of healthy humans. It has become clinically important since its absence was comprehended as a midline malformation of the brain and brought in connection with schizophrenia indicating that some symptoms could be a consequence of disturbed neuron chains underlying the mechanisms of attention and processing of information. The aim of the investigation was to find out the incidence, position, and size of massa intermedia in the brains of the Serbian population.</AbstractText>Our investigation was performed on 41 brains of adult Serbian cadavers using a macro dissection method.</AbstractText>Massa intermedia was present in 80.49% of cases, in 1 case it was double. In most of the cases it was located in the superior quadrants of the lateral wall of the third ventricle, the larger part being in the anterosuperior one. Some other combinations were also present. The horizontal diameter of the cross-section was larger than vertical and was not in correlation with the length of the third ventricle. The average cross-sectional area was 29.58 mm2, significantly larger in females.</AbstractText>Massa intermedia is present in most of the investigated brains, usually connecting the anterior-superior quadrants of the lateral walls of the third ventricle. Different in shape and size its cross-section is a horizontal ellipse, significantly larger in females. The cross-sectional area and the size of the third ventricle are not in correlation.</AbstractText> |
2,329,230 | Impact of left ventricular pacing threshold on ventricular arrhythmia occurrence in cardiac resynchronization therapy. | Cardiac resynchronization therapy (CRT) is an established heart failure (HF) treatment option, however its effect on ventricular arrhythmias (VAs) is controversial. Regional scar burden and high left ventricular (LV) pacing threshold (PT) are associated with poor outcome in CRT patients. The aim of our study was to analyze the impact of intraoperative LVPT on VA occurrence.</AbstractText>Eighty consecutive patients with advanced HF scheduled for a CRT defibrillator device [aged 63.3±10.9 years; New York Heart Association II-III 86.2%; 52 males (65%); 34 ischemic etiology (42.5%); 71 sinus rhythm (88.7%); QRS duration 168±25.7ms] were evaluated using single-photon emission computed tomography myocardial perfusion imaging. Regional myocardial viability was calculated as the mean tracer activity in the corresponding segments at the LV lead pacing site. Fluoroscopic position and intraoperative LVPT were determined at implant after the final LV lead position was determined.</AbstractText>LVPT was inversely associated with regional myocardial viability (ρ -0.785, p<0.001). After a median follow-up of 36 months (24-57) months VAs were registered in 27 patients (33.7%). Patients with VAs had higher median intraoperative LVPT compared to those without VAs [2.2V (1.9-2.8) vs. 0.8V (0.6-1.2), p<0.001]. In a multivariate logistic regression model intraoperative LVPT was identified as a strong independent predictor of VAs.</AbstractText>Increased intraoperative LVPT during CRT could be associated with lower regional myocardial viability at LV lead location. CRT patients with higher LVPT could have an increased risk of VA occurrence.</AbstractText>Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation> |
2,329,231 | Impaired hippocampal development and outcomes in very preterm infants with perinatal brain injury. | Preterm infants are at high risk for brain injury during the perinatal period. Intraventricular hemorrhage and periventricular leukomalacia, the two most common patterns of brain injury in prematurely-born children, are associated with poor neurodevelopmental outcomes. The hippocampus is known to be critical for learning and memory; however, it remains unknown how these forms of brain injury affect hippocampal growth and how the resulting alterations in hippocampal development relate to childhood outcomes. To investigate these relationships, hippocampal segmentations were performed on term equivalent MRI scans from 55 full-term infants, 85 very preterm infants (born ≤32 weeks gestation) with no to mild brain injury and 73 very preterm infants with brain injury (e.g., grade III/IV intraventricular hemorrhage, post-hemorrhagic hydrocephalus, cystic periventricular leukomalacia). Infants then underwent standardized neurodevelopmental testing using the Bayley Scales of Infant and Toddler Development, 3rd edition at age 2 years, corrected for prematurity. To delineate the effects of brain injury on early hippocampal development, hippocampal volumes were compared across groups and associations between neonatal volumes and neurodevelopmental outcomes at age 2 years were explored. Very preterm infants with brain injury had smaller hippocampal volumes at term equivalent age compared to term and very preterm infants with no to mild injury, with the smallest hippocampi among those with grade III/IV intraventricular hemorrhage and post-hemorrhagic hydrocephalus. Further, larger ventricle size was associated with smaller hippocampal size. Smaller hippocampal volumes were related to worse motor performance at age 2 years across all groups. In addition, smaller hippocampal volumes in infants with brain injury were correlated with impaired cognitive scores at age 2 years, a relationship specific to this group. Consistent with our preclinical findings, these findings demonstrate that perinatal brain injury is associated with hippocampal size in preterm infants, with smaller volumes related to domain-specific neurodevelopmental impairments in this high-risk clinical population. |
2,329,232 | Lipopolysaccharide-Binding Protein Is an Early Biomarker of Cardiac Function After Radiation Therapy for Breast Cancer. | To evaluate the prognostic potential of lipopolysaccharide-binding protein (LBP) levels after breast cancer radiation therapy (RT) for incipient cardiac dysfunction.</AbstractText>In this single-centered study, we prospectively enrolled female patients treated for left breast cancer. Healthy age- and sex-matched participants were recruited as controls. LBP levels, cardiac troponin T, N-terminal propeptide of the brain natriuretic peptide, fatty acid binding protein, and C-reactive protein were assessed at three timepoints-before RT, after the last RT fraction, and 1 month after the last fraction. Echocardiographic evaluation was done 3 to 3.75 years after RT.</AbstractText>We recruited 51 patients and 78 controls. Baseline LBP concentrations in the study group were significantly higher than in controls at baseline (P < .001), at 24 hours, and at 1 month after RT (P = .003 and P < .001, respectively). Other biomarkers (cardiac troponin T, N-terminal propeptide of the brain natriuretic peptide, fatty acid binding protein, and C-reactive protein) did not differ in any of the timepoints. Posttreatment LBP concentrations were significantly and positively correlated with heart- and lung-associated dose-volume histogram variables. Posttreatment and follow-up LBP levels correlated positively with the E/E' echocardiographic index reflective of the diastolic function. After adjustment for left anterior descending artery mean dose, left ventricle mean dose, mean heart dose, and type of surgery, LBP remained significantly correlated with E/E' when measured 24 hours after RT (beta = 0.41, P = .032) and 1 month after RT (beta = 0.43, P = .028).</AbstractText>Serum LBP concentrations correlate with diastolic function evaluated 3 years after the completion of RT, making LBP a potentially useful prognostic parameter.</AbstractText>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,233 | [Electrhopysiological Effect of the Polyamine Spermine in Normoxic and Ischemic Ventricular Myocardium]. | Cytoplasmic polyamines (PA) are involved in control of many cellular functions and are well known as regulators of so called inward-rectifier potassium ion channels. Nevertheless, functional significance of extracellular PA in the heart is poorly elucidated. Aim of this study was to study effects of endogenous PA spermine in the ventricular myocardium. Effects of the extracellular spermine were investigated in isolated multicellular preparations of rabbit and rat ventricular myocardium. Langendorff-perfused  isolated rat and rabbit hearts were also used. Action potential (APs) duration and pattern of excitation in ventricular myocardium were estimated using standard microelectrode technique and optical mapping. Functional refractory periods were assessed in Langendorff perfused hearts with the help of programmedelectrical stimulation of the ventricle. In this study extracellular PA spermine (0.1-5 mM) induced shortening of the APs in multicellular preparations of rat ventricular myocardium registered using sharp microelectrode technique. However, spermine caused only weak effect in preparations of ventricular myocardium from rabbit heart: highest tested concentration of spermine (5 mM) induced 4.7 % APs shortening. Similarly, 0.1-1 mM of spermine was unable to alter substantially ventricular effective refractory periods in isolated perfused rabbit hearts. In two animal species tested (rat and rabbit) 0.1-1 mM of spermine failed to affect conduction velocity and activation pattern in ventricles of isolated Langendorff-perfused hearts under normoxia. However, in the rat no-flow model of ischemia-reperfusion extracellular spermine improved conduction of excitation in ventricles. Our results allow suggesting that extracellular spermine can prevent ischemia-induced proarrhythmic changes in ventricular myocardium probably due to reduction of calcium accumulation, but this effect is significant only when PA is applied in millimolar concentrations. Also, potential anti-ischemic effect of the PA may be species specific. |
2,329,234 | Chronic effects of platinum(IV) complex and its diamine ligand on rat heart function: comparison with cisplatin. | The aim of the present study was to compare the cardiodynamic parameters in the isolated rat heart in animals chronically treated with cisplatin, platinum(IV) complex and its diamine ligand. Sixty Wistar albino rats (8 weeks old) were divided into five groups: three experimental and two control groups. Animals in all groups were treated with a dose of 4 mg/kg body weight once a week for 4 weeks with different substances; experimental groups received cisplatin, ligand and octahedral platinum(IV) complex, and control groups received saline and dimethyl sulfoxide. After sacrificing the animals, hearts were isolated and perfused according to the Langendorff technique at gradually increased coronary perfusion pressures (40-120 cmH<sub>2</sub>O). The following parameters of cardiac function were continuously recorded: maximum and minimum rate of change of pressure in the left ventricle, systolic and diastolic left ventricular pressure, heart rate and coronary flow. The results showed statistically significant differences between all experimental groups in maximum and minimum rate of pressure development as well as in systolic pressure of the left ventricle, whereas cisplatin, ligand and the platinum(IV) complex had effects on heart contractility without significant influences on coronary circulation. The findings of the present study could be important for a better understanding of anticancer drug cardiac side effects. Our results indicate that compared to cisplatin as a "gold standard", novel platinum complexes and ligands do not possess fewer negative effects on the heart, indicating insufficient safety for their usage in terms of affecting cardiac function, a result that can be of great interest for further investigations. |
2,329,235 | Usefulness of ultrasound in the management of acute respiratory distress syndrome. | Acute respiratory distress syndrome (ARDS) is a life-threatening disease. Different imaging techniques have been used to diagnose and guide the ventilatory management of patients with ARDS. Chest ultrasound is a reliable tool to identify interstitial syndrome, lung consolidation, lung collapse, and pleural effusion. In addition, echocardiography is essential in the diagnosis of diastolic left ventricle dysfunction and the estimation of elevated ventricle filling pressures, which is necessary before diagnosing ARDS. Therefore, combining chest and heart ultrasound assessment is useful to diagnose ARDS and guide the ventilatory management of the disease. Available data in the literature suggest that protocol-based approaches should be implemented for the purposes of diagnosis and management. |
2,329,236 | A viscoelastic adhesive epicardial patch for treating myocardial infarction. | Acellular epicardial patches that treat myocardial infarction by increasing the mechanical integrity of damaged left ventricular tissues exhibit widely scattered therapeutic efficacy. Here, we introduce a viscoelastic adhesive patch, made of an ionically crosslinked transparent hydrogel, that accommodates the cyclic deformation of the myocardium and outperforms most existing acellular epicardial patches in reversing left ventricular remodelling and restoring heart function after both acute and subacute myocardial infarction in rats. The superior performance of the patch results from its relatively low dynamic modulus, designed at the so-called 'gel point' via finite-element simulations of left ventricular remodelling so as to balance the fluid and solid properties of the material. |
2,329,237 | Different effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats. | Clinical studies consistently report structural impairments (i.e.: ventricular enlargement, decreased volume of anterior cingulate cortex or hippocampus) and functional abnormalities including changes in regional cerebral blood flow in individuals suffering from schizophrenia, which can be evaluated by magnetic resonance imaging (MRI) techniques. The aim of this study was to assess cerebral blood perfusion in several schizophrenia-related brain regions using Arterial Spin Labelling MRI (ASL MRI, 9.4 T Bruker BioSpec 94/30USR scanner) in rats. In this study, prenatal exposure to methylazoxymethanol acetate (MAM, 22 mg/kg) at gestational day (GD) 17 and the perinatal treatment with Δ-9-tetrahydrocannabinol (THC, 5 mg/kg) from GD15 to postnatal day 9 elicited behavioral deficits consistent with schizophrenia-like phenotype, which is in agreement with the neurodevelopmental hypothesis of schizophrenia. In MAM exposed rats a significant enlargement of lateral ventricles and perfusion changes (i.e.: increased blood perfusion in the circle of Willis and sensorimotor cortex and decreased perfusion in hippocampus) were detected. On the other hand, the THC perinatally exposed rats did not show differences in the cerebral blood perfusion in any region of interest. These results suggest that although both pre/perinatal insults showed some of the schizophrenia-like deficits, these are not strictly related to distinct hemodynamic features. |
2,329,238 | Cardiac Biomarkers and Cardiovascular Outcome in Children with Chronic Kidney Disease. | Myocardial dysfunction is a leading cause of mortality in chronic kidney disease (CKD) children specially those on regular hemodialysis. Cardiac biomarkers play a key role for early detection of myocardial injury. We aim to clarify the prognostic role of circulating cardiac biomarkers, heart type fatty acid binding protein (H-FABP) and pregnancy associated plasma protein-A (PAPP-A) in CKD children on regular hemodialysis.</AbstractText>This is a prospective case control study over 2 years duration. Initial assessment included 20 CKD children on regular hemodialysis and 20 age- and sex- matched healthy children as a control group. Serum level of H-FABP and PAPP-A were measured and correlated to conventional echocardiographic findings and cardiovascular outcome in CKD children.</AbstractText>60% of CKD children developed cardiovascular comorbidities. H-FABP and PAPP-A levels were significantly elevated especially in those with worse cardiovascular outcome. H-FABP and PASP-A levels were positively correlated with LVM index. At cut off point > 17.65 pg/mL, H-FABP has 91% sensitivity and 87.5% specificity for prediction of cardiac morbidity. Elevated H-FABP (OR = 33; CI 95%: 2.455 - 443.591), LVM indexed to body surface area (OR = 21; CI 95%: 1.777 - 248.103), LVM indexed to lean body mass (OR = 15; CI 95%: 1.652 -136.172), elevated PAPP-A (OR = 9.8; CI 95%: 0.898 - 106.845) and Hypertension (OR = 8.333; CI 95%: 1.034 - 67.142) are the main risk factors for cardiac morbidities in CKD children.</AbstractText>Elevated H-FABP and PAPP-A are valuable prognostic markers for cardiovascular outcome in CKD children on regular hemodialysis.</AbstractText> |
2,329,239 | Interstitial Adipocytes in the Beagle Dog and New Zealand White Rabbit Choroid Plexus. | The choroid plexus (CP) produces cerebrospinal fluid and has epithelial, interstitial, and vascular compartments. The CP is a potential site of toxicity, and recognizing the normal microanatomy in different animal models is important for the pathologist. In preclinical studies with beagle dog and New Zealand white rabbits, we observed variable numbers of adipocytes in the CP interstitium of control and xenobiotic-treated animals. The adipocytes were unilocular and consistent morphologically with white adipose tissue. There was a striking variability in the number of adipocytes; however, the presence of adipocytes was not associated with other microscopic findings that would suggest a pathologic process. The morphology of adipocytes was reminiscent of what is observed normally in the interstitium of other tissues like skeletal muscle, bone marrow, and the subcutis. Therefore, we propose that the interstitial adipocytes not be recorded as a finding in preclinical studies unless the adipocytes are altered spontaneously (ie, lipoma) or after xenobiotic treatment. |
2,329,240 | Evaluation of intracerebral ventricles volume of patients with Parkinson's disease using the atlas-based method: A methodological study. | Knowing the volumetric changes in brain can allow for the estimation of the disease progression of various neurodegenerative disorders. Many studies have been shown that the volumetric changes in the some brain structures especially including the dopaminergic neurons, in patients with Parkinson's disease (PD). The objective of this study was to compare intracerebral ventricles volume in patients with PD and healthy subjects to compare an automated atlas-based method (MRIStudio software) and a manual method (ImageJ). T1-weighted brain Magnetic Resonance Imaging (MRI) data of 21 patients with PD and 20 healthy individuals were used to calculate the intracerebral ventricle volumes. Measurement results obtained by ImageJ were considered as the gold standard. We found a significant increase in the left occipital part of the lateral ventricle volume in the patients with PD compared to the control subjects (p < 0.05). Also, no significant difference was found between the two methods of measurement (p > 0.05), meaning that a substantial agreement was found between the results obtained with the atlas-based analysis and manual method. The present study showed that MRIStudio can be performed easily and accurately on routine MRI scans for which the total intracerebral ventricles volume is to be estimated in PD. We suggest that, the attained volume values of intracerebral ventricles may provide a precious data for volumetric dependences of the anatomical structures in several clinical conditions. |
2,329,241 | Incidence trends of adult malignant brain tumors in Finland, 1990-2016. | <b>Background:</b> Several studies have reported increased incidence trends of malignant gliomas in the late 1900s with a plateau in the 2000s, but also some recent increases have been reported. The purpose of our study was to analyze incidence trends of malignant gliomas in Finland by morphology and tumor location. <b>Material and methods:</b> Data on 4730 malignant glioma patients were obtained from case notifications to the nationwide, population-based Finnish Cancer Registry (FCR), and less detailed data on 3590 patients up to 2016. Age-standardized incidence rates (ASR) and average annual percent changes (APCs) in the incidence rates were calculated by histological subtype and tumor location. <b>Results:</b> The incidence rate of gliomas was 7.7/100,000 in 1990-2006 and 7.3 in 2007-2016. The incidence of all gliomas combined was stable during both study periods, with no departure from linearity. In an analysis by age group, increasing incidence was found only for ages 80 years and older (1990-2006). During both study periods, incidence rates were increasing in glioblastoma and decreasing in unspecified brain tumors. In 1990-2006, rates were also increasing for anaplastic oligodendroglioma, oligoastrocytoma and unspecified malignant glioma, while decreasing for astrocytoma. As for tumor location, incidence in 1990-2006 was increasing for frontal lobe and brainstem tumors, as well as those with an unspecified location, but decreasing for the parietal lobes, cerebrum and ventricles. <b>Conclusions:</b> No increasing incidence trend was observed for malignant gliomas overall. An increasing incidence trend of malignant gliomas was found in the oldest age group during 1990-2006. |
2,329,242 | An Intraventricular Type of Chondroma: A Case Report. | Intracranial chondromas are unusual benign tumors. They commonly occur at the base of the skull, whereas an intraventricular type is very rare. We present the case of a 19-year-old female patient with a giant intraventricular chondroma detected incidentally by imaging after a car accident. The spiral head CT scan and MRI findings revealed a large solid mass with a lobular border and coarse calcified components. A wide craniotomy was performed, and a very firm tumor was observed with no internal debulking capacity. The tumor was completely removed in one piece. Differentiation of an intraventricular chondroma from other intraventricular lesions, such as choroid plexus carcinoma, meningioma, and cavernoma, is of great importance in neuroimaging and surgical planning. |
2,329,243 | Morphological classification of the moderator band and its relationship with the anterior papillary muscle. | This study investigated and classified the various types of moderator band (MB) in relation to the anterior papillary muscle, with the aim of providing anatomical reference information and fundamental knowledge for use when repairing the congenital defects and understanding the conduction system. The study investigated 38 formalin-fixed human hearts of both sexes obtained from donors aged 38-90 years. The MB was evident in 36 of the 38 specimens (94.7%). The morphology of the MB and its connection with the APM took various forms. The MBs that had a distinct shape were classified into three types according to their shape: cylindrical column, long and thin column, and wide and flat column. Types 2 and 3 were the most common, appearing in 15 (41.7%) and 14 (38.9%) of the 36 specimens, respectively, while type 1 was observed in seven specimens (19.4%). Type 3 was divided into subtypes based on their length. The MB usually originated from a single root (91.7%), with the remainder exhibiting double roots. The pairs of roots in the latter cases had different shapes. The originating point of the MB ranged from the supraventricular crest to the apex of the ventricle. The most-common originating point was in the middle (25 of 36 specimens, 69.4%), followed by the upper third (13.9%), the lower third (11.1%), and the top fifth (5.6%) of the interventricular septum. This study has produced fundamental anatomical and clinical information that will be useful when designing cardiac surgical procedures. |
2,329,244 | Short-term effects of sleeve gastrectomy on weight loss and diastolic function in obese patients. | diac structure and function in obese patients. This study was an examination of the short-term effects of sleeve gastrectomy on body measurements and diastolic function.</AbstractText>A total of 41 consecutive obese patients who were scheduled to undergo a sleeve gastrectomy procedure were included in the study. Baseline body and echocardiographic measurements and the follow-up counterpart data, including total and excess weight loss percentages, were recorded.</AbstractText>The mean age of the patients was 42.85+-11.47 years. Of the total, 21 (51.1%) patients were female. The mean body mass index (BMI) was 44.86+-5.62 kg/m². The mean duration of follow-up was 91.24+-44.48 days. The participants demonstrated statistically significant weight loss (26.64+-10.95 kg), as well as a decrease in BMI (8.84+-3.93 kg/m²) and body surface area (0.27+-0.12 m²). A significant increase in E velocity and mitral annular e velocity were observed, as well as a significant decrease in A velocity, E/e ratio, left ventricle mass, and left atrial volume (LAV). No significant correlations between the body measurement changes and changes in echocardiographic parameters were observed, with the exception that the excessive weight loss percentage was moderately correlated with a change in LAV.</AbstractText>Sleeve gastrectomy led to a significant decrease in body weight and improved diastolic function parameters in the short-term. No significant relationship was found between the amount of weight loss and change in echocardiographic measurements.</AbstractText> |
2,329,245 | Right ventricular function after cardiac surgery: the diagnostic and prognostic role of echocardiography. | Cardiac surgical techniques and circulatory supports have strongly evolved in the last years. Right ventricular (RV) function during the post-operatory period is still subject of study, although its relevant prognostic impact has been variably described in different papers. RV post-surgical dysfunction's underlying mechanisms are still not clear and include a different hypothesis. Echocardiography, with both first and second level parameters, offers the possibility to accurately analyze the right ventricle and optimize these patients' management. This paper describes the pathophysiology of the right ventricle, the most used echo indexes of RV function, whether they alter after surgery, the different supposed mechanisms of RV dysfunction and its role in the prognosis of patients undergoing cardiac surgery. |
2,329,246 | CKLF1 Aggravates Focal Cerebral Ischemia Injury at Early Stage Partly by Modulating Microglia/Macrophage Toward M1 Polarization Through CCR4. | CKLF1 is a chemokine with increased expression in ischemic brain, and targeting CKLF1 has shown therapeutic effects in cerebral ischemia model. Microglia/macrophage polarization is a mechanism involved in poststroke injury expansion. Considering the quick and obvious response of CKLF1 and expeditious evolution of stroke lesions, we focused on the effects of CKLF1 on microglial/macrophage polarization at early stage of ischemic stroke (IS). The present study is to investigate the CKLF1-mediated expression of microglia/macrophage phenotypes in vitro and in vivo, discussing the involved pathway. Primary microglia culture was used in vitro, and mice transient middle cerebral artery occlusion (MCAO) model was adopted to mimic IS. CKLF1 was added to the primary microglia for 24 h, and we found that CKLF1 modulated primary microglia skew toward M1 phenotype. In mice transient IS model, CKLF1 was stereotactically microinjected to the lateral ventricle of ischemic hemisphere. CKLF1 aggravated ischemic injury, accompanied by promoting microglia/macrophage toward M1 phenotypic polarization. Increased expression of pro-inflammatory cytokines and decreased expression of anti-inflammatory cytokines were observed in mice subjected to cerebral ischemia and administrated with CKLF1. CKLF1<sup>-/-</sup> mice were used to confirm the effects of CKLF1. CKLF1<sup>-/-</sup> mice showed lighter cerebral damage and decreased M1 phenotype of microglia/macrophage compared with the WT control subjected to cerebral ischemia. Moreover, NF-κB activation enhancement was detected in CKLF1 treatment group. Our results demonstrated that CKLF1 is an important mediator that skewing microglia/macrophage toward M1 phenotype at early stage of cerebral ischemic injury, which further deteriorates followed inflammatory response, contributing to early expansion of cerebral ischemia injury. Targeting CKLF1 may be a novel way for IS therapy. |
2,329,247 | Schwalbe's Triangular Fossa: Normal and Pathologic Anatomy on Frozen Cadavers. Anatomo-Magnetic Resonance Imaging Comparison and Surgical Implications in Colloid Cyst Surgery. | The fornix is a region of greatest neurosurgical interest in regards to its complex anatomy and surgical approaches to this area. The objective of this study was to evaluate the morphology of the triangular recess (TR) and its role in the growth pattern of the colloid cysts (CC) within the third ventricle and in the choice of the surgical approach for their removal. Furthermore, to compare the results of the dissections with measurements performed on a magnetic resonance imaging scan.</AbstractText>In the anatomic study, 20 cadaveric specimens were dissected and analyzed. In the radiologic study, a magnetic resonance imaging scan was performed in 20 healthy volunteers. In the clinical study, a retrospective analysis of all the patients affected with CCs microsurgically removed at our institute between 2010 and 2018 was conducted.</AbstractText>In the anatomic study, the width, height, and the area of the TR were respectively 0.31 cm, 0.33cm, and 0.051 cm2</sup>. In the radiologic study, 3 different typologies of TR were identified: open recess in ventriculomegaly (7 patients); open recess in physiologic ventricular system (3 patients); closed or blind recess (10 patients). Three different growth patterns of CCs were identified: type 1) CCs localized at the foramen of Monro growing behind the fornix and below the third ventricular roof; type 2) CCs growing rostrally between the column of fornix; and type 3) CCs growing above the plane of the third ventricular roof.</AbstractText>The anatomy of the TR influences the growth pattern of CC within the ventricular cavity and determines the surgical strategy for their removal.</AbstractText>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,248 | Strap Muscle Type I Thyroplasty After Gore-Tex Implant Extrusion: Case Report and Literature Review. | To discuss the presentation and management techniques of implant extrusion following type I thyroplasty and to illustrate the potential of strap muscle for augmentation following implant removal.</AbstractText>We report a unique case of a patient with late Gore-Tex implant extrusion after type I thyroplasty treated with removal and autologous strap muscle graft for augmentation.</AbstractText>A 41-year-old female nearly 3.5 years status post Gore-Tex type I thyroplasty for left vocal fold paralysis presented for evaluation of dysphonia. Upon flexible laryngoscopy, erythema, edema, and granulation tissue were identified at the left vocal fold and ventricle. The patient subsequently underwent removal of her implant. Intraoperatively, a free portion of sternothyroid muscle was dissected free and placed into the paraglottic space. One month following surgery, the patient reported an improvement in her Voice Handicap Index (VHI) score from 40 to 0. In addition, no major complications were observed and complete glottic closure was achieved. Nine months postsurgery, she continued to function well with a VHI score of 0. At 50 months postop, the patient still reports a VHI score of 0.</AbstractText>Implant extrusion is a rare complication of type I thyroplasty usually occurring in the first few months after surgery and more commonly presenting in females. Current management options consist of observation or augmentation with autologous fat or vocal fold injection following implant removal. This is the first report of a successful strap muscle free graft revision thyroplasty following implant extrusion. The patient's excellent long-term outcome highlights the potential of strap muscle augmentation as a feasible management option for implant extrusion.</AbstractText>Copyright © 2019 The Voice Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,249 | Endoscopic Transanterior Middle Temporal Approach to the Atrium-An Anatomical Feasibility Study. | The atrium is the most common location for masses in the lateral ventricle. However, access to this area is limited owing to its deep location and adjacent eloquent neurovascular structures, such as the choroidal arteries, perisylvian white matter (WM) tracts, and optic radiations. We investigated the feasibility and safety of an endoscopic approach to the atrium via the anterior middle temporal gyrus (MTG).</AbstractText>Radiological assessment of a minimally invasive surgical trajectory to the atrium was achieved in 10 patients. Surgical simulation to assess the feasibility of our endoscopic approach was performed on 24 cadaveric specimens using a transzygomatic corridor and temporal craniotomy. Preoperative computed tomography was performed to confirm the surgical trajectory using neuronavigation. Using Klinger's method, 5 hemispheres were dissected to assess the relationship of our approach to the WM tracts.</AbstractText>The optimal entry angle to reach the atrium through the anterior MTG was related to the temporal horn in the axial plane and to the Sylvian fissure in the sagittal plane. Our entry point in the anterior MTG was 19 ± 1.92 mm from the temporal pole. The transparenchymal distance to atrium was 24.55 ± 4.3 mm. The WM dissections confirmed that our approach did not violate the optic radiations, uncinate fasciculus, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, or superior longitudinal fasciculus.</AbstractText>Our findings have confirmed the feasibility of an anterior endoscopic approach to the atrium through the anterior MTG, with preservation of the functional integrity of the eloquent cortex and WM tracts.</AbstractText>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,250 | Hepatocellular carcinoma diagnosed in a patient who had Fontan operation 30 years ago: a case report. | The Fontan operation is performed in patients with a single ventricle. As the systemic venous return is directly connected to the pulmonary circulation during this procedure, chronic hepatic congestion is induced, leading to Fontan-associated liver disease (FALD) including liver cirrhosis and hepatocellular carcinoma (HCC). In this report, we present a case of HCC diagnosed in a patient who underwent the Fontan operation 30 years ago. The patient underwent regular surveillance for FALD, which revealed a 4 cm-sized hepatic mass with elevated serum alpha-fetoprotein. After surgical treatment, there was no evidence of HCC recurrence during 3 years of follow-up. As the risk of HCC and Fontan-associated liver cirrhosis increases with the duration elapsed since the operation, regular surveillance should be emphasized. Serial follow-up of serum alpha-fetoprotein levels and abdominal imaging are necessary to achieve early and accurate diagnosis of HCC in post-Fontan patients. |
2,329,251 | Left Atrial-Veno-Arterial Extracorporeal Membrane Oxygenation: Step-By-Step Procedure and Case Example. | Veno-arterial extracorporeal membrane oxygenation is used in patients requiring biventricular support; however, its use increases the afterload. In patients with severe aortic insufficiency or severe left ventricular disfunction, it will increase left-side filling pressures, hence the need for left ventricle unloading with an additional mechanical circulatory support device. We present a case of a patient with cardiogenic shock and severe aortic insufficiency who underwent left atrial veno-arterial extracorporeal membrane oxygenation and provide a step-by-step explanation of the technique. |
2,329,252 | Synchronous Bilateral Laryngeal Oncocytic Papillary Cystadenoma: An Uncommon Occurrence. | Oncocytic papillary cystadenoma is a rare, benign tumor highly uncommon in the larynx. Although controversy exists regarding its true nature it is considered a phenomenon of metaplasia. We present the case of a 57-year-old patient with synchronous, bilateral oncocytic papillary cystadenoma of the ventricles and we discuss the current literature. |
2,329,253 | Endoscopic Endonasal Approach to the Third Ventricle Using the Surgical Corridor of the Reverse Third Ventriculostomy: Anatomo-Surgical Nuances. | <b>Objective</b>  Surgical access to the third ventricle can be achieved through various corridors depending on the location and extent of the lesion; however, traditional transcranial approaches risk damage to multiple critical neural structures. <b>Methods</b>  Endonasal approach similar to corridor of the reverse third ventriculostomy (ERTV) was surgically simulated in eight cadaveric heads. Fiber dissections were additionally performed within the third ventricle along the endoscopic route. Additionally, we present a case of ERTV in a patient with craniopharyngioma extending into the third ventricle. <b>Results</b>  The ERTV allowed adequate intraventricular visualization along the third ventricle. The extracranial step of the surgical corridor included a bony window in the sellar floor, tuberculum sella, and the lower part of the planum sphenoidale. ERTV provided an intraventricular surgical field along the foramen of Monro to expose an area bordered by the fornix anteriorly, thalamus laterally, anterior commissure anterior superiorly, posterior commissure, habenula and pineal gland posteriorly, and aqueduct of Sylvius centered posterior inferiorly. <b>Conclusion</b>  The third ventricle can safely be accessed through ERTV either above or below the pituitary gland. ERTV provides a wide exposure of the third ventricle through the tuber cinereum and offers access to the anterior part as far as the anterior commissure and precommissural part of fornix and the whole length of the posterior part. Endoscopic ERTV may be a suitable alternative to transcranial approaches to access the third ventricle in selected patients. |
2,329,254 | Revisiting Folger's pouch in double-chambered right ventricle. | Folger's pouch is a right ventricular outflow pouch arising from the distal low-pressure chamber in double-chambered right ventricle. It is rarely described on echocardiogram due to difficult visualization and lack of knowledge of its existence. Retrospective assessment of echocardiogram after an angiocardiographic evaluation demonstrates the pouch in a modified high parasternal view. |
2,329,255 | First Report of Massive Myocardial Calcifications in a Vervet Monkey (<i>Chlorocebus pygerythrus</i>). | A 13-years-old male vervet monkey that was kept in a primates breeding and research facility at Razi Vaccine and Serum Research Institute, Karaj, Iran (RVSRI) died suddenly. Massively scattered grayish-yellow mottling on both ventricles were the most significant gross necropsy findings. There was a gritty feeling on palpation and sectioning of the yellow areas. Microscopically, the lesions demonstrated scattered degeneration and necrosis of myocardial cells. Inside the affected areas, large calcium deposit plaques were detected using the Von kossa staining method. The development of myocardial calcification in the present case can be attributed to the dystrophic calcification following spontaneous myocardial necrosis or an undetected infection/inflammatory process. Persistent anxiety might trigger spontaneous biventricular necrosis in vervet monkeys. In conclusion, due to similarities between the clinical and histological presentation of the current case with sudden death syndrome associated with myocardial calcification in humans, it was suggested that vervet monkeys might be a relevant animal model for research on the pathophysiological processes of this complication. |
2,329,256 | How I do it: Novel technique to "Unmask" and treat congenital portosystemic venous connections in congenital heart disease. | Congenital portosystemic venous connections are rare vascular anomalies that connect the portal and systemic venous circulations. These vascular lesions can lead to complex and varied physiologic manifestations in single-ventricle patients as they progress through the various stages of palliation in the Fontan pathway. Specifically, these connections may be unmasked after a superior cavopulmonary anastomosis operation, but then "re-masked" after Fontan completion. We describe the complex physiology with an illustrative case report and present a novel method to unmask these pathologic connections after Fontan completion to facilitate transcatheter occlusion and resolve downstream symptoms. |
2,329,257 | Rodent models of senile normal-pressure hydrocephalus. | Cerebrospinal fluid (CSF) and its drainage are crucial in clearing metabolic waste and maintaining the microenvironment of the central nervous system for proper functioning. Normal-pressure hydrocephalus (NPH) is a serious neurological disorder of the elderly with obstruction of CSF flow outside the cerebral ventricles, causing ventriculomegaly. The stasis of CSF in NPH compromises brain functioning. Although treatable, often with shunt implantation for drainage, the outcome depends highly on early diagnosis, which, however, is challenging. The initial symptoms of NPH are hard to be aware of and the complete symptoms overlap with those of other neurological diseases. Ventriculomegaly is not specific to NPH as well. The lack of knowledge on the initial stages in its development and throughout its progression further deters early diagnosis. Thus, we are in dire need for an appropriate animal model for researches into a more thorough understanding of its development and pathophysiology so that we can enhance the diagnosis and therapeutic strategies to improve the prognosis of NPH following treatment. With this, we review the few currently available experimental rodent NPH models for these animals are smaller in sizes, easier in maintenance, and having a rapid life cycle. Among these, a parietal convexity subarachnoid space kaolin injection adult rat model appears promising as it shows a slow onset of ventriculomegaly in association with cognitive and motor disabilities resembling the elderly NPH in humans. |
2,329,258 | Oncocytic Papillary Cystadenoma, an Unusual Variant Presenting as a Laryngeal Ventricular Cyst. | Cystadenoma arising from the larynx is a rare benign minor salivary gland tumor that can show mucinous or papillary morphology. The epithelial lining of the salivary gland tumor can present with oncocytic features, which is attributed to an increased number of mitochondria. We present a rare case of oncocytic papillary cystadenoma (OPC) of the larynx which has a combination of these features. The WHO defines OPC tumors as entities which closely resemble Warthin tumor, but lack its classic lymphoid component. The immunohistochemical profile and molecular genetic features are largely unknown. We present an 84-year-old female, former smoker, who presented with progressive dysphonia, dysphagia, and shortness of breath. Laryngoscopy revealed a large, smooth mass originating from the ventricle of the right vocal fold. Subsequent biopsy demonstrated cyst wall fragments lined by a bilayer of large columnar to cuboidal oncocytic cells that had granular eosinophilic cytoplasm, round to oval nuclei with finely dispersed chromatin, and small but distinct nucleoli. The surrounding stroma was slightly fibrotic with scant lymphoid elements. No nuclear pleomorphism, increased mitosis, or necrosis was identified. In the larynx, benign salivary gland tumors are rare and less frequent than malignant neoplasms. Awareness of rare benign entities like OPC help ensure proper management and aid in avoiding unnecessary therapy. |
2,329,259 | Interventricular-Septal Output While Supported on Left Ventricular Assist Device Therapy.<Pagination><StartPage>424</StartPage><EndPage>428</EndPage><MedlinePgn>424-428</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001851</ELocationID><Abstract><AbstractText>The effects of left ventricular unloading on septal function in patients with left ventricular assist devices (LVADs) have not been well characterized in vivo. The purpose of this study was to evaluate the relationship between markers of septal function with echocardiography in relationship to RV dysfunction and late RV failure after LVAD implantation. A retrospective study was conducted of patients supported on centrifugal-flow LVADs implanted over a 10-year period. Echocardiographic data were collected pre-operatively and up to 2 years after implantation. Interventricular septum (IVS) measurements were taken at end-systole and end-diastole. Interventricular-septal output (ISO) was calculated using the formula: (IVSs-IVSd)×heart rate. A total of 110 patients were included. An immediate and sustained reduction in both lateral annulus systolic velocity (RVS') and TAPSE were observed after implant ( p < 0.0001). However, ISO gradually decreased over time ( p < 0.0001). While ISO was not predictive of late RV failure, a decrease in ISO by 25% or greater from pre-implant to hospital discharge was associated with late RV failure (OR 4.8; 95% CI, 1.4-16.5; p = 0.012) even after adjusting for relevant clinical variables ( p ≤ 0.01 for each model). RV function is known to be influenced by mechanical ventricular interdependence and we demonstrate that measurement of ISO may be a useful marker in assessing RV dysfunction and predicting RV failure in patients following LVAD implantation.</AbstractText><CopyrightInformation>Copyright © ASAIO 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inglis</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>From the Internal Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villavicencio</LastName><ForeName>Mauricio T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schettle</LastName><ForeName>Sarah D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stulak</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clavell</LastName><ForeName>Alfredo L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kushwaha</LastName><ForeName>Sudhir S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behfar</LastName><ForeName>Atta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbaum</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054088" MajorTopicYN="Y">Ventricular Septum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="Y">Ventricular Dysfunction, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>There are no conflicts of interest to disclose and no sources of funding.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>15</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36730725</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001851</ArticleId><ArticleId IdType="pii">00002480-990000000-00122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lampert BC, Teuteberg JJ: Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant 34: 1123–1130, 2015.</Citation></Reference><Reference><Citation>Frankfurter C, Molinero M, Vishram-Nielsen JKK, et al.: Predicting the risk of right ventricular failure in patients undergoing left ventricular assist device implantation: A systematic review. Circ Heart Fail 13: 518–528, 2020.</Citation></Reference><Reference><Citation>Hayek S, Sims DB, Markham DW, Butler J, Kalogeropoulos AP: Assessment of right ventricular function in left ventricular assist device candidates. Circ Cardiovas Imaging 7: 379–389, 2014.</Citation></Reference><Reference><Citation>Moon MR, Bolger AF, Deanda A, et al.: Septal function during left ventricular unloading. Circulation 95: 1320–1327, 1997.</Citation></Reference><Reference><Citation>Fida N, Loebe M, Estep JD, Guha A: Predictors and management of right heart failure after left ventricular assist device implantation. Methodist Debakey Cardiovas J 11: 18–23, 2015.</Citation></Reference><Reference><Citation>Aissaoui N, Salem JE, Paluszkiewicz L, et al.: Assessment of right ventricular dysfunction predictors before the implantation of a left ventricular assist device in end-stage heart failure patients using echocardiographic measures (ARVADE): Combination of left and right ventricular echocardiographic variables. Arch Cardiovas Dis 108: 300–309, 2015.</Citation></Reference><Reference><Citation>Puwanant S, Hamilton KK, Klodell CT, et al.: Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant 27: 1102–1107, 2018.</Citation></Reference><Reference><Citation>Potapov E, Stepanenko A, Dandel M, et al.: Tricuspid incompetence and geometry of the right ventricle as predictors of right ventricular function after implantation of a left ventricular assist device. J Heart Lung Transplant 27: 1275–1281, 2008.</Citation></Reference><Reference><Citation>Daly RC, Chandrasekaran K, Cavarocchi NC, Tajik AJ, Schaff HV: Ischemia of the interventricular septum: A mechanism of right ventricular failure during mechanical left ventricular assist. J Thorac Cardiovasc Surg 103: 1186–1191, 1992.</Citation></Reference><Reference><Citation>Topilsky Y, Hasin T, Oh JK, et al.: Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. Circ Cardiovas Imaging 4: 648–661, 2011.</Citation></Reference><Reference><Citation>Unsworth B, Casula RP, Yadav H, et al.: Contrasting effect of different cardiothoracic operations on echocardiographic right ventricular long axis velocities, and implications for interpretation of post-operative values. Int J Cardiol 165: 151–160, 2013.</Citation></Reference><Reference><Citation>Bitcon CJ, Tousignant C: The effect of pericardial incision on right ventricular systolic function: A prospective observational study. Can J Anesth 64: 1194–1201, 2017.</Citation></Reference><Reference><Citation>Addetia K, Uriel N, Maffessanti F, et al.: 3D Morphological changes in LV and RV during LVAD ramp studies. JACC Cardiovas Imaging 11: 159–169, 2018.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36728820</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-4683</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>29</Day></PubDate></JournalIssue><Title>Cardiology in review</Title><ISOAbbreviation>Cardiol Rev</ISOAbbreviation></Journal>Stress and Rest Pulmonary Transit Times Assessed by Cardiovascular Magnetic Resonance. | The effects of left ventricular unloading on septal function in patients with left ventricular assist devices (LVADs) have not been well characterized in vivo. The purpose of this study was to evaluate the relationship between markers of septal function with echocardiography in relationship to RV dysfunction and late RV failure after LVAD implantation. A retrospective study was conducted of patients supported on centrifugal-flow LVADs implanted over a 10-year period. Echocardiographic data were collected pre-operatively and up to 2 years after implantation. Interventricular septum (IVS) measurements were taken at end-systole and end-diastole. Interventricular-septal output (ISO) was calculated using the formula: (IVSs-IVSd)×heart rate. A total of 110 patients were included. An immediate and sustained reduction in both lateral annulus systolic velocity (RVS') and TAPSE were observed after implant ( p < 0.0001). However, ISO gradually decreased over time ( p < 0.0001). While ISO was not predictive of late RV failure, a decrease in ISO by 25% or greater from pre-implant to hospital discharge was associated with late RV failure (OR 4.8; 95% CI, 1.4-16.5; p = 0.012) even after adjusting for relevant clinical variables ( p ≤ 0.01 for each model). RV function is known to be influenced by mechanical ventricular interdependence and we demonstrate that measurement of ISO may be a useful marker in assessing RV dysfunction and predicting RV failure in patients following LVAD implantation.<CopyrightInformation>Copyright © ASAIO 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inglis</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>From the Internal Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villavicencio</LastName><ForeName>Mauricio T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schettle</LastName><ForeName>Sarah D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stulak</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clavell</LastName><ForeName>Alfredo L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kushwaha</LastName><ForeName>Sudhir S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behfar</LastName><ForeName>Atta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbaum</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054088" MajorTopicYN="Y">Ventricular Septum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="Y">Ventricular Dysfunction, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>There are no conflicts of interest to disclose and no sources of funding.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>15</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36730725</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001851</ArticleId><ArticleId IdType="pii">00002480-990000000-00122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lampert BC, Teuteberg JJ: Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant 34: 1123–1130, 2015.</Citation></Reference><Reference><Citation>Frankfurter C, Molinero M, Vishram-Nielsen JKK, et al.: Predicting the risk of right ventricular failure in patients undergoing left ventricular assist device implantation: A systematic review. Circ Heart Fail 13: 518–528, 2020.</Citation></Reference><Reference><Citation>Hayek S, Sims DB, Markham DW, Butler J, Kalogeropoulos AP: Assessment of right ventricular function in left ventricular assist device candidates. Circ Cardiovas Imaging 7: 379–389, 2014.</Citation></Reference><Reference><Citation>Moon MR, Bolger AF, Deanda A, et al.: Septal function during left ventricular unloading. Circulation 95: 1320–1327, 1997.</Citation></Reference><Reference><Citation>Fida N, Loebe M, Estep JD, Guha A: Predictors and management of right heart failure after left ventricular assist device implantation. Methodist Debakey Cardiovas J 11: 18–23, 2015.</Citation></Reference><Reference><Citation>Aissaoui N, Salem JE, Paluszkiewicz L, et al.: Assessment of right ventricular dysfunction predictors before the implantation of a left ventricular assist device in end-stage heart failure patients using echocardiographic measures (ARVADE): Combination of left and right ventricular echocardiographic variables. Arch Cardiovas Dis 108: 300–309, 2015.</Citation></Reference><Reference><Citation>Puwanant S, Hamilton KK, Klodell CT, et al.: Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant 27: 1102–1107, 2018.</Citation></Reference><Reference><Citation>Potapov E, Stepanenko A, Dandel M, et al.: Tricuspid incompetence and geometry of the right ventricle as predictors of right ventricular function after implantation of a left ventricular assist device. J Heart Lung Transplant 27: 1275–1281, 2008.</Citation></Reference><Reference><Citation>Daly RC, Chandrasekaran K, Cavarocchi NC, Tajik AJ, Schaff HV: Ischemia of the interventricular septum: A mechanism of right ventricular failure during mechanical left ventricular assist. J Thorac Cardiovasc Surg 103: 1186–1191, 1992.</Citation></Reference><Reference><Citation>Topilsky Y, Hasin T, Oh JK, et al.: Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. Circ Cardiovas Imaging 4: 648–661, 2011.</Citation></Reference><Reference><Citation>Unsworth B, Casula RP, Yadav H, et al.: Contrasting effect of different cardiothoracic operations on echocardiographic right ventricular long axis velocities, and implications for interpretation of post-operative values. Int J Cardiol 165: 151–160, 2013.</Citation></Reference><Reference><Citation>Bitcon CJ, Tousignant C: The effect of pericardial incision on right ventricular systolic function: A prospective observational study. Can J Anesth 64: 1194–1201, 2017.</Citation></Reference><Reference><Citation>Addetia K, Uriel N, Maffessanti F, et al.: 3D Morphological changes in LV and RV during LVAD ramp studies. JACC Cardiovas Imaging 11: 159–169, 2018.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36728820</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-4683</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>29</Day></PubDate></JournalIssue><Title>Cardiology in review</Title><ISOAbbreviation>Cardiol Rev</ISOAbbreviation></Journal><ArticleTitle>Stress and Rest Pulmonary Transit Times Assessed by Cardiovascular Magnetic Resonance.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CRD.0000000000000495</ELocationID><Abstract>Acquiring pulmonary circulation parameters as a potential marker of cardiopulmonary function is not new. Methods to obtain these parameters have been developed over time, with the latest being first-pass perfusion sequences in cardiovascular magnetic resonance (CMR). Even though more data on these parameters has been recently published, different nomenclature and acquisition methods are used across studies; some works even reported conflicting data. The most commonly used circulation parameters obtained using CMR include pulmonary transit time (PTT) and pulmonary transit beats (PTB). PTT is the time needed for a contrast agent (typically gadolinium-based) to circulate from the right ventricle (RV) to the left ventricle (LV). PTB is the number of cardiac cycles the process takes. Some authors also include corrected heart rate (HR) versions along with standard PTT. Besides other methods, CMR offers an option to assess stress circulation parameters, but data are minimal. This review aims to summarize the up-to-date findings and provide an overview of the latest progress on this promising, dynamically evolving topic. |
2,329,260 | [Hydrocephalus in children: clinical, paraclinical and therapeutic features in four medical facilities in Lubumbashi]. | hydrocephalus is a progressive distension of the anatomical spaces (ventricles and subarachnoid space) containing the cerebrospinal fluid. It most commonly affects children. In developed countries, its prevalence and incidence are estimated between 0.9 to 1.2 per 1000 and 0.2 to 0.6 per 1000 live births respectively and between 50 000 and 100 000 new cases develop each year in the world. The purpose of this study was to describe the clinical, paraclinical and therapeutic features of hydrocephalus in 4 medical facilities in Lubumbashi.</AbstractText>we conducted a descriptive cross-sectional study at the University Clinics of Lubumbashi, Cinquantenaire Hospital, Sendwe General Reference Hospital and ARS Clinic from April 1st</sup>, 2015 to September 30th</sup>, 2019. Data were collected on the basis of a data collection sheet containing several study parameters including age, sex, clinical signs, birth weight, patient's history, head circumference, CT scan assessment and disease progression. Our sample consisted of 91 subjects with hydrocephalus.</AbstractText>the age group 29 days to 24 months (infant) was most commonly affected, i.e. 57.14%, with a sex ratio of 1.67 and a male predominance. The main detecting sign was macrocrania in all patients, followed by setting-sun sign in 53.85% of patients. Brain CT scan was performed in all patients and 65.92% of them had tetraventricular hydrocephalus. Ventriculoperitoneal shunt was performed in all patients. There were no deaths in the postoperative period; postoperative infectious and mechanical complications accounted for 8.79% and 4.40% respectively. The average length of stay in the hospital was 5.65 days.</AbstractText>hydrocephalus is the most common reason for pediatric neurosurgery. Clinicians should focus on these results which highlight the importance of early diagnosis and proper management.</AbstractText>Copyright: Nathalie Dinganga Kapessa et al.</CopyrightInformation> |
2,329,261 | A Low-Molecular-Weight BDNF Mimetic, Dipeptide GSB-214, Prevents Memory Impairment in Rat Models of Alzheimer's Disease. | Brain-derived neurotrophic factor (BDNF) is known to be involved in the pathogenesis of Alzheimer's disease (AD). However, the pharmacological use of full-length neurotrophin is limited, because of its macromolecular protein nature. A dimeric dipeptide mimetic of the BDNF loop 1, bis-(N-monosuccinyl-L-methionyl-L-serine) heptamethylene diamide (GSB-214), was designed at the Zakusov Research Institute of Pharmacology. GSB-214 activates TrkB, PI3K/AKT, and PLC-γ1 in vitro. GSB-214 exhibited a neuroprotective activity during middle cerebral artery occlusion in rats when administered intraperitoneally (i.p.) at a dose of 0.1 mg/kg and improved memory in the novel object recognition test (0.1 and 1.0 mg/kg, i.p.). In the present study, we investigated the effects of GSB-214 on memory in the scopolamine- and steptozotocin-induced AD models, with reference to activation of TrkB receptors. AD was modeled in rats using a chronic i.p. scopolamine injection or a single streptozotocin injection into the cerebral ventricles. GSB-214 was administered within 10 days after the exposure to scopolamine at doses of 0.05, 0.1, and 1 mg/kg (i.p.) or within 14 days after the exposure to streptozotocin at a dose of 0.1 mg/kg (i.p.). The effect of the dipeptide was evaluated in the novel object recognition test; K252A, a selective inhibitor of tyrosine kinase receptors, was used to reveal a dependence between the mnemotropic action and Trk receptors. GSB-214 at doses of 0.05 and 0.1 mg/kg statistically significantly prevented scopolamine-induced long-term memory impairment, while not affecting short-term memory. In the streptozotocin-induced model, GSB-214 completely eliminated the impairment of short-term memory. No mnemotropic effect of GSB-214 was registered when Trk receptors were inhibited by K252A. |
2,329,262 | Clinical prognostic factors for central neurocytoma and subgroup analysis of different treatment measures: A SEER database-based retrospective analysis from 2003 to 2019. | The study aimed to identify clinical prognostic factors affecting overall survival (OS) in patients with central neurocytoma (CN) and to determine independent prognostic factors in the subgroups of different treatment modalities using a retrospective analysis based on the SEER database from 2003 to 2019.</AbstractText>Data regarding patients with CN, including basic clinical characteristics, treatment measures, and prognosis follow-up, were extracted from the SEER database. The prognostic variables for all patients were assessed using log-rank test as well as univariate and multivariate analyses based on the Cox proportional hazards model. The same statistical methods were used for analysis in different subgroups of gross total resection (GTR), subtotal resection (STR), no surgery, radiotherapy (RT), and no RT.</AbstractText>In total, 413 patients were enrolled in this study. Tumor size, primary site surgery, and RT were independent prognostic factors in all patients with CN. In subgroup analyses, RT was not an independent prognostic factor in patients with GTR. However, sex and race were independent prognostic factors in patients with STR. Additionally, tumor size was an independent prognostic factor in patients who did not undergo surgery. Furthermore, sex and primary site were independent prognostic factors in patients who received RT. Size and primary site surgery were independent prognostic factors in patients without RT.</AbstractText>In our study, patients with small tumors or GTR or those who did not receive RT showed a better prognosis. GTR was the preferred treatment for CN. RT was not recommended for patients after GTR. Men and African American showed certain advantages after STR surgery. Tumors with a size of >4 cm were recommended for active treatment. In the RT subgroup, patients with tumors outside the ventricle or women had a poorer prognosis than those with tumors within the ventricle or men, respectively. These findings will help clinicians and patients understand the treatment and prognosis of CN visually and intuitively.</AbstractText>Copyright © 2023 Zhang, Yu, Zhang, Pang, Wei, Lv, Chen, Jin and Zhan.</CopyrightInformation> |
2,329,263 | Ontogeny of ependymoglial cells lining the third ventricle in mice. | During hypothalamic development, the germinative neuroepithelium gives birth to diverse neural cells that regulate numerous physiological functions in adulthood.</AbstractText>Here, we studied the ontogeny of ependymal cells in the mouse mediobasal hypothalamus using the BrdU approach and publicly available single-cell RNAseq datasets.</AbstractText>We observed that while typical ependymal cells are mainly produced at E13, tanycyte birth depends on time and subtypes and lasts up to P8. Typical ependymocytes and β tanycytes are the first to arise at the top and bottom of the dorsoventral axis around E13, whereas α tanycytes emerge later in development, generating an outside-in dorsoventral gradient along the third ventricle. Additionally, α tanycyte generation displayed a rostral-to-caudal pattern. Finally, tanycytes mature progressively until they reach transcriptional maturity between P4 and P14.</AbstractText>Altogether, this data shows that ependyma generation differs in time and distribution, highlighting the heterogeneity of the third ventricle.</AbstractText>Copyright © 2023 Lopez-Rodriguez, Rohrbach, Lanzillo, Gervais, Croizier and Langlet.</CopyrightInformation> |
2,329,264 | Effects of RFRP‑3 on an ovariectomized estrogen‑primed rat model and HEC‑1A human endometrial carcinoma cells. | The hypothalamic peptide gonadotropin inhibitory hormone (GnIH) is a relatively novel hypothalamic neuropeptide, identified in 2000. It can influence the hypothalamic-pituitary-gonadal axis and reproductive function through various neuroendocrine systems. The present study aimed to explore the effects and potential underlying molecular mechanism of RFamide-related peptide-3 (RFRP-3) injection on the uterine fluid protein profile of ovariectomized estrogen-primed (OEP) rats using proteomics. In addition, the possible effects of RFRP-3 on the viability and apoptosis of the human endometrial cancer cell line HEC-1A and associated molecular mechanism were investigated. The OEP rat model was established through injection with GnIH/RFRP-3 through the lateral ventricle. At 6 h after injection, the protein components of uterine fluid of rats in the experimental and control groups were analyzed using liquid chromatography (LC)-tandem mass spectrometry (MS/MS). Differentially expressed proteins (DEPs) were analyzed using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Protein-protein interactions (PPI) were investigated using the STRING database. PPI networks were then established before hub proteins were selected using OmicsBean software. The expression of one of the hub proteins, Kras, was then detected using western blot analysis. Cell Counting Kit-8, Annexin V-FITC/PI, reverse transcription-quantitative PCR and western blotting were also performed to analyze cell viability and apoptosis. In total, 417 DEPs were obtained using LC-MS/MS, including 279 upregulated and 138 downregulated proteins. GO analysis revealed that the majority of the DEPs were secretory proteins. According to KEGG enrichment analysis, the DEPs found were generally involved in tumor-associated pathways. In particular, five hub proteins, namely G protein subunit α (Gna)13, Gnaq, Gnai3, Kras and MMP9, were obtained following PPI network analysis. Western blot analysis showed that expression of the hub protein Kras was downregulated following treatment with 10,000 ng/ml RFRP-3. RFRP-3 treatment (10,000 ng/ml) also suppressed HEC-1A cell viability, induced apoptosis, downregulated Bcl-2 and upregulated Bax protein expression, compared with those in the control group. In addition, compared with those in the control group, RFRP-3 significantly reduced the mRNA expression levels of PI3K, AKT and mTOR, while upregulating those of LC3-II. Compared with those in the control group, RFRP-3 significantly decreased the protein expression levels of PI3K, AKT, mTOR and p62, in addition to decreasing AKT phosphorylation. By contrast, RFRP-3 significantly increased the LC3-II/I ratio and G protein-coupled receptor 147 (GPR147) protein expression. In conclusion, the present data suggest that RFRP-3 can alter the protein expression profile of the uterine fluid of OEP rats by upregulating MMP9 expression whilst downregulating that of key hub proteins Gna13, GnaQ, Gnai3 and Kras. Furthermore, RFRP-3 can inhibit HEC-1A cell viability while promoting apoptosis. The underlying molecular mechanism may involve activation of GPR147 receptor by the direct binding of RFRP-3, which further downregulates the hub protein Kras to switch on the PI3K/AKT/mTOR pathway. This subsequently reduces the Bcl-2 expression and promotes Bax expression to induce autophagy. |
2,329,265 | Impact of aging on mitochondrial respiration in various organs. | Mitochondria are considered central regulator of the aging process; however, majority of studies dealing with the impact of age on mitochondrial oxygen consumption focused on skeletal muscle concluding (although not uniformly) a general declining trend with advancing age. In addition, gender related differences in mitochondrial respiration have not been satisfactorily described yet. The aim of the present study was to evaluate mitochondrial oxygen consumption in various organs of aging male and female Fischer 344 rats at the ages of 6, 12 and 24 months. Mitochondrial respiration of homogenized (skeletal muscle, left and right heart ventricle, hippocampus, cerebellum, kidney cortex), gently mechanically permeabilized (liver) tissue or intact cells (platelets) was determined using high-resolution respirometry (oxygraphs O2k, Oroboros, Austria). The pattern of age-related changes differed in each tissue: in the skeletal muscle and kidney cortex of both sexes and in female heart, parameters of mitochondrial respiration significantly declined with age. Resting respiration of intact platelets displayed an increasing trend and it did not correlate with skeletal muscle respiratory states. In the heart of male rats and brain tissues of both sexes, respiratory states remained relatively stable over analyzed age categories with few exceptions of lower mitochondrial oxygen consumption at the age of 24 months. In the liver, OXPHOS capacity was higher in females than in males with either no difference between the ages of 6 and 24 months or even significant increase at the age of 24 months in the male rats. In conclusion, the results of our study indicate that the concept of general pattern of age-dependent decline in mitochondrial oxygen consumption across different organs and tissues could be misleading. Also, the statement of higher mitochondrial respiration in females seems to be conflicting, since the gender-related differences may vary with the tissue studied, combination of substrates used and might be better detectable at younger ages than in old animals. |
2,329,266 | Preliminary Experience Suggests the Addition of Choroid Plexus Cauterization to Functional Hemispherectomy May Reduce Posthemispherectomy Hydrocephalus. | Cerebral hemispherectomy can effectively treat unihemispheric epilepsy. However, posthemispherectomy hydrocephalus (PHH), a serious life-long complication, remains prevalent, requiring careful considerations in technique selection and postoperative management. In 2016, we began incorporating open choroid plexus cauterization (CPC) into our institution's hemispherectomy procedure in an attempt to prevent PHH.</AbstractText>To determine whether routine CPC prevented PHH without exacerbating hemispherectomy efficacy or safety.</AbstractText>A retrospective review of consecutive patients who underwent hemispherectomy for intractable epilepsy between 2011 and 2021 was performed. Multivariate logistic regression was used to identify factors independently associated with PHH requiring cerebrospinal fluid (CSF) shunting.</AbstractText>Sixty-eight patients were included in this study, of whom 26 (38.2%) underwent CPC. Fewer patients required CSF shunting in the CPC group (7.7% vs 28.7%, P = .033) and no patients who underwent de novo hemispherectomy with CPC developed PHH. Both cohorts experienced seizure freedom (65.4% vs 59.5%, P = .634) and postoperative complications, including infection (3.8% vs 2.4%, P = .728), hemorrhage (0.0% vs 2.4%, P = .428), and revision hemispherectomy (19.2% vs 14.3%, P = .591) at similar rates. Patients without CPC had greater odds of developing PHH requiring CSF shunting (odds ratio = 8.36, P = .026). The number needed to treat with CPC to prevent an additional case of PHH was 4.8, suggesting high effectiveness.</AbstractText>Preventing PHH is critical. Our early experience demonstrated that routinely incorporating CPC into hemispherectomy effectively prevents PHH without causing additional complications, especially in first-time hemispherectomies. A multicenter randomized controlled trial with long-term follow-up is required to corroborate the findings of our single-institutional case series and determine whether greater adoption of this technique is justified.</AbstractText>Copyright © Congress of Neurological Surgeons 2022. All rights reserved.</CopyrightInformation> |
2,329,267 | Transitional vascular anomaly of a persistent medial procephalic vein causing obstructive hydrocephalus and intracranial haemorrhage. | We report a case of obstructive hydrocephalus caused by a transitional (shunting) developmental venous anomaly not previously reported in the literature. Both thalami in this patient drain into a midline vein in the floor of the third ventricle that crosses the cerebral aqueduct and exerts mass effect. While this patient's hydrocephalus was managed by a ventriculoperitoneal shunt catheter, their hospital course was complicated by a spontaneous intraparenchymal bleed of the left thalamus thought to be caused by their vascular malformation. Given the risk of venous infarcts, this transitional venous anomaly could not be treated safely. |
2,329,268 | Linear Energy Transfer and Relative Biological Effectiveness Investigation of Various Structures for a Cohort of Proton Patients With Brain Tumors. | The current knowledge on biological effects associated with proton therapy is limited. Therefore, we investigated the distributions of dose, dose-averaged linear energy transfer (LETd</sub>), and the product between dose and LETd</sub> (DLETd</sub>) for a patient cohort treated with proton therapy. Different treatment planning system features and visualization tools were explored.</AbstractText>For a cohort of 24 patients with brain tumors, the LETd</sub>, DLETd</sub>, and dose was calculated for a fixed relative biological effectiveness value and 2 variable models: plan-based and phenomenological. Dose threshold levels of 0, 5, and 20 Gy were imposed for LETd</sub> visualization. The relationship between physical dose and LETd</sub> and the frequency of LETd</sub> hotspots were investigated.</AbstractText>The phenomenological relative biological effectiveness model presented consistently higher dose values. For lower dose thresholds, the LETd</sub> distribution was steered toward higher values related to low treatment doses. Differences up to 26.0% were found according to the threshold. Maximum LETd</sub> values were identified in the brain, periventricular space, and ventricles. An inverse relationship between LETd</sub> and dose was observed. Frequency information to the domain of dose and LETd</sub> allowed for the identification of clusters, which steer the mean LETd</sub> values, and the identification of higher, but sparse, LETd</sub> values.</AbstractText>Identifying, quantifying, and recording LET distributions in a standardized fashion is necessary, because concern exists over a link between toxicity and LET hotspots. Visualizing DLETd</sub> or dose × LETd</sub> during treatment planning could allow for clinicians to make informed decisions.</AbstractText>© 2022 The Authors.</CopyrightInformation> |
2,329,269 | High cardiomyocyte diversity in human early prenatal heart development.<Pagination><StartPage>105857</StartPage><MedlinePgn>105857</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105857</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2022.105857</ELocationID><Abstract><AbstractText>Cardiomyocytes play key roles during cardiogenesis, but have poorly understood features, especially in prenatal stages. Here, we characterized human prenatal cardiomyocytes, 6.5-7 weeks post-conception, by integrating single-cell RNA sequencing, spatial transcriptomics, and ligand-receptor interaction information. Using a computational workflow developed to dissect cell type heterogeneity, localize cell types, and explore their molecular interactions, we identified eight types of developing cardiomyocyte, more than double compared to the ones identified in the <i>Human Developmental Cell Atlas</i>. These have high variability in cell cycle activity, mitochondrial content, and connexin gene expression, and are differentially distributed in the ventricles, including outflow tract, and atria, including sinoatrial node. Moreover, cardiomyocyte ligand-receptor crosstalk is mainly with non-cardiomyocyte cell types, encompassing cardiogenesis-related pathways. Thus, early prenatal human cardiomyocytes are highly heterogeneous and develop unique location-dependent properties, with complex ligand-receptor crosstalk. Further elucidation of their developmental dynamics may give rise to new therapies.</AbstractText><CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sylvén</LastName><ForeName>Christer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wärdell</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Månsson-Broberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cingolani</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cedars-Sinai, Smidt Heart Institute, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ampatzis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Ludvig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Björklund</LastName><ForeName>Åsa</ForeName><Initials>Å</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomello</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Biological sciences</Keyword><Keyword MajorTopicYN="N">Cell biology</Keyword><Keyword MajorTopicYN="N">Transcriptomics</Keyword></KeywordList><CoiStatement>S.G. is scientific advisor to 10x Genomics, which holds IP rights to the ST technology, and holds 10x Genomics stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36624836</ArticleId><ArticleId IdType="pmc">PMC9823232</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105857</ArticleId><ArticleId IdType="pii">S2589-0042(22)02130-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sylva M., van den Hoff M.J.B., Moorman A.F.M. Development of the human heart. Am. J. Med. Genet. 2014;164A:1347–1371. doi: 10.1002/ajmg.a.35896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.35896</ArticleId><ArticleId IdType="pubmed">23633400</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsa L.A., Yang B., Liu J. Embryonic cardiac chamber maturation: trabeculation, conduction, and cardiomyocyte proliferation. Am. J. Med. Genet. C Semin. Med. Genet. 2013;163C:157–168. doi: 10.1002/ajmg.c.31366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31366</ArticleId><ArticleId IdType="pmc">PMC3723796</ArticleId><ArticleId IdType="pubmed">23720419</ArticleId></ArticleIdList></Reference><Reference><Citation>Günthel M., Barnett P., Christoffels V.M. Development, proliferation, and growth of the mammalian heart. Mol. Ther. 2018;26:1599–1609. doi: 10.1016/j.ymthe.2018.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.05.022</ArticleId><ArticleId IdType="pmc">PMC6037201</ArticleId><ArticleId IdType="pubmed">29929790</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRuiter M.C., Gittenberger-De Groot A.C., Wenink A.C., Poelmann R.E., Mentink M.M. In normal development pulmonary veins are connected to the sinus venosus segment in the left atrium. Anat. Rec. 1995;243:84–92. doi: 10.1002/ar.1092430110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1092430110</ArticleId><ArticleId IdType="pubmed">8540635</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber J.W., Boukens B.J., Oostra R.-J., Moorman A.F.M., Christoffels V.M., Jensen B. Sinus venosus incorporation: contentious issues and operational criteria for developmental and evolutionary studies. J. Anat. 2019;234:583–591. doi: 10.1111/joa.12962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joa.12962</ArticleId><ArticleId IdType="pmc">PMC6481585</ArticleId><ArticleId IdType="pubmed">30861129</ArticleId></ArticleIdList></Reference><Reference><Citation>Soufan A.T., van den Hoff M.J.B., Ruijter J.M., de Boer P.A.J., Hagoort J., Webb S., Anderson R.H., Moorman A.F.M. Reconstruction of the patterns of gene expression in the developing mouse heart reveals an architectural arrangement that facilitates the understanding of atrial malformations and arrhythmias. Circ. Res. 2004;95:1207–1215. doi: 10.1161/01.RES.0000150852.04747.e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000150852.04747.e1</ArticleId><ArticleId IdType="pubmed">15550689</ArticleId></ArticleIdList></Reference><Reference><Citation>Steding G., Jinwen X., Seidl W., Männer J., Xia H. Developmental aspects of the sinus valves and the sinus venosus septum of the right atrium in human embryos. Anat. Embryol. 1990;181:469–475. doi: 10.1007/BF02433794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02433794</ArticleId><ArticleId IdType="pubmed">2372133</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas Y.L., Mahtab E.A.F., Jongbloed M.R.M., Uhrin P., Zaujec J., Binder B.R., Schalij M.J., Poelmann R.E., Deruiter M.C., Gittenberger-de Groot A.C. Pulmonary vein, dorsal atrial wall and atrial septum abnormalities in podoplanin knockout mice with disturbed posterior heart field contribution. Pediatr. Res. 2009;65:27–32. doi: 10.1203/PDR.0b013e31818bc11a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e31818bc11a</ArticleId><ArticleId IdType="pubmed">18784615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego A., Durán A.C., De Andrés A.V., Navarro P., Muñoz-Chápuli R. Anatomy and development of the sinoatrial valves in the dogfish (Scyliorhinus canicula) Anat. Rec. 1997;248:224–232. doi: 10.1002/(SICI)1097-0185(199706)248:2<224::AID-AR9>3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0185(199706)248:2<224::AID-AR9>3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">9185988</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmén F., Ståhl P.L., Mollbrink A., Navarro J.F., Vickovic S., Frisén J., Lundeberg J. Barcoded solid-phase RNA capture for Spatial Transcriptomics profiling in mammalian tissue sections. Nat. Protoc. 2018;13:2501–2534. doi: 10.1038/s41596-018-0045-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0045-2</ArticleId><ArticleId IdType="pubmed">30353172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ståhl P.L., Salmén F., Vickovic S., Lundmark A., Navarro J.F., Magnusson J., Giacomello S., Asp M., Westholm J.O., Huss M., et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78–82. doi: 10.1126/science.aaf2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf2403</ArticleId><ArticleId IdType="pubmed">27365449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G.X.Y., Terry J.M., Belgrader P., Ryvkin P., Bent Z.W., Wilson R., Ziraldo S.B., Wheeler T.D., McDermott G.P., Zhu J., et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 2017;8 doi: 10.1038/ncomms14049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R., Mignardi M., Pacureanu A., Svedlund J., Botling J., Wählby C., Nilsson M. In situ sequencing for RNA analysis in preserved tissue and cells. Nat. Methods. 2013;10:857–860. doi: 10.1038/nmeth.2563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2563</ArticleId><ArticleId IdType="pubmed">23852452</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X., Harris K.D., Hauling T., Nicoloutsopoulos D., Muñoz-Manchado A.B., Skene N., Hjerling-Leffler J., Nilsson M. Probabilistic cell typing enables fine mapping of closely related cell types in situ. Nat. Methods. 2020;17:101–106. doi: 10.1038/s41592-019-0631-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0631-4</ArticleId><ArticleId IdType="pmc">PMC6949128</ArticleId><ArticleId IdType="pubmed">31740815</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E., McInnes L., Healy J., Dutertre C.-A., Kwok I.W.H., Ng L.G., Ginhoux F., Newell E.W. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 2018;37:38–44. doi: 10.1038/nbt.4314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4314</ArticleId><ArticleId IdType="pubmed">30531897</ArticleId></ArticleIdList></Reference><Reference><Citation>Asp M., Giacomello S., Larsson L., Wu C., Fürth D., Qian X., Wärdell E., Custodio J., Reimegård J., Salmén F., et al. A spatiotemporal organ-wide gene expression and cell atlas of the developing human heart. Cell. 2019;179:1647–1660.e19. doi: 10.1016/j.cell.2019.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.025</ArticleId><ArticleId IdType="pubmed">31835037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolanowski T.J., Busek M., Schubert M., Dmitrieva A., Binnewerg B., Pöche J., Fisher K., Schmieder F., Grünzner S., Hansen S., et al. Enhanced structural maturation of human induced pluripotent stem cell-derived cardiomyocytes under a controlled microenvironment in a microfluidic system. Acta Biomater. 2020;102:273–286. doi: 10.1016/j.actbio.2019.11.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2019.11.044</ArticleId><ArticleId IdType="pubmed">31778832</ArticleId></ArticleIdList></Reference><Reference><Citation>Saheli M., Pirhajati Mahabadi V., Mesbah-Namin S.A., Seifalian A., Bagheri-Hosseinabadi Z. DNA methyltransferase inhibitor 5-azacytidine in high dose promotes ultrastructural maturation of cardiomyocyte. Stem Cell Invest. 2020;7:22. doi: 10.21037/sci-2020-007.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci-2020-007</ArticleId><ArticleId IdType="pmc">PMC7791156</ArticleId><ArticleId IdType="pubmed">33437842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Xin Y., Zhang L., Hu J., Sun Y., Zhao Y. Iroquois Homeodomain transcription factors in ventricular conduction system and arrhythmia. Int. J. Med. Sci. 2018;15:808–815. doi: 10.7150/ijms.25140.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.25140</ArticleId><ArticleId IdType="pmc">PMC6036080</ArticleId><ArticleId IdType="pubmed">30008591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.-H., Rosen A., Hussein S.M.I., Puviindran V., Korogyi A.S., Chiarello C., Nagy A., Hui C.-C., Backx P.H. Irx3 is required for postnatal maturation of the mouse ventricular conduction system. Sci. Rep. 2016;6 doi: 10.1038/srep19197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19197</ArticleId><ArticleId IdType="pmc">PMC4726432</ArticleId><ArticleId IdType="pubmed">26786475</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukens B.J., Sylva M., de Gier-de Vries C., Remme C.A., Bezzina C.R., Christoffels V.M., Coronel R. Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract. Circ. Res. 2013;113:137–141. doi: 10.1161/CIRCRESAHA.113.301565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.113.301565</ArticleId><ArticleId IdType="pubmed">23661717</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham N., Huang G.N. Endocrine influence on cardiac metabolism in development and regeneration. Endocrinology. 2021;162:bqab081. doi: 10.1210/endocr/bqab081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endocr/bqab081</ArticleId><ArticleId IdType="pmc">PMC8282123</ArticleId><ArticleId IdType="pubmed">33880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X., Zhang P., Zhang L. Fetal hypoxia impacts on proliferation and differentiation of sca-1+ cardiac progenitor cells and maturation of cardiomyocytes: a role of MicroRNA-210. Genes. 2020;11:E328. doi: 10.3390/genes11030328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11030328</ArticleId><ArticleId IdType="pmc">PMC7140790</ArticleId><ArticleId IdType="pubmed">32244901</ArticleId></ArticleIdList></Reference><Reference><Citation>Firulli B.A., George R.M., Harkin J., Toolan K.P., Gao H., Liu Y., Zhang W., Field L.J., Liu Y., Shou W., et al. HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure. Cardiovasc. Res. 2020;116:605–618. doi: 10.1093/cvr/cvz182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz182</ArticleId><ArticleId IdType="pmc">PMC7252443</ArticleId><ArticleId IdType="pubmed">31286141</ArticleId></ArticleIdList></Reference><Reference><Citation>Steimle J.D., Moskowitz I.P. TBX5: a key regulator of heart development. Curr. Top. Dev. Biol. 2017;122:195–221. doi: 10.1016/bs.ctdb.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ctdb.2016.08.008</ArticleId><ArticleId IdType="pmc">PMC5371404</ArticleId><ArticleId IdType="pubmed">28057264</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C.E., Nguyen Q., Lukowski S.W., Helfer A., Chiu H.S., Miklas J., Levy S., Suo S., Han J.-D.J., Osteil P., et al. Single-cell transcriptomic analysis of cardiac differentiation from human PSCs reveals HOPX-dependent cardiomyocyte maturation. Cell Stem Cell. 2018;23:586–598.e8. doi: 10.1016/j.stem.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.09.009</ArticleId><ArticleId IdType="pmc">PMC6220122</ArticleId><ArticleId IdType="pubmed">30290179</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Baruffi M., Stowell S.R., Song S.-C., Arthur C.M., Cho M., Rodrigues L.C., Montes M.A.B., Rossi M.A., James J.A., McEver R.P., Cummings R.D. Differential expression of immunomodulatory galectin-1 in peripheral leukocytes and adult tissues and its cytosolic organization in striated muscle. Glycobiology. 2010;20:507–520. doi: 10.1093/glycob/cwp203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwp203</ArticleId><ArticleId IdType="pmc">PMC2900886</ArticleId><ArticleId IdType="pubmed">20053628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Zheng Y., Liu X., Yan L., Fan X., Yong J., Hu Y., Dong J., Li Q., Wu X., et al. Single-cell transcriptome analysis maps the developmental track of the human heart. Cell Rep. 2019;26:1934–1950.e5. doi: 10.1016/j.celrep.2019.01.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.01.079</ArticleId><ArticleId IdType="pubmed">30759401</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukens B.J.D., Christoffels V.M., Coronel R., Moorman A.F.M. Developmental basis for electrophysiological heterogeneity in the ventricular and outflow tract myocardium as a substrate for life-threatening ventricular arrhythmias. Circ. Res. 2009;104:19–31. doi: 10.1161/CIRCRESAHA.108.188698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.188698</ArticleId><ArticleId IdType="pubmed">19118284</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoff M.J., Kruithof B.P., Moorman A.F., Markwald R.R., Wessels A. formation of myocardium after the initial development of the linear heart tube. Dev. Biol. 2001;240:61–76. doi: 10.1006/dbio.2001.0449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2001.0449</ArticleId><ArticleId IdType="pubmed">11784047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara M., Santoro F., Sohlmér J., Zhou C., Witman N., Leung C.Y., Mononen M., Bylund K., Gruber P., Chien K.R. Population and single-cell analysis of human cardiogenesis reveals unique LGR5 ventricular progenitors in embryonic outflow tract. Dev. Cell. 2019;48:475–490.e7. doi: 10.1016/j.devcel.2019.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2019.01.005</ArticleId><ArticleId IdType="pubmed">30713072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathan M., Fonseka P., Chitti S.V., Kang T., Sanwlani R., Van Deun J., Hendrix A., Mathivanan S. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019;47:D516–D519. doi: 10.1093/nar/gky1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1029</ArticleId><ArticleId IdType="pmc">PMC6323905</ArticleId><ArticleId IdType="pubmed">30395310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F., Zeng Z., Song Y., Li L., Wu Z., Zhang X., Li Z., Ke X., Hu X. YBX-1 mediated sorting of miR-133 into hypoxia/reoxygenation-induced EPC-derived exosomes to increase fibroblast angiogenesis and MEndoT. Stem Cell Res. Ther. 2019;10:263. doi: 10.1186/s13287-019-1377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-019-1377-8</ArticleId><ArticleId IdType="pmc">PMC6708233</ArticleId><ArticleId IdType="pubmed">31443679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shurtleff M.J., Yao J., Qin Y., Nottingham R.M., Temoche-Diaz M.M., Schekman R., Lambowitz A.M. Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc. Natl. Acad. Sci. USA. 2017;114:E8987–E8995. doi: 10.1073/pnas.1712108114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1712108114</ArticleId><ArticleId IdType="pmc">PMC5663387</ArticleId><ArticleId IdType="pubmed">29073095</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh P.S., Tsutsumi R., Venkatesh T. YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. Eur. J. Cell Biol. 2018;97:163–167. doi: 10.1016/j.ejcb.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcb.2018.02.003</ArticleId><ArticleId IdType="pubmed">29478751</ArticleId></ArticleIdList></Reference><Reference><Citation>Easterling M., Rossi S., Mazzella A.J., Bressan M. Assembly of the cardiac pacemaking complex: electrogenic principles of sinoatrial node morphogenesis. J. Cardiovasc. Dev. Dis. 2021;8:40. doi: 10.3390/jcdd8040040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd8040040</ArticleId><ArticleId IdType="pmc">PMC8068396</ArticleId><ArticleId IdType="pubmed">33917972</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X., Evans S.M., Sun Y. Development of the cardiac pacemaker. Cell. Mol. Life Sci. 2017;74:1247–1259. doi: 10.1007/s00018-016-2400-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2400-1</ArticleId><ArticleId IdType="pmc">PMC5540370</ArticleId><ArticleId IdType="pubmed">27770149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese C., Grieskamp T., Airik R., Mommersteeg M.T.M., Gardiwal A., de Gier-de Vries C., Schuster-Gossler K., Moorman A.F.M., Kispert A., Christoffels V.M. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ. Res. 2009;104:388–397. doi: 10.1161/CIRCRESAHA.108.187062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.187062</ArticleId><ArticleId IdType="pubmed">19096026</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza-Lewis R.A., Yu L., He F., Liu H., Tang R., Shi J., Sun X., Martin J.F., Wang D., Yang J., Chen Y. Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5. Dev. Biol. 2009;327:376–385. doi: 10.1016/j.ydbio.2008.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2008.12.028</ArticleId><ArticleId IdType="pmc">PMC2694185</ArticleId><ArticleId IdType="pubmed">19166829</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Espinoza-Lewis R.A., Chen C., Hu X., Zhang Y., Chen Y. The role of Shox2 in SAN development and function. Pediatr. Cardiol. 2012;33:882–889. doi: 10.1007/s00246-012-0179-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-012-0179-x</ArticleId><ArticleId IdType="pubmed">22307400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C.-L., Martin J.C., Sun Y., Cui L., Wang L., Ouyang K., Yang L., Bu L., Liang X., Zhang X., et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature. 2008;454:104–108. doi: 10.1038/nature06969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06969</ArticleId><ArticleId IdType="pmc">PMC5540369</ArticleId><ArticleId IdType="pubmed">18480752</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eif V.W.W., Stefanovic S., van Duijvenboden K., Bakker M., Wakker V., de Gier-de Vries C., Zaffran S., Verkerk A.O., Boukens B.J., Christoffels V.M. Transcriptome analysis of mouse and human sinoatrial node cells reveals a conserved genetic program. Development. 2019;146:dev173161. doi: 10.1242/dev.173161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.173161</ArticleId><ArticleId IdType="pubmed">30936179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirenko S.T., Zahanich I., Li Y., Lukyanenko Y.O., Lyashkov A.E., Ziman B.D., Tarasov K.V., Younes A., Riordon D.R., Tarasova Y.S., et al. Phosphoprotein phosphatase 1 but not 2A activity modulates coupled-clock mechanisms to impact on intrinsic automaticity of sinoatrial nodal pacemaker cells. Cells. 2021;10:3106. doi: 10.3390/cells10113106.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113106</ArticleId><ArticleId IdType="pmc">PMC8623309</ArticleId><ArticleId IdType="pubmed">34831329</ArticleId></ArticleIdList></Reference><Reference><Citation>Efremova M., Vento-Tormo M., Teichmann S.A., Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 2020;15:1484–1506. doi: 10.1038/s41596-020-0292-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0292-x</ArticleId><ArticleId IdType="pubmed">32103204</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki N., Thiel K.W., Miller F.J. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 2013;14:20597–20613. doi: 10.3390/ijms141020597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms141020597</ArticleId><ArticleId IdType="pmc">PMC3821633</ArticleId><ArticleId IdType="pubmed">24132149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder J.A., Jackson L.F., Lee D.C., Camenisch T.D. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J. Mol. Med. 2003;81:392–403. doi: 10.1007/s00109-003-0456-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-003-0456-5</ArticleId><ArticleId IdType="pubmed">12827270</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Amato G., Luxán G., de la Pompa J.L. Notch signalling in ventricular chamber development and cardiomyopathy. FEBS J. 2016;283:4223–4237. doi: 10.1111/febs.13773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13773</ArticleId><ArticleId IdType="pubmed">27260948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen D.W., van Berlo J.H. The role of TGF-β signaling in cardiomyocyte proliferation. Curr. Heart Fail. Rep. 2020;17:225–233. doi: 10.1007/s11897-020-00470-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-020-00470-2</ArticleId><ArticleId IdType="pmc">PMC7486245</ArticleId><ArticleId IdType="pubmed">32686010</ArticleId></ArticleIdList></Reference><Reference><Citation>Allukian M., Xu J., Morris M., Caskey R., Dorsett-Martin W., Plappert T., Griswold M., Gorman J.H., Gorman R.C., Liechty K.W. Mammalian cardiac regeneration after fetal myocardial infarction requires cardiac progenitor cell recruitment. Ann. Thorac. Surg. 2013;96:163–170. doi: 10.1016/j.athoracsur.2013.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.04.005</ArticleId><ArticleId IdType="pmc">PMC3817737</ArticleId><ArticleId IdType="pubmed">23816072</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes R.M., Black B.L. In: Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology. Nakanishi T., Markwald R.R., Baldwin H.S., Keller B.B., Srivastava D., Yamagishi H., editors. Springer; 2016. Nodal signaling and congenital heart defects.</Citation><ArticleIdList><ArticleId IdType="pubmed">29787042</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens A.N., Ren Y., Ferdous A., Garry D.J., Martin C.M. Nkx2-5 regulates Tdgf1 (cripto) early during cardiac development. J clin exp cardiolog. J. Clin. Exp. Cardiol. 2012;11:1–4. doi: 10.4172/2155-9880.S11-003.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9880.S11-003</ArticleId><ArticleId IdType="pmc">PMC3779917</ArticleId><ArticleId IdType="pubmed">24069547</ArticleId></ArticleIdList></Reference><Reference><Citation>Noseda M., Peterkin T., Simões F.C., Patient R., Schneider M.D. Cardiopoietic factors: extracellular signals for cardiac lineage commitment. Circ. Res. 2011;108:129–152. doi: 10.1161/CIRCRESAHA.110.223792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.110.223792</ArticleId><ArticleId IdType="pubmed">21212394</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois N.C., Craft A.M., Sharma P., Elliott D.A., Stanley E.G., Elefanty A.G., Gramolini A., Keller G. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 2011;29:1011–1018. doi: 10.1038/nbt.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2005</ArticleId><ArticleId IdType="pmc">PMC4949030</ArticleId><ArticleId IdType="pubmed">22020386</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelton R.J.P., Costa M., Anderson D.J., Bruveris F., Finnin B.W., Koutsis K., Arasaratnam D., White A.J., Rafii A., Ng E.S., et al. SIRPA, VCAM1 and CD34 identify discrete lineages during early human cardiovascular development. Stem Cell Res. 2014;13:172–179. doi: 10.1016/j.scr.2014.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2014.04.016</ArticleId><ArticleId IdType="pubmed">24968096</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGrogan D., Münch J., de la Pompa J.L. Notch and interacting signalling pathways in cardiac development, disease, and regeneration. Nat. Rev. Cardiol. 2018;15:685–704. doi: 10.1038/s41569-018-0100-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-018-0100-2</ArticleId><ArticleId IdType="pubmed">30287945</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdembri D., Regano D., Maione F., Giraudo E., Serini G. Class 3 semaphorins in cardiovascular development. Cell Adhes. Migrat. 2016;10:641–651. doi: 10.1080/19336918.2016.1212805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336918.2016.1212805</ArticleId><ArticleId IdType="pmc">PMC5160038</ArticleId><ArticleId IdType="pubmed">27439112</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Chen J. Laminin-332 mediates proliferation, apoptosis, invasion, migration and epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Mol. Med. Rep. 2021;23:11. doi: 10.3892/mmr.2020.11649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11649</ArticleId><ArticleId IdType="pmc">PMC7673329</ArticleId><ArticleId IdType="pubmed">33179081</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N. FGF10: a multifunctional mesenchymal-epithelial signaling growth factor in development, health, and disease. Cytokine Growth Factor Rev. 2016;28:63–69. doi: 10.1016/j.cytogfr.2015.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2015.10.001</ArticleId><ArticleId IdType="pubmed">26559461</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieden L.A., Townsend T.A., Vaught D.B., Delaughter D.M., Hwang Y., Barnett J.V., Chen J. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev. Dynam. 2010;239:3226–3234. doi: 10.1002/dvdy.22458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.22458</ArticleId><ArticleId IdType="pmc">PMC3023820</ArticleId><ArticleId IdType="pubmed">20960543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Liang F., Yue J., Liu P., Wang J., Wang Z., Li H., Cheng D., Du J., Zhang K., Du P. MicroRNA-137 regulates hypoxia-mediated migration and epithelial-mesenchymal transition in prostate cancer by targeting LGR4 via the EGFR/ERK signaling pathway. Int. J. Oncol. 2020;57:540–549. doi: 10.3892/ijo.2020.5064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2020.5064</ArticleId><ArticleId IdType="pubmed">32626928</ArticleId></ArticleIdList></Reference><Reference><Citation>Greulich F., Rudat C., Kispert A. Mechanisms of T-box gene function in the developing heart. Cardiovasc. Res. 2011;91:212–222. doi: 10.1093/cvr/cvr112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr112</ArticleId><ArticleId IdType="pubmed">21498422</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Epstein J. Epicardial lineages and cardiac repair. J. Dev. Biol. 2013;1:141–158. doi: 10.3390/jdb1020141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jdb1020141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Ma Q., Rajagopal S., Wu S.M., Domian I., Rivera-Feliciano J., Jiang D., von Gise A., Ikeda S., Chien K.R., Pu W.T. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008;454:109–113. doi: 10.1038/nature07060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07060</ArticleId><ArticleId IdType="pmc">PMC2574791</ArticleId><ArticleId IdType="pubmed">18568026</ArticleId></ArticleIdList></Reference><Reference><Citation>Marco Salas S., Yuan X., Sylven C., Nilsson M., Wählby C., Partel G. De novo spatiotemporal modelling of cell-type signatures in the developmental human heart using graph convolutional neural networks. PLoS Comput. Biol. 2022;18 doi: 10.1371/journal.pcbi.1010366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1010366</ArticleId><ArticleId IdType="pmc">PMC9401155</ArticleId><ArticleId IdType="pubmed">35960757</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Tian L., Goodyer W., Kort E.J., Buikema J.W., Xu A., Wu J., Jovinge S., Wu S.M. Single cell expression analysis reveals anatomical and cell cycle-dependent transcriptional shifts during heart development. Development. 2019;146:dev173476. doi: 10.1242/dev.173476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.173476</ArticleId><ArticleId IdType="pmc">PMC6602356</ArticleId><ArticleId IdType="pubmed">31142541</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile L., Moccetti T., Marbán E., Vassalli G. Roles of exosomes in cardioprotection. Eur. Heart J. 2017;38:1372–1379. doi: 10.1093/eurheartj/ehw304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw304</ArticleId><ArticleId IdType="pubmed">27443883</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoff M.J.B., Wessels A. Muscularization of the mesenchymal outlet septum during cardiac development. J. Cardiovasc. Dev. Dis. 2020;7:E51. doi: 10.3390/jcdd7040051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd7040051</ArticleId><ArticleId IdType="pmc">PMC7711588</ArticleId><ArticleId IdType="pubmed">33158304</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411–420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson A., Bergenstråhle J., Asp M., Bergenstråhle L., Jurek A., Fernández Navarro J., Lundeberg J. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography. Commun. Biol. 2020;3:565. doi: 10.1038/s42003-020-01247-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01247-y</ArticleId><ArticleId IdType="pmc">PMC7547664</ArticleId><ArticleId IdType="pubmed">33037292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.-G., Han Y., He Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibar S., González-Blas C.B., Moerman T., Huynh-Thu V.A., Imrichova H., Hulselmans G., Rambow F., Marine J.-C., Geurts P., Aerts J., et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods. 2017;14:1083–1086. doi: 10.1038/nmeth.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4463</ArticleId><ArticleId IdType="pmc">PMC5937676</ArticleId><ArticleId IdType="pubmed">28991892</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36622020</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>190</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal>Assessment of Ex Vivo Murine Biventricular Function in a Langendorff Model. | Cardiomyocytes play key roles during cardiogenesis, but have poorly understood features, especially in prenatal stages. Here, we characterized human prenatal cardiomyocytes, 6.5-7 weeks post-conception, by integrating single-cell RNA sequencing, spatial transcriptomics, and ligand-receptor interaction information. Using a computational workflow developed to dissect cell type heterogeneity, localize cell types, and explore their molecular interactions, we identified eight types of developing cardiomyocyte, more than double compared to the ones identified in the <i>Human Developmental Cell Atlas</i>. These have high variability in cell cycle activity, mitochondrial content, and connexin gene expression, and are differentially distributed in the ventricles, including outflow tract, and atria, including sinoatrial node. Moreover, cardiomyocyte ligand-receptor crosstalk is mainly with non-cardiomyocyte cell types, encompassing cardiogenesis-related pathways. Thus, early prenatal human cardiomyocytes are highly heterogeneous and develop unique location-dependent properties, with complex ligand-receptor crosstalk. Further elucidation of their developmental dynamics may give rise to new therapies.<CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sylvén</LastName><ForeName>Christer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wärdell</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Månsson-Broberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institute, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cingolani</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cedars-Sinai, Smidt Heart Institute, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ampatzis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Ludvig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Björklund</LastName><ForeName>Åsa</ForeName><Initials>Å</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomello</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Biological sciences</Keyword><Keyword MajorTopicYN="N">Cell biology</Keyword><Keyword MajorTopicYN="N">Transcriptomics</Keyword></KeywordList><CoiStatement>S.G. is scientific advisor to 10x Genomics, which holds IP rights to the ST technology, and holds 10x Genomics stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36624836</ArticleId><ArticleId IdType="pmc">PMC9823232</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105857</ArticleId><ArticleId IdType="pii">S2589-0042(22)02130-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sylva M., van den Hoff M.J.B., Moorman A.F.M. Development of the human heart. Am. J. Med. Genet. 2014;164A:1347–1371. doi: 10.1002/ajmg.a.35896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.35896</ArticleId><ArticleId IdType="pubmed">23633400</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsa L.A., Yang B., Liu J. Embryonic cardiac chamber maturation: trabeculation, conduction, and cardiomyocyte proliferation. Am. J. Med. Genet. C Semin. Med. Genet. 2013;163C:157–168. doi: 10.1002/ajmg.c.31366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31366</ArticleId><ArticleId IdType="pmc">PMC3723796</ArticleId><ArticleId IdType="pubmed">23720419</ArticleId></ArticleIdList></Reference><Reference><Citation>Günthel M., Barnett P., Christoffels V.M. Development, proliferation, and growth of the mammalian heart. Mol. Ther. 2018;26:1599–1609. doi: 10.1016/j.ymthe.2018.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.05.022</ArticleId><ArticleId IdType="pmc">PMC6037201</ArticleId><ArticleId IdType="pubmed">29929790</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRuiter M.C., Gittenberger-De Groot A.C., Wenink A.C., Poelmann R.E., Mentink M.M. In normal development pulmonary veins are connected to the sinus venosus segment in the left atrium. Anat. Rec. 1995;243:84–92. doi: 10.1002/ar.1092430110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1092430110</ArticleId><ArticleId IdType="pubmed">8540635</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber J.W., Boukens B.J., Oostra R.-J., Moorman A.F.M., Christoffels V.M., Jensen B. Sinus venosus incorporation: contentious issues and operational criteria for developmental and evolutionary studies. J. Anat. 2019;234:583–591. doi: 10.1111/joa.12962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joa.12962</ArticleId><ArticleId IdType="pmc">PMC6481585</ArticleId><ArticleId IdType="pubmed">30861129</ArticleId></ArticleIdList></Reference><Reference><Citation>Soufan A.T., van den Hoff M.J.B., Ruijter J.M., de Boer P.A.J., Hagoort J., Webb S., Anderson R.H., Moorman A.F.M. Reconstruction of the patterns of gene expression in the developing mouse heart reveals an architectural arrangement that facilitates the understanding of atrial malformations and arrhythmias. Circ. Res. 2004;95:1207–1215. doi: 10.1161/01.RES.0000150852.04747.e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000150852.04747.e1</ArticleId><ArticleId IdType="pubmed">15550689</ArticleId></ArticleIdList></Reference><Reference><Citation>Steding G., Jinwen X., Seidl W., Männer J., Xia H. Developmental aspects of the sinus valves and the sinus venosus septum of the right atrium in human embryos. Anat. Embryol. 1990;181:469–475. doi: 10.1007/BF02433794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02433794</ArticleId><ArticleId IdType="pubmed">2372133</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas Y.L., Mahtab E.A.F., Jongbloed M.R.M., Uhrin P., Zaujec J., Binder B.R., Schalij M.J., Poelmann R.E., Deruiter M.C., Gittenberger-de Groot A.C. Pulmonary vein, dorsal atrial wall and atrial septum abnormalities in podoplanin knockout mice with disturbed posterior heart field contribution. Pediatr. Res. 2009;65:27–32. doi: 10.1203/PDR.0b013e31818bc11a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e31818bc11a</ArticleId><ArticleId IdType="pubmed">18784615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego A., Durán A.C., De Andrés A.V., Navarro P., Muñoz-Chápuli R. Anatomy and development of the sinoatrial valves in the dogfish (Scyliorhinus canicula) Anat. Rec. 1997;248:224–232. doi: 10.1002/(SICI)1097-0185(199706)248:2<224::AID-AR9>3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0185(199706)248:2<224::AID-AR9>3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">9185988</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmén F., Ståhl P.L., Mollbrink A., Navarro J.F., Vickovic S., Frisén J., Lundeberg J. Barcoded solid-phase RNA capture for Spatial Transcriptomics profiling in mammalian tissue sections. Nat. Protoc. 2018;13:2501–2534. doi: 10.1038/s41596-018-0045-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0045-2</ArticleId><ArticleId IdType="pubmed">30353172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ståhl P.L., Salmén F., Vickovic S., Lundmark A., Navarro J.F., Magnusson J., Giacomello S., Asp M., Westholm J.O., Huss M., et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78–82. doi: 10.1126/science.aaf2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf2403</ArticleId><ArticleId IdType="pubmed">27365449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G.X.Y., Terry J.M., Belgrader P., Ryvkin P., Bent Z.W., Wilson R., Ziraldo S.B., Wheeler T.D., McDermott G.P., Zhu J., et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 2017;8 doi: 10.1038/ncomms14049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R., Mignardi M., Pacureanu A., Svedlund J., Botling J., Wählby C., Nilsson M. In situ sequencing for RNA analysis in preserved tissue and cells. Nat. Methods. 2013;10:857–860. doi: 10.1038/nmeth.2563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2563</ArticleId><ArticleId IdType="pubmed">23852452</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X., Harris K.D., Hauling T., Nicoloutsopoulos D., Muñoz-Manchado A.B., Skene N., Hjerling-Leffler J., Nilsson M. Probabilistic cell typing enables fine mapping of closely related cell types in situ. Nat. Methods. 2020;17:101–106. doi: 10.1038/s41592-019-0631-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0631-4</ArticleId><ArticleId IdType="pmc">PMC6949128</ArticleId><ArticleId IdType="pubmed">31740815</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E., McInnes L., Healy J., Dutertre C.-A., Kwok I.W.H., Ng L.G., Ginhoux F., Newell E.W. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 2018;37:38–44. doi: 10.1038/nbt.4314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4314</ArticleId><ArticleId IdType="pubmed">30531897</ArticleId></ArticleIdList></Reference><Reference><Citation>Asp M., Giacomello S., Larsson L., Wu C., Fürth D., Qian X., Wärdell E., Custodio J., Reimegård J., Salmén F., et al. A spatiotemporal organ-wide gene expression and cell atlas of the developing human heart. Cell. 2019;179:1647–1660.e19. doi: 10.1016/j.cell.2019.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.025</ArticleId><ArticleId IdType="pubmed">31835037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolanowski T.J., Busek M., Schubert M., Dmitrieva A., Binnewerg B., Pöche J., Fisher K., Schmieder F., Grünzner S., Hansen S., et al. Enhanced structural maturation of human induced pluripotent stem cell-derived cardiomyocytes under a controlled microenvironment in a microfluidic system. Acta Biomater. 2020;102:273–286. doi: 10.1016/j.actbio.2019.11.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2019.11.044</ArticleId><ArticleId IdType="pubmed">31778832</ArticleId></ArticleIdList></Reference><Reference><Citation>Saheli M., Pirhajati Mahabadi V., Mesbah-Namin S.A., Seifalian A., Bagheri-Hosseinabadi Z. DNA methyltransferase inhibitor 5-azacytidine in high dose promotes ultrastructural maturation of cardiomyocyte. Stem Cell Invest. 2020;7:22. doi: 10.21037/sci-2020-007.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci-2020-007</ArticleId><ArticleId IdType="pmc">PMC7791156</ArticleId><ArticleId IdType="pubmed">33437842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Xin Y., Zhang L., Hu J., Sun Y., Zhao Y. Iroquois Homeodomain transcription factors in ventricular conduction system and arrhythmia. Int. J. Med. Sci. 2018;15:808–815. doi: 10.7150/ijms.25140.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.25140</ArticleId><ArticleId IdType="pmc">PMC6036080</ArticleId><ArticleId IdType="pubmed">30008591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.-H., Rosen A., Hussein S.M.I., Puviindran V., Korogyi A.S., Chiarello C., Nagy A., Hui C.-C., Backx P.H. Irx3 is required for postnatal maturation of the mouse ventricular conduction system. Sci. Rep. 2016;6 doi: 10.1038/srep19197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19197</ArticleId><ArticleId IdType="pmc">PMC4726432</ArticleId><ArticleId IdType="pubmed">26786475</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukens B.J., Sylva M., de Gier-de Vries C., Remme C.A., Bezzina C.R., Christoffels V.M., Coronel R. Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract. Circ. Res. 2013;113:137–141. doi: 10.1161/CIRCRESAHA.113.301565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.113.301565</ArticleId><ArticleId IdType="pubmed">23661717</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham N., Huang G.N. Endocrine influence on cardiac metabolism in development and regeneration. Endocrinology. 2021;162:bqab081. doi: 10.1210/endocr/bqab081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endocr/bqab081</ArticleId><ArticleId IdType="pmc">PMC8282123</ArticleId><ArticleId IdType="pubmed">33880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X., Zhang P., Zhang L. Fetal hypoxia impacts on proliferation and differentiation of sca-1+ cardiac progenitor cells and maturation of cardiomyocytes: a role of MicroRNA-210. Genes. 2020;11:E328. doi: 10.3390/genes11030328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11030328</ArticleId><ArticleId IdType="pmc">PMC7140790</ArticleId><ArticleId IdType="pubmed">32244901</ArticleId></ArticleIdList></Reference><Reference><Citation>Firulli B.A., George R.M., Harkin J., Toolan K.P., Gao H., Liu Y., Zhang W., Field L.J., Liu Y., Shou W., et al. HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure. Cardiovasc. Res. 2020;116:605–618. doi: 10.1093/cvr/cvz182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz182</ArticleId><ArticleId IdType="pmc">PMC7252443</ArticleId><ArticleId IdType="pubmed">31286141</ArticleId></ArticleIdList></Reference><Reference><Citation>Steimle J.D., Moskowitz I.P. TBX5: a key regulator of heart development. Curr. Top. Dev. Biol. 2017;122:195–221. doi: 10.1016/bs.ctdb.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ctdb.2016.08.008</ArticleId><ArticleId IdType="pmc">PMC5371404</ArticleId><ArticleId IdType="pubmed">28057264</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C.E., Nguyen Q., Lukowski S.W., Helfer A., Chiu H.S., Miklas J., Levy S., Suo S., Han J.-D.J., Osteil P., et al. Single-cell transcriptomic analysis of cardiac differentiation from human PSCs reveals HOPX-dependent cardiomyocyte maturation. Cell Stem Cell. 2018;23:586–598.e8. doi: 10.1016/j.stem.2018.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.09.009</ArticleId><ArticleId IdType="pmc">PMC6220122</ArticleId><ArticleId IdType="pubmed">30290179</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Baruffi M., Stowell S.R., Song S.-C., Arthur C.M., Cho M., Rodrigues L.C., Montes M.A.B., Rossi M.A., James J.A., McEver R.P., Cummings R.D. Differential expression of immunomodulatory galectin-1 in peripheral leukocytes and adult tissues and its cytosolic organization in striated muscle. Glycobiology. 2010;20:507–520. doi: 10.1093/glycob/cwp203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwp203</ArticleId><ArticleId IdType="pmc">PMC2900886</ArticleId><ArticleId IdType="pubmed">20053628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Zheng Y., Liu X., Yan L., Fan X., Yong J., Hu Y., Dong J., Li Q., Wu X., et al. Single-cell transcriptome analysis maps the developmental track of the human heart. Cell Rep. 2019;26:1934–1950.e5. doi: 10.1016/j.celrep.2019.01.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.01.079</ArticleId><ArticleId IdType="pubmed">30759401</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukens B.J.D., Christoffels V.M., Coronel R., Moorman A.F.M. Developmental basis for electrophysiological heterogeneity in the ventricular and outflow tract myocardium as a substrate for life-threatening ventricular arrhythmias. Circ. Res. 2009;104:19–31. doi: 10.1161/CIRCRESAHA.108.188698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.188698</ArticleId><ArticleId IdType="pubmed">19118284</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoff M.J., Kruithof B.P., Moorman A.F., Markwald R.R., Wessels A. formation of myocardium after the initial development of the linear heart tube. Dev. Biol. 2001;240:61–76. doi: 10.1006/dbio.2001.0449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2001.0449</ArticleId><ArticleId IdType="pubmed">11784047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara M., Santoro F., Sohlmér J., Zhou C., Witman N., Leung C.Y., Mononen M., Bylund K., Gruber P., Chien K.R. Population and single-cell analysis of human cardiogenesis reveals unique LGR5 ventricular progenitors in embryonic outflow tract. Dev. Cell. 2019;48:475–490.e7. doi: 10.1016/j.devcel.2019.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2019.01.005</ArticleId><ArticleId IdType="pubmed">30713072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathan M., Fonseka P., Chitti S.V., Kang T., Sanwlani R., Van Deun J., Hendrix A., Mathivanan S. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019;47:D516–D519. doi: 10.1093/nar/gky1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1029</ArticleId><ArticleId IdType="pmc">PMC6323905</ArticleId><ArticleId IdType="pubmed">30395310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F., Zeng Z., Song Y., Li L., Wu Z., Zhang X., Li Z., Ke X., Hu X. YBX-1 mediated sorting of miR-133 into hypoxia/reoxygenation-induced EPC-derived exosomes to increase fibroblast angiogenesis and MEndoT. Stem Cell Res. Ther. 2019;10:263. doi: 10.1186/s13287-019-1377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-019-1377-8</ArticleId><ArticleId IdType="pmc">PMC6708233</ArticleId><ArticleId IdType="pubmed">31443679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shurtleff M.J., Yao J., Qin Y., Nottingham R.M., Temoche-Diaz M.M., Schekman R., Lambowitz A.M. Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc. Natl. Acad. Sci. USA. 2017;114:E8987–E8995. doi: 10.1073/pnas.1712108114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1712108114</ArticleId><ArticleId IdType="pmc">PMC5663387</ArticleId><ArticleId IdType="pubmed">29073095</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh P.S., Tsutsumi R., Venkatesh T. YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. Eur. J. Cell Biol. 2018;97:163–167. doi: 10.1016/j.ejcb.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcb.2018.02.003</ArticleId><ArticleId IdType="pubmed">29478751</ArticleId></ArticleIdList></Reference><Reference><Citation>Easterling M., Rossi S., Mazzella A.J., Bressan M. Assembly of the cardiac pacemaking complex: electrogenic principles of sinoatrial node morphogenesis. J. Cardiovasc. Dev. Dis. 2021;8:40. doi: 10.3390/jcdd8040040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd8040040</ArticleId><ArticleId IdType="pmc">PMC8068396</ArticleId><ArticleId IdType="pubmed">33917972</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X., Evans S.M., Sun Y. Development of the cardiac pacemaker. Cell. Mol. Life Sci. 2017;74:1247–1259. doi: 10.1007/s00018-016-2400-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2400-1</ArticleId><ArticleId IdType="pmc">PMC5540370</ArticleId><ArticleId IdType="pubmed">27770149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese C., Grieskamp T., Airik R., Mommersteeg M.T.M., Gardiwal A., de Gier-de Vries C., Schuster-Gossler K., Moorman A.F.M., Kispert A., Christoffels V.M. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ. Res. 2009;104:388–397. doi: 10.1161/CIRCRESAHA.108.187062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.187062</ArticleId><ArticleId IdType="pubmed">19096026</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza-Lewis R.A., Yu L., He F., Liu H., Tang R., Shi J., Sun X., Martin J.F., Wang D., Yang J., Chen Y. Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5. Dev. Biol. 2009;327:376–385. doi: 10.1016/j.ydbio.2008.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2008.12.028</ArticleId><ArticleId IdType="pmc">PMC2694185</ArticleId><ArticleId IdType="pubmed">19166829</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Espinoza-Lewis R.A., Chen C., Hu X., Zhang Y., Chen Y. The role of Shox2 in SAN development and function. Pediatr. Cardiol. 2012;33:882–889. doi: 10.1007/s00246-012-0179-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-012-0179-x</ArticleId><ArticleId IdType="pubmed">22307400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C.-L., Martin J.C., Sun Y., Cui L., Wang L., Ouyang K., Yang L., Bu L., Liang X., Zhang X., et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature. 2008;454:104–108. doi: 10.1038/nature06969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06969</ArticleId><ArticleId IdType="pmc">PMC5540369</ArticleId><ArticleId IdType="pubmed">18480752</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eif V.W.W., Stefanovic S., van Duijvenboden K., Bakker M., Wakker V., de Gier-de Vries C., Zaffran S., Verkerk A.O., Boukens B.J., Christoffels V.M. Transcriptome analysis of mouse and human sinoatrial node cells reveals a conserved genetic program. Development. 2019;146:dev173161. doi: 10.1242/dev.173161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.173161</ArticleId><ArticleId IdType="pubmed">30936179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirenko S.T., Zahanich I., Li Y., Lukyanenko Y.O., Lyashkov A.E., Ziman B.D., Tarasov K.V., Younes A., Riordon D.R., Tarasova Y.S., et al. Phosphoprotein phosphatase 1 but not 2A activity modulates coupled-clock mechanisms to impact on intrinsic automaticity of sinoatrial nodal pacemaker cells. Cells. 2021;10:3106. doi: 10.3390/cells10113106.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113106</ArticleId><ArticleId IdType="pmc">PMC8623309</ArticleId><ArticleId IdType="pubmed">34831329</ArticleId></ArticleIdList></Reference><Reference><Citation>Efremova M., Vento-Tormo M., Teichmann S.A., Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 2020;15:1484–1506. doi: 10.1038/s41596-020-0292-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0292-x</ArticleId><ArticleId IdType="pubmed">32103204</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki N., Thiel K.W., Miller F.J. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 2013;14:20597–20613. doi: 10.3390/ijms141020597.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms141020597</ArticleId><ArticleId IdType="pmc">PMC3821633</ArticleId><ArticleId IdType="pubmed">24132149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder J.A., Jackson L.F., Lee D.C., Camenisch T.D. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J. Mol. Med. 2003;81:392–403. doi: 10.1007/s00109-003-0456-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-003-0456-5</ArticleId><ArticleId IdType="pubmed">12827270</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Amato G., Luxán G., de la Pompa J.L. Notch signalling in ventricular chamber development and cardiomyopathy. FEBS J. 2016;283:4223–4237. doi: 10.1111/febs.13773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13773</ArticleId><ArticleId IdType="pubmed">27260948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen D.W., van Berlo J.H. The role of TGF-β signaling in cardiomyocyte proliferation. Curr. Heart Fail. Rep. 2020;17:225–233. doi: 10.1007/s11897-020-00470-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-020-00470-2</ArticleId><ArticleId IdType="pmc">PMC7486245</ArticleId><ArticleId IdType="pubmed">32686010</ArticleId></ArticleIdList></Reference><Reference><Citation>Allukian M., Xu J., Morris M., Caskey R., Dorsett-Martin W., Plappert T., Griswold M., Gorman J.H., Gorman R.C., Liechty K.W. Mammalian cardiac regeneration after fetal myocardial infarction requires cardiac progenitor cell recruitment. Ann. Thorac. Surg. 2013;96:163–170. doi: 10.1016/j.athoracsur.2013.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.04.005</ArticleId><ArticleId IdType="pmc">PMC3817737</ArticleId><ArticleId IdType="pubmed">23816072</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes R.M., Black B.L. In: Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology. Nakanishi T., Markwald R.R., Baldwin H.S., Keller B.B., Srivastava D., Yamagishi H., editors. Springer; 2016. Nodal signaling and congenital heart defects.</Citation><ArticleIdList><ArticleId IdType="pubmed">29787042</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens A.N., Ren Y., Ferdous A., Garry D.J., Martin C.M. Nkx2-5 regulates Tdgf1 (cripto) early during cardiac development. J clin exp cardiolog. J. Clin. Exp. Cardiol. 2012;11:1–4. doi: 10.4172/2155-9880.S11-003.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9880.S11-003</ArticleId><ArticleId IdType="pmc">PMC3779917</ArticleId><ArticleId IdType="pubmed">24069547</ArticleId></ArticleIdList></Reference><Reference><Citation>Noseda M., Peterkin T., Simões F.C., Patient R., Schneider M.D. Cardiopoietic factors: extracellular signals for cardiac lineage commitment. Circ. Res. 2011;108:129–152. doi: 10.1161/CIRCRESAHA.110.223792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.110.223792</ArticleId><ArticleId IdType="pubmed">21212394</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois N.C., Craft A.M., Sharma P., Elliott D.A., Stanley E.G., Elefanty A.G., Gramolini A., Keller G. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 2011;29:1011–1018. doi: 10.1038/nbt.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2005</ArticleId><ArticleId IdType="pmc">PMC4949030</ArticleId><ArticleId IdType="pubmed">22020386</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelton R.J.P., Costa M., Anderson D.J., Bruveris F., Finnin B.W., Koutsis K., Arasaratnam D., White A.J., Rafii A., Ng E.S., et al. SIRPA, VCAM1 and CD34 identify discrete lineages during early human cardiovascular development. Stem Cell Res. 2014;13:172–179. doi: 10.1016/j.scr.2014.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2014.04.016</ArticleId><ArticleId IdType="pubmed">24968096</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGrogan D., Münch J., de la Pompa J.L. Notch and interacting signalling pathways in cardiac development, disease, and regeneration. Nat. Rev. Cardiol. 2018;15:685–704. doi: 10.1038/s41569-018-0100-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-018-0100-2</ArticleId><ArticleId IdType="pubmed">30287945</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdembri D., Regano D., Maione F., Giraudo E., Serini G. Class 3 semaphorins in cardiovascular development. Cell Adhes. Migrat. 2016;10:641–651. doi: 10.1080/19336918.2016.1212805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336918.2016.1212805</ArticleId><ArticleId IdType="pmc">PMC5160038</ArticleId><ArticleId IdType="pubmed">27439112</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Chen J. Laminin-332 mediates proliferation, apoptosis, invasion, migration and epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Mol. Med. Rep. 2021;23:11. doi: 10.3892/mmr.2020.11649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11649</ArticleId><ArticleId IdType="pmc">PMC7673329</ArticleId><ArticleId IdType="pubmed">33179081</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N. FGF10: a multifunctional mesenchymal-epithelial signaling growth factor in development, health, and disease. Cytokine Growth Factor Rev. 2016;28:63–69. doi: 10.1016/j.cytogfr.2015.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2015.10.001</ArticleId><ArticleId IdType="pubmed">26559461</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieden L.A., Townsend T.A., Vaught D.B., Delaughter D.M., Hwang Y., Barnett J.V., Chen J. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev. Dynam. 2010;239:3226–3234. doi: 10.1002/dvdy.22458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.22458</ArticleId><ArticleId IdType="pmc">PMC3023820</ArticleId><ArticleId IdType="pubmed">20960543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Liang F., Yue J., Liu P., Wang J., Wang Z., Li H., Cheng D., Du J., Zhang K., Du P. MicroRNA-137 regulates hypoxia-mediated migration and epithelial-mesenchymal transition in prostate cancer by targeting LGR4 via the EGFR/ERK signaling pathway. Int. J. Oncol. 2020;57:540–549. doi: 10.3892/ijo.2020.5064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2020.5064</ArticleId><ArticleId IdType="pubmed">32626928</ArticleId></ArticleIdList></Reference><Reference><Citation>Greulich F., Rudat C., Kispert A. Mechanisms of T-box gene function in the developing heart. Cardiovasc. Res. 2011;91:212–222. doi: 10.1093/cvr/cvr112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr112</ArticleId><ArticleId IdType="pubmed">21498422</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Epstein J. Epicardial lineages and cardiac repair. J. Dev. Biol. 2013;1:141–158. doi: 10.3390/jdb1020141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jdb1020141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Ma Q., Rajagopal S., Wu S.M., Domian I., Rivera-Feliciano J., Jiang D., von Gise A., Ikeda S., Chien K.R., Pu W.T. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008;454:109–113. doi: 10.1038/nature07060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07060</ArticleId><ArticleId IdType="pmc">PMC2574791</ArticleId><ArticleId IdType="pubmed">18568026</ArticleId></ArticleIdList></Reference><Reference><Citation>Marco Salas S., Yuan X., Sylven C., Nilsson M., Wählby C., Partel G. De novo spatiotemporal modelling of cell-type signatures in the developmental human heart using graph convolutional neural networks. PLoS Comput. Biol. 2022;18 doi: 10.1371/journal.pcbi.1010366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1010366</ArticleId><ArticleId IdType="pmc">PMC9401155</ArticleId><ArticleId IdType="pubmed">35960757</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Tian L., Goodyer W., Kort E.J., Buikema J.W., Xu A., Wu J., Jovinge S., Wu S.M. Single cell expression analysis reveals anatomical and cell cycle-dependent transcriptional shifts during heart development. Development. 2019;146:dev173476. doi: 10.1242/dev.173476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.173476</ArticleId><ArticleId IdType="pmc">PMC6602356</ArticleId><ArticleId IdType="pubmed">31142541</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile L., Moccetti T., Marbán E., Vassalli G. Roles of exosomes in cardioprotection. Eur. Heart J. 2017;38:1372–1379. doi: 10.1093/eurheartj/ehw304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw304</ArticleId><ArticleId IdType="pubmed">27443883</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoff M.J.B., Wessels A. Muscularization of the mesenchymal outlet septum during cardiac development. J. Cardiovasc. Dev. Dis. 2020;7:E51. doi: 10.3390/jcdd7040051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd7040051</ArticleId><ArticleId IdType="pmc">PMC7711588</ArticleId><ArticleId IdType="pubmed">33158304</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411–420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson A., Bergenstråhle J., Asp M., Bergenstråhle L., Jurek A., Fernández Navarro J., Lundeberg J. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography. Commun. Biol. 2020;3:565. doi: 10.1038/s42003-020-01247-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01247-y</ArticleId><ArticleId IdType="pmc">PMC7547664</ArticleId><ArticleId IdType="pubmed">33037292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L.-G., Han Y., He Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibar S., González-Blas C.B., Moerman T., Huynh-Thu V.A., Imrichova H., Hulselmans G., Rambow F., Marine J.-C., Geurts P., Aerts J., et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods. 2017;14:1083–1086. doi: 10.1038/nmeth.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4463</ArticleId><ArticleId IdType="pmc">PMC5937676</ArticleId><ArticleId IdType="pubmed">28991892</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36622020</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>190</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal><ArticleTitle>Assessment of Ex Vivo Murine Biventricular Function in a Langendorff Model.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3791/64384</ELocationID><Abstract>Primary graft dysfunction (PGD) remains the leading cause of early death following heart transplantation. Prolonged ischemic time during cold preservation is an important risk factor for PGD, and reliable evaluation of cardiac function is essential to study the functional responses of the donor heart after cold preservation. The accompanying video describes a technique to assess murine right and left ventricular function using ex vivo perfusion based in a Langendorff model after cold preservation for different durations. In brief, the heart is isolated and stored in a cold histidine-tryptophan-ketoglutarate (HTK) solution. Then, the heart is perfused with a Kreb buffer in a Langendorff model for 60 min. A silicone balloon is inserted into the left and right ventricle, and cardiac functional parameters are recorded (dP/dt, pressure-volume relationships). This protocol allows the reliable evaluation of cardiac function after different heart preservation protocols. Importantly, this technique allows the study of cardiac preservation responses specifically in native cardiac cells. The use of very small murine hearts allows access to an enormous array of transgenic mice to investigate the mechanisms of PGD. |
2,329,270 | Anomalous coronary artery connecting left and right coronaries crossing right ventricular outflow tract in Hoffman variant tetralogy of Fallot.<ELocationID EIdType="pii" ValidYN="Y">ezac592</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezac592</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagaria</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-2141-9439</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Sri Sathya Sai Institute of Higher Medical Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badragiri</LastName><ForeName>Lahari</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Sri Sathya Sai Institute of Higher Medical Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dattani</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Sri Sathya Sai Institute of Higher Medical Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiremath</LastName><ForeName>Channabasavaraj S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic and Vascular Surgery, Sri Sathya Sai Institute of Higher Medical Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013771" MajorTopicYN="Y">Tetralogy of Fallot</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="N">Coronary Vessels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003330" MajorTopicYN="Y">Coronary Vessel Anomalies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Computed tomography</Keyword><Keyword MajorTopicYN="N">Coronary artery anomalies</Keyword><Keyword MajorTopicYN="N">Tetralogy of Fallot</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>2</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36592041</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezac592</ArticleId><ArticleId IdType="pii">6967036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36591985</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>190</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal>Microdissection and Whole Mount Scanning Electron Microscopy Visualization of Mouse Choroid Plexus.<ELocationID EIdType="doi" ValidYN="Y">10.3791/64733</ELocationID><Abstract><AbstractText>The choroid plexus (CP), a highly vascularized structure protruding into the ventricles of the brain, is one of the most understudied tissues in neuroscience. As it is becoming increasingly clear that this tiny structure plays a crucial role in health and disease of the central nervous system (CNS), it is of utmost importance to properly dissect the CP out of the brain ventricles in a way that allows downstream processing, ranging from functional to structural analysis. Here, isolation of the lateral and fourth brain ventricle mouse CP without the need for specialized tools or equipment is described. This isolation technique preserves the viability, function, and structure of cells within the CP. On account of its high vascularization, the CP can be visualized floating inside the ventricular cavities of the brain using a binocular microscope. However, transcardial perfusion required for downstream analysis can complicate the identification of the CP tissue. Depending on the further processing steps (e.g., RNA and protein analysis), this can be solved by visualizing the CP via transcardial perfusion with bromophenol blue. After isolation, the CP can be processed using several techniques, including RNA, protein, or single cell analysis, to gain further understanding on the function of this special brain structure. Here, scanning electron microscopy (SEM) on whole mount CP is used to get an overall view of the structure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Wonterghem</LastName><ForeName>Elien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Hoecke</LastName><ForeName>Lien</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Imschoot</LastName><ForeName>Griet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhaege</LastName><ForeName>Daan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgelman</LastName><ForeName>Marlies</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenbroucke</LastName><ForeName>Roosmarijn E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University; roosmarijn.vandenbroucke@irc.vib-ugent.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vis Exp</MedlineTA><NlmUniqueID>101313252</NlmUniqueID><ISSNLinking>1940-087X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="Y">Choroid Plexus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042282" MajorTopicYN="Y">Microdissection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>2</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36591985</ArticleId><ArticleId IdType="doi">10.3791/64733</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36591981</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>190</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal>High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals. | The choroid plexus (CP), a highly vascularized structure protruding into the ventricles of the brain, is one of the most understudied tissues in neuroscience. As it is becoming increasingly clear that this tiny structure plays a crucial role in health and disease of the central nervous system (CNS), it is of utmost importance to properly dissect the CP out of the brain ventricles in a way that allows downstream processing, ranging from functional to structural analysis. Here, isolation of the lateral and fourth brain ventricle mouse CP without the need for specialized tools or equipment is described. This isolation technique preserves the viability, function, and structure of cells within the CP. On account of its high vascularization, the CP can be visualized floating inside the ventricular cavities of the brain using a binocular microscope. However, transcardial perfusion required for downstream analysis can complicate the identification of the CP tissue. Depending on the further processing steps (e.g., RNA and protein analysis), this can be solved by visualizing the CP via transcardial perfusion with bromophenol blue. After isolation, the CP can be processed using several techniques, including RNA, protein, or single cell analysis, to gain further understanding on the function of this special brain structure. Here, scanning electron microscopy (SEM) on whole mount CP is used to get an overall view of the structure.</Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Wonterghem</LastName><ForeName>Elien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Hoecke</LastName><ForeName>Lien</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Imschoot</LastName><ForeName>Griet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhaege</LastName><ForeName>Daan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgelman</LastName><ForeName>Marlies</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenbroucke</LastName><ForeName>Roosmarijn E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, VIB; Department of Biomedical Molecular Biology, Ghent University; roosmarijn.vandenbroucke@irc.vib-ugent.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vis Exp</MedlineTA><NlmUniqueID>101313252</NlmUniqueID><ISSNLinking>1940-087X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="Y">Choroid Plexus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042282" MajorTopicYN="Y">Microdissection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>2</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36591985</ArticleId><ArticleId IdType="doi">10.3791/64733</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36591981</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>190</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal><ArticleTitle>High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3791/64066</ELocationID><Abstract>Positron emission tomography (PET) and computed tomography (CT) are among the most employed diagnostic imaging techniques, and both serve in understanding cardiac function and metabolism. In preclinical research, dedicated scanners with high sensitivity and high spatio-temporal resolution are employed, designed to cope with the demanding technological requirements posed by the small heart size and very high heart rates of mice and rats. In this paper, a bimodal cardiac PET/CT imaging protocol for experimental mouse and/or rat models of cardiac diseases is described, from animal preparation and image acquisition and reconstruction to image processing and visualization. In particular, the <sup>18</sup>F-labeled fluorodeoxyglucose ([<sup>18</sup>F]FDG)-PET scan allows for the measurement and visualization of glucose metabolism in the different segments of the left ventricle (LV). Polar maps are convenient tools to display this information. The CT part consists of a time-resolved 3D reconstruction of the entire heart (4D-CT) using retrospective gating without electrocardiography (ECG) leads, allowing the morphofunctional evaluation of the LV and the subsequent quantification of the most important cardiac function parameters, such as ejection fraction (EF) and stroke volume (SV). Using an integrated PET/CT scanner, this protocol can be executed within the same anesthesia induction without the need to reposition the animal between different scanners. Hence, PET/CT can be seen as a comprehensive tool for the morphofunctional and metabolic evaluation of the heart in several small animal models of cardiac diseases. |
2,329,271 | Can a Cerebral Congenital Anomaly Present in Adulthood? | Colpocephaly, a congenital anomaly in the ventricles, is usually discovered early in infancy and rarely during adulthood. Partial or complete agenesis of the corpus callosum or Chiari malformations (developmental arrest of white matter formation in early fetal development) can lead to abnormal asymmetrical ventricular enlargement. Minimal literature about colpocephaly is available for clinicians, making diagnosis and treatment very challenging. Colpocephaly in adults is an infrequent condition, mostly found as an incidental finding with no neurological or cognitive impairment. Symptoms usually represent the affected lobe in the brain as our patient's visual hallucination may be attributed to the lesioned occipital horn. Differentiating from normal pressure hydrocephalus, representing new-onset dementia, can help avoid unnecessary procedures. Neurological and psychiatric consultation should be practiced to exclude other causes of neurological and cognitive impairment. While there is no definitive treatment for this condition, seizure prophylaxis has been helpful. Cognitive behavioral therapy, psychotherapy, and social skills training are recommended in some literature. Typical and atypical antipsychotics can control symptoms with uncertain efficacy. |
2,329,272 | Pre- and Postnatal Characterization of Autosomal Recessive <i>KIDINS220</i>-Associated Ventriculomegaly. | Heterozygous loss-of-function variants in the last 2 exons of KIDINS220</i> have been associated with spastic paraplegia, intellectual disability, nystagmus, and obesity (SINO). Syndromic features of this condition include macrocephaly and dilatation of the lateral ventricles. Homozygous variants in the more proximal exons of KIDINS220</i> have been reported in several fetuses with a similar but more severe phenotype of limb contractures and severe ventriculomegaly identified in the second trimester of pregnancy.</AbstractText>We present here a 2.5-year-old female with profound global developmental delays and spasticity who was found by fetal ultrasound in week 19 of gestation to have bilateral talipes equinovarus and severe bilateral ventriculomegaly. Postnatal genetic testing revealed biallelic variants in KIDINS220.</i></AbstractText>To our knowledge, this is the first living individual reported with the autosomal recessive form of a KIDINS220</i>-associated condition. This case provides additional information about the postnatal phenotype and a detailed history of development from prenatal ultrasonography.</AbstractText>Copyright © 2022 by S. Karger AG, Basel.</CopyrightInformation> |
2,329,273 | Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.<Pagination><StartPage>1368</StartPage><EndPage>1377</EndPage><MedlinePgn>1368-1377</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-022-03034-z</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">To predict treatment-related cardiovascular disease (CVD) and second cancer 30-year absolute mortality risks (AMR<sub>30</sub>) for patients with mediastinal Hodgkin lymphoma in a large multicentre radiation oncology network in Ireland.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">This study includes consecutive patients treated for mediastinal lymphoma using chemotherapy and involved site radiotherapy (RT) 2016-2019. Radiation doses to heart, left ventricle, cardiac valves, lungs, oesophagus, carotid arteries and female breasts were calculated. Individual CVD and second cancer AMR<sub>30</sub> were predicted using Irish background population rates and dose-response relationships.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-four patients with Hodgkin lymphoma were identified, 23 females, median age 28 years. Ninety-eight percent received anthracycline, 80% received 4-6 cycles ABVD. Volumetric modulated arc therapy (VMAT) ± deep inspiration breath hold (DIBH) was delivered, median total prescribed dose 30 Gy. Average mean heart dose 9.8 Gy (range 0.2-23.8 Gy). Excess treatment-related mean AMR<sub>30</sub> from CVD was 2.18% (0.79, 0.90, 0.01, 0.13 and 0.35% for coronary disease, heart failure, valvular disease, stroke and other cardiac diseases), 1.07% due to chemotherapy and a further 1.11% from RT. Excess mean AMR<sub>30</sub> for second cancers following RT were: lung cancer 2.20%, breast cancer in females 0.34%, and oesophageal cancer 0.28%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Houlihan</LastName><ForeName>Orla A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0001-9199-460X</Identifier><AffiliationInfo><Affiliation>St Luke's Radiation Oncology Network, Dublin, Ireland. ohoulihan01@qub.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, UK. ohoulihan01@qub.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ntentas</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutter</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>St Luke's Radiation Oncology Network, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Trinity St James's Cancer Institute, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillham</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>St Luke's Radiation Oncology Network, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Trinity St James's Cancer Institute, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>McArdle</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>St Luke's Radiation Oncology Network, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Duane</LastName><ForeName>Frances K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>St Luke's Radiation Oncology Network, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Trinity St James's Cancer Institute, St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C8225/A21133</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11056-06-7</RegistryNumber><NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7GR28W0FJI</RegistryNumber><NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>5V9KLZ54CY</RegistryNumber><NameOfSubstance UI="D014747">Vinblastine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050397" MajorTopicYN="Y">Radiotherapy, Intensity-Modulated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006689" MajorTopicYN="Y">Hodgkin Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="Y">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062485" MajorTopicYN="N">Breath Holding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011879" MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058958" MajorTopicYN="N">Organs at Risk</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001761" MajorTopicYN="N">Bleomycin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003606" MajorTopicYN="N">Dacarbazine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014747" MajorTopicYN="N">Vinblastine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008479" MajorTopicYN="Y">Mediastinal Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008223" MajorTopicYN="Y">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011880" MajorTopicYN="N">Radiotherapy Planning, Computer-Assisted</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Mediastinal lymphoma</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">Second cancer</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36585562</ArticleId><ArticleId IdType="pmc">PMC10119211</ArticleId><ArticleId IdType="doi">10.1007/s12094-022-03034-z</ArticleId><ArticleId IdType="pii">10.1007/s12094-022-03034-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794. doi: 10.1200/JCO.2016.68.6394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.68.6394</ArticleId><ArticleId IdType="pubmed">28291393</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):323–330. doi: 10.1182/asheducation-2016.1.323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/asheducation-2016.1.323</ArticleId><ArticleId IdType="pmc">PMC6142518</ArticleId><ArticleId IdType="pubmed">27913498</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607. doi: 10.1056/NEJMoa1408648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1408648</ArticleId><ArticleId IdType="pubmed">25901426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, et al. Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys. 2020;107(5):909–933. doi: 10.1016/j.ijrobp.2020.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2020.03.019</ArticleId><ArticleId IdType="pubmed">32272184</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652. doi: 10.1056/NEJMoa1000067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1000067</ArticleId><ArticleId IdType="pubmed">20818855</ArticleId></ArticleIdList></Reference><Reference><Citation>Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(4):1522–1527. doi: 10.1016/j.ijrobp.2011.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2011.05.015</ArticleId><ArticleId IdType="pubmed">21705151</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60–66. doi: 10.3109/0284186X.2014.932435.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/0284186X.2014.932435</ArticleId><ArticleId IdType="pubmed">25025999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, et al. Different IMRT solutions vs 3D-conformal radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol. 2012;7:186. doi: 10.1186/1748-717X-7-186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-717X-7-186</ArticleId><ArticleId IdType="pmc">PMC3502518</ArticleId><ArticleId IdType="pubmed">23122028</ArticleId></ArticleIdList></Reference><Reference><Citation>Voong KR, McSpadden K, Pinnix CC, Shihadeh F, Reed V, Salehpour MR, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94. doi: 10.1186/1748-717X-9-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-717X-9-94</ArticleId><ArticleId IdType="pmc">PMC4013438</ArticleId><ArticleId IdType="pubmed">24735767</ArticleId></ArticleIdList></Reference><Reference><Citation>Starke A, Bowden J, Lynn R, Hall K, Hudson K, Rato A, et al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiother Oncol. 2018;129(3):449–455. doi: 10.1016/j.radonc.2018.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2018.08.017</ArticleId><ArticleId IdType="pubmed">30245037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, et al. Proton therapy in supradiaphragmatic lymphoma: predicting treatment-related mortality to help optimize patient selection. Int J Radiat Oncol Biol Phys. 2022;112(4):913–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865523</ArticleId><ArticleId IdType="pubmed">34762970</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–1017. doi: 10.1001/jamainternmed.2015.1180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2015.1180</ArticleId><ArticleId IdType="pubmed">25915855</ArticleId></ArticleIdList></Reference><Reference><Citation>Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG) Int J Radiat Oncol Biol Phys. 2014;89(4):854–862. doi: 10.1016/j.ijrobp.2013.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2013.05.005</ArticleId><ArticleId IdType="pubmed">23790512</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10–18. doi: 10.1016/j.ijrobp.2009.10.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2009.10.058</ArticleId><ArticleId IdType="pmc">PMC2937165</ArticleId><ArticleId IdType="pubmed">20421148</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake RA, Vogl W, Mitchell A, Tibbitts R, Richardson P. Gray's atlas of anatomy. 3. Philadelphia: Elsevier/Churchill Livingstone; 2020.</Citation></Reference><Reference><Citation>IMAIOS. E-anatomy [Internet]. 2021 [cited 2022 Jul 09]. Available from: https://www.imaios.com/en/e-Anatomy.</Citation></Reference><Reference><Citation>Duane F, Aznar MC, Bartlett F, Cutter DJ, Darby SC, Jagsi R, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017;122(3):416–422. doi: 10.1016/j.radonc.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2017.01.008</ArticleId><ArticleId IdType="pmc">PMC5356506</ArticleId><ArticleId IdType="pubmed">28233564</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlihan OA, Rangaswamy G, Dunne M, Rohan C, O’Neill L, Chalke S, et al. Deep inspiration breath hold versus free breathing technique in mediastinal radiotherapy for lymphoma. BJR Open. 2021;3(1):20200067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931409</ArticleId><ArticleId IdType="pubmed">33718767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutter DJ, Ramroth J, Diez P, Buckle A, Ntentas G, Popova B, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography–directed therapy for early-stage Hodgkin lymphoma. J Clin Oncol. 2021;39(32):3591–3601. doi: 10.1200/JCO.21.00408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.00408</ArticleId><ArticleId IdType="pmc">PMC8577686</ArticleId><ArticleId IdType="pubmed">34388007</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruin ML, Dorresteijn LDA, van’t Veer MB, Krol ADG, van der Pal HJ, Kappelle AC, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101:928–37. doi: 10.1093/jnci/djp147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djp147</ArticleId><ArticleId IdType="pubmed">19535773</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–243. doi: 10.1200/JCO.2015.63.4444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.63.4444</ArticleId><ArticleId IdType="pubmed">26573075</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–2265. doi: 10.1182/blood-2016-09-740332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-740332</ArticleId><ArticleId IdType="pmc">PMC5418626</ArticleId><ArticleId IdType="pubmed">28143884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol ADG, et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015; 107(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394894</ArticleId><ArticleId IdType="pubmed">25713164</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraldo MV, Lundemann M, Vogelius IR, Specht L. A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma. Radiother Oncol. 2015;114(2):206–211. doi: 10.1016/j.radonc.2015.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2015.01.008</ArticleId><ArticleId IdType="pubmed">25620063</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94(3):182–192. doi: 10.1093/jnci/94.3.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/94.3.182</ArticleId><ArticleId IdType="pubmed">11830608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res. 2003;159(2):161–173. doi: 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2</ArticleId><ArticleId IdType="pubmed">12537521</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: a national cohort study. J Clin Oncol. 2012;30(22):2745–2752. doi: 10.1200/JCO.2011.38.8835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.8835</ArticleId><ArticleId IdType="pubmed">22734026</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373(26):2499–2511. doi: 10.1056/NEJMoa1505949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505949</ArticleId><ArticleId IdType="pubmed">26699166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay MM, Ethel SG, Marilyn S, EvL Flora, Graça MD, Charles FL, et al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica. 2014;99(10):e193–e6. doi: 10.3324/haematol.2014.108258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2014.108258</ArticleId><ArticleId IdType="pmc">PMC4181268</ArticleId><ArticleId IdType="pubmed">25271315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricardi U, Maraldo MV, Levis M, Parikh RR. Proton therapy for lymphomas: current state of the art. Onco Targets Ther. 2019;12:8033–8046. doi: 10.2147/OTT.S220730.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S220730</ArticleId><ArticleId IdType="pmc">PMC6781741</ArticleId><ArticleId IdType="pubmed">31632057</ArticleId></ArticleIdList></Reference><Reference><Citation>Levis M, Filippi AR, Fiandra C, De Luca V, Bartoncini S, Vella D, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin’s lymphoma patients. Radiother Oncol. 2019;138:52–58. doi: 10.1016/j.radonc.2019.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2019.05.009</ArticleId><ArticleId IdType="pubmed">31146071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635–1646. doi: 10.1182/blood-2018-03-837633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-03-837633</ArticleId><ArticleId IdType="pmc">PMC6212652</ArticleId><ArticleId IdType="pubmed">30108066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntentas G, Dedeckova K, Andrlik M, Aznar MC, George B, Kubeš J, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9(3):179–187. doi: 10.1016/j.prro.2019.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prro.2019.01.006</ArticleId><ArticleId IdType="pmc">PMC6493042</ArticleId><ArticleId IdType="pubmed">30708133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vries Sd, Haaksma ML, Jóźwiak K, Schaapveld M, Hodgson DC, Lugtenburg PJ, et al. Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma. J Clin Oncol. 2022; 0(0):JCO.21.02613.</Citation><ArticleIdList><ArticleId IdType="pubmed">35947813</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36585272</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-1692</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Pediatrics and neonatology</Title><ISOAbbreviation>Pediatr Neonatol</ISOAbbreviation></Journal>Associated factors with parental pregnancy decision-making and use of consultation after a prenatal congenital heart disease diagnosis. | To predict treatment-related cardiovascular disease (CVD) and second cancer 30-year absolute mortality risks (AMR30</sub>) for patients with mediastinal Hodgkin lymphoma in a large multicentre radiation oncology network in Ireland.</AbstractText>This study includes consecutive patients treated for mediastinal lymphoma using chemotherapy and involved site radiotherapy (RT) 2016-2019. Radiation doses to heart, left ventricle, cardiac valves, lungs, oesophagus, carotid arteries and female breasts were calculated. Individual CVD and second cancer AMR30</sub> were predicted using Irish background population rates and dose-response relationships.</AbstractText>Forty-four patients with Hodgkin lymphoma were identified, 23 females, median age 28 years. Ninety-eight percent received anthracycline, 80% received 4-6 cycles ABVD. Volumetric modulated arc therapy (VMAT) ± deep inspiration breath hold (DIBH) was delivered, median total prescribed dose 30 Gy. Average mean heart dose 9.8 Gy (range 0.2-23.8 Gy). Excess treatment-related mean AMR30</sub> from CVD was 2.18% (0.79, 0.90, 0.01, 0.13 and 0.35% for coronary disease, heart failure, valvular disease, stroke and other cardiac diseases), 1.07% due to chemotherapy and a further 1.11% from RT. Excess mean AMR30</sub> for second cancers following RT were: lung cancer 2.20%, breast cancer in females 0.34%, and oesophageal cancer 0.28%.</AbstractText>For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.</AbstractText>© 2022. The Author(s).</CopyrightInformation> |
2,329,274 | Impact of spraying eggs with betaine after exposure to short-term thermal stress during early embryogenesis on pre and post-hatch performance of Japanese quail. | It is essential to understand and manage environmental factors for good quail production and welfare. One of the most important environmental stressors that hinder quail productivity is heat stress. This study aimed to evaluate the impact of spraying Japanese quail (Coturnix coturnix japonica) eggs with betaine after exposure to short-term high temperature during early embryogenesis on pre and post-hatch performance of quail. A total of 750 eggs were equally divided into two groups. Eggs in the first group were incubated at normal incubation temperature (37.5 °C/NIT), while those in the second group were incubated at high incubation temperature (39.0 °C/HIT) for 3 h daily from day 4-6 of incubation. Eggs in both groups were subjected to five treatments, NC (negative control), PC sprayed distilled water (positive control), while B0.5, B1, and B2 treatments were sprayed with distilled water supplemented with 500, 1000, and 2000 mg betaine/L, respectively. The chick weight at hatch, slaughter weight, and first egg weight was significantly impaired by the HIT treatment. The HIT group revealed a significant increase in cloacal temperature, H/L ratio, liver enzymes, triglyceride, and cholesterol and a significant decrease in hatchability, T3 hormone, and blood protein levels than the NIT group. Regarding betaine effects, the embryonic mortality rates, hatchability, hatched chick weight, and oviduct percentage in groups treated with 1000 or 2000 mg betaine/L were significantly improved compared with the control. Also, spraying betaine at 1000 or 2000 mg/L significantly increased blood protein and triiodothyronine (T3) hormone levels and significantly decrease liver enzyme levels and total feed consumption compared with the untreated group. The right/total ventricle ratio (RV/TV) of quail in HIT group was significantly increased, while betaine treatment significantly decreased this ratio. Considering these results, it is strongly suggested that spraying of betaine on eggs at 2000 mg/L optimizes Japanese quail performance. |
2,329,275 | Non-typeable Haemophilus influenza ventriculitis, a case report and literature review. | and importance: Haemophilus influenza severe presentations have decreased dramatically after the Hib vaccination was introduced. However, due to the emergence of Multi-drug resistance organisms, severe presentations like meningitis and ventriculitis may occur.</AbstractText>Here, we have described a rarely reported case of non-typeable Haemophilus influenza ventriculitis in a previously healthy patient. MRI of the head with contrast was suggestive of tiny foci of diffusion restriction in occipital horns of bilateral ventricles with minimal intraventricular pus formation. The diagnosis was confirmed based on blood culture results and MRI findings as the patient refused to have a lumbar puncture procedure for CSF analysis. The patient was treated with intravenous antibiotics and showed a good response.</AbstractText>In the post-HiB immunization era, we have seen a decline in invasive diseases caused by Type B Haemophilus influenza. However, non-typeable Haemophilus influenzae is now on the rise. Central nervous system infection due to non-typable Haemophilus influenza is infrequent as this organism is predominantly a respiratory mucosal pathogen resulting in acute and chronic respiratory tract infections. Multi-drug resistance of non-typeable Haemophilus influenzae is also becoming a cause of concern.</AbstractText>Ventriculitis secondary to non-typeable beta-lactamase non-producing, ampicillin-resistant (BLNAR) Haemophilus influenza is rare, and more such cases need to be reported within the adult population to avoid under-recognition.</AbstractText>© 2022 The Authors.</CopyrightInformation> |
2,329,276 | Outcomes of Cardiac Gunshot Injuries Presenting at an Urban Trauma Facility in Johannesburg, South Africa. | Gunshot wounds to the heart are regarded as one of the most lethal penetrating injuries. There has been an increase in gunshot wounds to the chest in our institution in recent years. Injuries to the heart caused by gunshot wounds can be challenging, with patients arriving in hospital in different physiological states. We report our trauma unit's experience with civilian gunshot wounds to the heart.</AbstractText>A retrospective review from January 2005 till December 2018 of those 18 years of age and above who presented to our hospital with penetrating cardiac injuries over eight years was done. Those who presented with a carotid pulse and a cardiac rhythm were included in the study. Blood pressure of less than 90 mmHg was considered as haemodynamic instability. Demographics, physiological parameters, injuries sustained, preferred surgical access to the chest, and type of surgery were analysed. The complications during their hospital stay and outpatient clinic were documented. The incidences of in-hospital mortality were also noted. Descriptive statistics with STATA version 15 were conducted. A p-value of < 0.05 was considered statistically significant.</AbstractText>A total of 37 patients were enroled in the study; four were excluded for incomplete data. All presented directly from the scene, with a median age of 30 (IQR 24-36). Haemodynamic instability was in 64% of the cases. The most common injured chamber was the right ventricle (75.7%). There were only two complications recorded; local wound sepsis and empyema. All survivors received a post-surgical echocardiogram. The overall survival rate was 18.9% (n = 7). Of the ten that required emergency room thoracotomy, only one survived to discharge.</AbstractText>Gunshot wounds to the heart have a mortality rate greater than 80% in those arriving alive. Only one in ten of those who meet the strict criteria for emergency room thoracotomy survive hospitalisation. The local complication rate was low.</AbstractText>© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.</CopyrightInformation> |
2,329,277 | Takotsubo cardiomyopathy following liver transplantation and COVID-19 infection.<Pagination><StartPage>99</StartPage><EndPage>100</EndPage><MedlinePgn>99-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/08998280.2022.2114069</ELocationID><Abstract><AbstractText>Takotsubo cardiomyopathy involves transient systolic dysfunction of the left ventricle thought to be caused by a physiologic stress response and associated catecholamine release. We present a previously undocumented cause of this stress response involving a 53-year-old man with hepatocellular carcinoma and alcohol-associated cirrhosis who initially presented for liver transplantation. Shortly after successful transplantation, the patient developed a COVID-19 infection and takotsubo cardiomyopathy.</AbstractText><CopyrightInformation>Copyright © 2022 Baylor University Medical Center.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winrich</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belur</LastName><ForeName>Agastya D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shine</LastName><ForeName>Amal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jophlin</LastName><ForeName>Loretta L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 DK123381</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc (Bayl Univ Med Cent)</MedlineTA><NlmUniqueID>9302033</NlmUniqueID><ISSNLinking>0899-8280</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Liver transplant</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>2</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36578602</ArticleId><ArticleId IdType="pmc">PMC9762796</ArticleId><ArticleId IdType="doi">10.1080/08998280.2022.2114069</ArticleId><ArticleId IdType="pii">2114069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scantlebury DC, Prasad A.. Diagnosis of takotsubo cardiomyopathy. Circ J. 2014;78(9):2129–2139. doi:10.1253/circj.cj-14-0859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.cj-14-0859</ArticleId><ArticleId IdType="pubmed">25131525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni M, Dentali F, Grandi AM, et al. . Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006;27(13):1523–1529. doi:10.1093/eurheartj/ehl032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehl032</ArticleId><ArticleId IdType="pubmed">16720686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachotti Pires LJ, Cardoso Curiati MN, Vissoci Reiche F, et al. . Stress-induced cardiomyopathy (takotsubo cardiomyopathy) after liver transplantation-report of two cases. Transplant Proc. 2012;44(8):2497–2500. doi:10.1016/j.transproceed.2012.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2012.07.037</ArticleId><ArticleId IdType="pubmed">23026629</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ven F, Pennec PY, Timsit S, Blanc JJ.. Takotsubo syndrome associated with seizures: an underestimated cause of sudden death in epilepsy? Int J Cardiol. 2011;146(3):475–479. doi:10.1016/j.ijcard.2010.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2010.12.028</ArticleId><ArticleId IdType="pubmed">21194774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurisu S, Inoue I, Kawagoe T, et al. . Time course of electrocardiographic changes in patients with tako-tsubo syndrome: comparison with acute myocardial infarction with minimal enzymatic release. Circ J. 2004;68(1):77–81. doi:10.1253/circj.68.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.68.77</ArticleId><ArticleId IdType="pubmed">14695470</ArticleId></ArticleIdList></Reference><Reference><Citation>Akashi YJ, Goldstein DS, Barbaro G, Ueyama T.. Takotsubo cardiomyopathy. Circulation. 2008;118(25):2754–2762. doi:10.1161/CIRCULATIONAHA.108.767012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.767012</ArticleId><ArticleId IdType="pmc">PMC4893309</ArticleId><ArticleId IdType="pubmed">19106400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36577900</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-0961</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurocritical care</Title><ISOAbbreviation>Neurocrit Care</ISOAbbreviation></Journal>Poor Accuracy of Manually Derived Head Computed Tomography Parameters in Predicting Intracranial Hypertension After Nontraumatic Intracranial Hemorrhage. | Takotsubo cardiomyopathy involves transient systolic dysfunction of the left ventricle thought to be caused by a physiologic stress response and associated catecholamine release. We present a previously undocumented cause of this stress response involving a 53-year-old man with hepatocellular carcinoma and alcohol-associated cirrhosis who initially presented for liver transplantation. Shortly after successful transplantation, the patient developed a COVID-19 infection and takotsubo cardiomyopathy.<CopyrightInformation>Copyright © 2022 Baylor University Medical Center.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winrich</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belur</LastName><ForeName>Agastya D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shine</LastName><ForeName>Amal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jophlin</LastName><ForeName>Loretta L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 DK123381</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc (Bayl Univ Med Cent)</MedlineTA><NlmUniqueID>9302033</NlmUniqueID><ISSNLinking>0899-8280</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Liver transplant</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>2</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36578602</ArticleId><ArticleId IdType="pmc">PMC9762796</ArticleId><ArticleId IdType="doi">10.1080/08998280.2022.2114069</ArticleId><ArticleId IdType="pii">2114069</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scantlebury DC, Prasad A.. Diagnosis of takotsubo cardiomyopathy. Circ J. 2014;78(9):2129–2139. doi:10.1253/circj.cj-14-0859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.cj-14-0859</ArticleId><ArticleId IdType="pubmed">25131525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni M, Dentali F, Grandi AM, et al. . Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006;27(13):1523–1529. doi:10.1093/eurheartj/ehl032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehl032</ArticleId><ArticleId IdType="pubmed">16720686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachotti Pires LJ, Cardoso Curiati MN, Vissoci Reiche F, et al. . Stress-induced cardiomyopathy (takotsubo cardiomyopathy) after liver transplantation-report of two cases. Transplant Proc. 2012;44(8):2497–2500. doi:10.1016/j.transproceed.2012.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2012.07.037</ArticleId><ArticleId IdType="pubmed">23026629</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ven F, Pennec PY, Timsit S, Blanc JJ.. Takotsubo syndrome associated with seizures: an underestimated cause of sudden death in epilepsy? Int J Cardiol. 2011;146(3):475–479. doi:10.1016/j.ijcard.2010.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2010.12.028</ArticleId><ArticleId IdType="pubmed">21194774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurisu S, Inoue I, Kawagoe T, et al. . Time course of electrocardiographic changes in patients with tako-tsubo syndrome: comparison with acute myocardial infarction with minimal enzymatic release. Circ J. 2004;68(1):77–81. doi:10.1253/circj.68.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.68.77</ArticleId><ArticleId IdType="pubmed">14695470</ArticleId></ArticleIdList></Reference><Reference><Citation>Akashi YJ, Goldstein DS, Barbaro G, Ueyama T.. Takotsubo cardiomyopathy. Circulation. 2008;118(25):2754–2762. doi:10.1161/CIRCULATIONAHA.108.767012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.767012</ArticleId><ArticleId IdType="pmc">PMC4893309</ArticleId><ArticleId IdType="pubmed">19106400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36577900</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-0961</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurocritical care</Title><ISOAbbreviation>Neurocrit Care</ISOAbbreviation></Journal><ArticleTitle>Poor Accuracy of Manually Derived Head Computed Tomography Parameters in Predicting Intracranial Hypertension After Nontraumatic Intracranial Hemorrhage.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12028-022-01662-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The utility of head computed tomography (CT) in predicting elevated intracranial pressure (ICP) is known to be limited in traumatic brain injury; however, few data exist in patients with spontaneous intracranial hemorrhage.<AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective review of prospectively collected data in patients with nontraumatic intracranial hemorrhage (subarachnoid hemorrhage [SAH] or intraparenchymal hemorrhage [IPH]) who underwent external ventricular drain (EVD) placement. Head CT scans performed immediately prior to EVD placement were quantitatively reviewed for features suggestive of elevated ICP, including temporal horn diameter, bicaudate index, basal cistern effacement, midline shift, and global cerebral edema. The modified Fisher score (mFS), intraventricular hemorrhage score, and IPH volume were also measured, as applicable. We calculated the accuracy, positive predictive value (PPV), and negative predictive value (NPV) of these radiographic features for the coprimary outcomes of elevated ICP (> 20 mm Hg) at the time of EVD placement and at any time during the hospital stay. Multivariable backward stepwise logistic regression analysis was performed to identify significant radiographic factors associated with elevated ICP.<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 608 patients with intracranial hemorrhages enrolled during the study time frame, 243 (40%) received an EVD and 165 (n = 107 SAH, n = 58 IPH) had a preplacement head CT scan available for rating. Elevated opening pressure and elevated ICP during hospitalization were recorded in 48 of 152 (29%) and 103 of 165 (62%), respectively. The presence of ≥ 1 radiographic feature had only 32% accuracy for identifying elevated opening pressure (PPV 30%, NPV 58%, area under the curve [AUC] 0.537, 95% asymptotic confidence interval [CI] 0.436-0.637, P = 0.466) and 59% accuracy for predicting elevated ICP during hospitalization (PPV 63%, NPV 40%, AUC 0.514, 95% asymptotic CI 0.391-0.638, P = 0.820). There was no significant association between the number of radiographic features and ICP elevation. Head CT scans without any features suggestive of elevated ICP occurred in 25 of 165 (15%) patients. However, 10 of 25 (40%) of these patients had elevated opening pressure, and 15 of 25 (60%) had elevated ICP during their hospital stay. In multivariable models, mFS (adjusted odds ratio [aOR] 1.36, 95% CI 1.10-1.68) and global cerebral edema (aOR 2.93, 95% CI 1.27-6.75) were significantly associated with elevated ICP; however, their accuracies were only 69% and 60%, respectively. All other individual radiographic features had accuracies between 38 and 58% for identifying intracranial hypertension.<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More than 50% of patients with spontaneous intracranial hemorrhage without radiographic features suggestive of elevated ICP actually had ICP > 20 mm Hg during EVD placement or their hospital stay. Morphological head CT findings were only 32% and 59% accurate in identifying elevated opening pressure and ICP elevation during hospitalization, respectively. |
2,329,278 | Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma. | To evaluate the safety profile of bis-chloroethyl-nitrosourea (BCNU) wafer implantation after malignant glioma resection with or without ventricular opening (VO).</AbstractText>This single-center retrospective study included 66 consecutive patients with BCNU wafer implantation after malignant glioma resection between March 2013 and August 2021. The patients were categorized into 2 groups based on whether VO occurred during the malignant glioma resection. Fifty-eight patients had glioblastoma, and 8 had anaplastic astrocytoma or oligodendroglioma. Forty-eight patients underwent an initial treatment, and 18 underwent recurrent surgeries. Infection, hydrocephalus, subcutaneous fluid collection, chronic subdural hematoma, early seizure after surgery within 1 month, symptomatic edema surrounding the resected cavity, cyst formation, and postoperative hemorrhage were defined as adverse events (AEs).</AbstractText>Thirty-three patients underwent resection with VO, and 33 without. The median survival time was 28 months in the initial treatment group and 11.5 months in the recurrent treatment group. The with and without VO groups had similar median survival times. Postoperative AEs occurred in 7/33 patients (21.2%) with VO and 10/33 (30.3%) without VO, with no difference between them (P = 0.574).</AbstractText>This study showed that VO during surgery with BCNU wafer implantation might not influence the occurrence of postoperative AEs. If VO happens, BCNU wafer implantation can be performed safely with accurate closing of the ventricle.</AbstractText>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,279 | Impella Support for Surgical Ventricular Septal Defect Repair.<Pagination><StartPage>e278</StartPage><EndPage>e283</EndPage><MedlinePgn>e278-e283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001873</ELocationID><Abstract><AbstractText>Acute postinfarct ventricular septal defect (VSD) is associated with high mortality due to a combination of cardiogenic shock and a complex repair in recently infarcted fragile myocardium. 1 Although the Impella heart pump is established as support for cardiogenic shock, it is relatively contraindicated in postinfarct VSD because of potential right-to-left shunt or stroke due to VSD tissue-related embolus. On autopsy, early repair is technically difficult due to tissue friability and as a result, 38% of surgically repaired patients have evidence of recurrent interventricular septal rupture. 2 Delayed surgical repair (>7 days) is associated with superior survival-54% after 7 days versus 18% prior-but hemodynamic instability may prevent delay. 3 Case reports have shown successful early left ventricular unloading with Impella patients with acute postinfarct VSD before surgical repair. 4,5 We discuss our algorithm for pre-repair Impella support in which we stratify pre-repair support based on the Qp/Qs ratio. For VSD with Qp/Qs >2.5, we use a preoperative Impella heart pump and have not demonstrated reversal in the left-to-right shunt on echocardiography and/or stroke. Our findings are consistent with theoretical models of unloading as demonstrated by shifts in pressure-volume loops. 6.</AbstractText><CopyrightInformation>Copyright © ASAIO 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz Duque</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the University of Iowa Carver College of Medicine, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohenwarter</LastName><ForeName>Marian R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Nicholas R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Singhal</LastName><ForeName>Arun K</ForeName><Initials>AK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006345" MajorTopicYN="Y">Heart Septal Defects, Ventricular</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: There are no funding or conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36574463</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001873</ArticleId><ArticleId IdType="pii">00002480-990000000-00150</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giblett JP, Matetic A, Jenkins D, Ng CY: Post-infarction ventricular septal defect: Percutaneous or surgical management in the UK national registry. [published online ahead of print September 17, 2022] Eur Heart J, 2022.</Citation></Reference><Reference><Citation>Cinq-Mars A, Voisine P, Dagenais F, et al.: Risk factors of mortality after surgical correction of ventricular septal defect following myocardial infarction: Retrospective analysis and review of the literature. Int J Cardiol 206: 27–36, 2016.</Citation></Reference><Reference><Citation>Via G, Buson S, Tavazzi G, et al.: Early cardiac unloading with ImpellaCP in acute myocardial infarction with ventricular septal defect. ESC Heart Fail 7: 708–713, 2020.</Citation></Reference><Reference><Citation>La Torre MW, Centofanti P, et al.: Posterior ventricular septal defect in presence of cardiogenic shock: Early implantation of the Impella recover LP 5.0 as a bridge to surgery. Tex Heart Inst J 38: 42–49, 2011.</Citation></Reference><Reference><Citation>Madjarov JM, Katz MG, Madzharov S, Fazal S, Robicsek F: Advantages of intraoperative implantation of Impella 5.5 Smartassist in the management of acute post-infarction ventricular septal defect with cardiogenic shock. J Cardiothorac Surg 16: 132, 2021.</Citation></Reference><Reference><Citation>Pahuja M, Schrage B, Westermann D, Basir MB, Garan AR, Burkhoff D: Hemodynamic effects of mechanical circulatory support devices in ventricular septal defect. Circ Heart Fail 12: e005981, 2019.</Citation></Reference><Reference><Citation>Beyer E: Abiomed. Instruction for Use and Clinical Reference Manual. User Manual. https://www.abiomed.com/products-and-services/impella/impella-55-with-smartassist , 2018.</Citation></Reference><Reference><Citation>Ronco D, Matteucci M, Ravaux JM, et al.: Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv 14: 1053–1066, 2021.</Citation></Reference><Reference><Citation>Hobbs R, Korutla V, Suzuki Y, Acker M, Vallabhajosyula P: Mechanical circulatory support as a bridge to definitive surgical repair after post-myocardial infarct ventricular septal defect. J Card Surg 30: 535–540, 2015.</Citation></Reference><Reference><Citation>Asai T, Hosoba S, Suzuki T, Kinoshita T: Postinfarction ventricular septal defect: Right ventricular approach-the extended “sandwich” patch. Semin Thorac Cardiovasc Surg 24: 59–62, 2012.</Citation></Reference><Reference><Citation>Matteucci M, Ronco D, Corazzari C, et al.: Surgical repair of postinfarction ventricular septal rupture: Systematic review and meta-analysis. Ann Thorac Surg 112: 326–337, 2021.</Citation></Reference><Reference><Citation>Naidu SS: Novel percutaneous cardiac assist devices: The science of and indications for hemodynamic support. Circulation 123: 533–543, 2011.</Citation></Reference><Reference><Citation>Maeda K, Yoshioka I, Saiki Y: Emergence of right to left shunt via postmyocardial infarction ventricular septal defect under Impella support. Artif Organs 45: 316–317, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36574175</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6551</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology</Title><ISOAbbreviation>J Nucl Cardiol</ISOAbbreviation></Journal>Comparison of the prognostic value of impaired stress myocardial blood flow, myocardial flow reserve, and myocardial flow capacity on low-dose Rubidium-82 SiPM PET/CT. | Acute postinfarct ventricular septal defect (VSD) is associated with high mortality due to a combination of cardiogenic shock and a complex repair in recently infarcted fragile myocardium. 1 Although the Impella heart pump is established as support for cardiogenic shock, it is relatively contraindicated in postinfarct VSD because of potential right-to-left shunt or stroke due to VSD tissue-related embolus. On autopsy, early repair is technically difficult due to tissue friability and as a result, 38% of surgically repaired patients have evidence of recurrent interventricular septal rupture. 2 Delayed surgical repair (>7 days) is associated with superior survival-54% after 7 days versus 18% prior-but hemodynamic instability may prevent delay. 3 Case reports have shown successful early left ventricular unloading with Impella patients with acute postinfarct VSD before surgical repair. 4,5 We discuss our algorithm for pre-repair Impella support in which we stratify pre-repair support based on the Qp/Qs ratio. For VSD with Qp/Qs >2.5, we use a preoperative Impella heart pump and have not demonstrated reversal in the left-to-right shunt on echocardiography and/or stroke. Our findings are consistent with theoretical models of unloading as demonstrated by shifts in pressure-volume loops. 6.<CopyrightInformation>Copyright © ASAIO 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz Duque</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the University of Iowa Carver College of Medicine, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohenwarter</LastName><ForeName>Marian R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Nicholas R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Singhal</LastName><ForeName>Arun K</ForeName><Initials>AK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ASAIO J</MedlineTA><NlmUniqueID>9204109</NlmUniqueID><ISSNLinking>1058-2916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006345" MajorTopicYN="Y">Heart Septal Defects, Ventricular</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: There are no funding or conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36574463</ArticleId><ArticleId IdType="doi">10.1097/MAT.0000000000001873</ArticleId><ArticleId IdType="pii">00002480-990000000-00150</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giblett JP, Matetic A, Jenkins D, Ng CY: Post-infarction ventricular septal defect: Percutaneous or surgical management in the UK national registry. [published online ahead of print September 17, 2022] Eur Heart J, 2022.</Citation></Reference><Reference><Citation>Cinq-Mars A, Voisine P, Dagenais F, et al.: Risk factors of mortality after surgical correction of ventricular septal defect following myocardial infarction: Retrospective analysis and review of the literature. Int J Cardiol 206: 27–36, 2016.</Citation></Reference><Reference><Citation>Via G, Buson S, Tavazzi G, et al.: Early cardiac unloading with ImpellaCP in acute myocardial infarction with ventricular septal defect. ESC Heart Fail 7: 708–713, 2020.</Citation></Reference><Reference><Citation>La Torre MW, Centofanti P, et al.: Posterior ventricular septal defect in presence of cardiogenic shock: Early implantation of the Impella recover LP 5.0 as a bridge to surgery. Tex Heart Inst J 38: 42–49, 2011.</Citation></Reference><Reference><Citation>Madjarov JM, Katz MG, Madzharov S, Fazal S, Robicsek F: Advantages of intraoperative implantation of Impella 5.5 Smartassist in the management of acute post-infarction ventricular septal defect with cardiogenic shock. J Cardiothorac Surg 16: 132, 2021.</Citation></Reference><Reference><Citation>Pahuja M, Schrage B, Westermann D, Basir MB, Garan AR, Burkhoff D: Hemodynamic effects of mechanical circulatory support devices in ventricular septal defect. Circ Heart Fail 12: e005981, 2019.</Citation></Reference><Reference><Citation>Beyer E: Abiomed. Instruction for Use and Clinical Reference Manual. User Manual. https://www.abiomed.com/products-and-services/impella/impella-55-with-smartassist , 2018.</Citation></Reference><Reference><Citation>Ronco D, Matteucci M, Ravaux JM, et al.: Mechanical circulatory support as a bridge to definitive treatment in post-infarction ventricular septal rupture. JACC Cardiovasc Interv 14: 1053–1066, 2021.</Citation></Reference><Reference><Citation>Hobbs R, Korutla V, Suzuki Y, Acker M, Vallabhajosyula P: Mechanical circulatory support as a bridge to definitive surgical repair after post-myocardial infarct ventricular septal defect. J Card Surg 30: 535–540, 2015.</Citation></Reference><Reference><Citation>Asai T, Hosoba S, Suzuki T, Kinoshita T: Postinfarction ventricular septal defect: Right ventricular approach-the extended “sandwich” patch. Semin Thorac Cardiovasc Surg 24: 59–62, 2012.</Citation></Reference><Reference><Citation>Matteucci M, Ronco D, Corazzari C, et al.: Surgical repair of postinfarction ventricular septal rupture: Systematic review and meta-analysis. Ann Thorac Surg 112: 326–337, 2021.</Citation></Reference><Reference><Citation>Naidu SS: Novel percutaneous cardiac assist devices: The science of and indications for hemodynamic support. Circulation 123: 533–543, 2011.</Citation></Reference><Reference><Citation>Maeda K, Yoshioka I, Saiki Y: Emergence of right to left shunt via postmyocardial infarction ventricular septal defect under Impella support. Artif Organs 45: 316–317, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36574175</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6551</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology</Title><ISOAbbreviation>J Nucl Cardiol</ISOAbbreviation></Journal><ArticleTitle>Comparison of the prognostic value of impaired stress myocardial blood flow, myocardial flow reserve, and myocardial flow capacity on low-dose Rubidium-82 SiPM PET/CT.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12350-022-03155-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The most reliable quantitative variable on Rubidium-82 (<sup>82</sup>Rb) cardiac PET/CT for predicting major adverse cardiovascular events (MACE) has not been characterized with low-dose silicon photomultipliers (SiPM) technology, which allows halving injected activity and radiation dose delivering less than 1.0 mSv in a 70-kg individual.<AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We prospectively enrolled 234 consecutive participants with suspected myocardial ischemia. Participants underwent <sup>82</sup>Rb cardiac SiPM PET/CT (5 MBq/kg) and were followed up for MACE over 652 days (interquartile range 559-751 days). For each participant, global stress myocardial blood flow (stress MBF), global myocardial flow reserve (MFR), and regional severely reduced myocardial flow capacity (MFC<sub>severe</sub>) were measured. The Youden index was used to select optimal thresholds. In multivariate analysis after adjustments for clinical risk factors, reduced global stress MBF < 1.94 ml/min/g, reduced global MFR < 1.98, and regional MFC<sub>severe</sub> > 3.2% of left ventricle emerged all as independent predictors of MACE (HR 4.5, 3.1, and 3.67, respectively, p < 0.001). However, only reduced global stress MBF remained an independent prognostic factor for MACE after adjusting for clinical risk factors and the combined use of global stress MBF, global MFR, and regional MFC<sub>severe</sub> impairments (HR 2.81, p = 0.027).<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using the latest SiPM PET technology with low-dose <sup>82</sup>Rb halving the standard activity to deliver < 1 mSv for a 70-kg patient, impaired global stress MBF, global MFR, and regional MFC were powerful predictors of cardiovascular events, outperforming traditional cardiovascular risk factors. However, only reduced global stress MBF independently predicted MACE, being superior to global MFR and regional MFC impairments. |
2,329,280 | Left ventricular aneurysm: Truths and falsehoods.<Pagination><StartPage>308</StartPage><EndPage>309</EndPage><MedlinePgn>308-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.33963/KP.a2022.0293</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zioło</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warszawa, Poland. jerzy.ziolo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramotowski</LastName><ForeName>Bogumil</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaborska</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojdyga</LastName><ForeName>Ryszard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiosurgery, Medicover Hospital, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miśko</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MR Department Affidea Poland, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budaj</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warszawa, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Kardiol Pol</MedlineTA><NlmUniqueID>0376352</NlmUniqueID><ISSNLinking>0022-9032</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006322" MajorTopicYN="Y">Heart Aneurysm</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36573602</ArticleId><ArticleId IdType="doi">10.33963/KP.a2022.0293</ArticleId><ArticleId IdType="pii">VM/OJS/J/92944</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36573416</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal>Suction-based catheter retrieval of right ventricular clot-in-transit. | Right ventricular clot-in-transit (CIT) is a rare finding in venous thromboembolic disease and carries a high mortality rate. Its optimal treatments have yet to be established in the literature. Here we describe the usage of a suction-based catheter, the INARI FlowTriever® system (INARI Medical Inc.) to successfully retrieve a CIT from the right ventricle of a patient with coronavirus disease 2019 acute respiratory distress syndrome on veno-veno extracorporeal membrane oxygenation. |
2,329,281 | Lateral Horizontal Head Position Approach for the Lateral and Anterior Third Ventricles: A Subependymoma Clinical Case and Literature Review. | Subependymomas are benign, slow-growing, noninvasive solitary lesions of World Health Organization Grade I cerebral ependymal origin that are rare compared with other types of ependymomas. Anterior third ventricle subependymomas are usually detected during autopsies in cases of sudden death due to acute or intermittent obstruction of the cerebrospinal fluid passage. Different surgical approaches are used for these cerebral lateral and third ventricular lesions. Serious complications can occur, either because of brain edema and acute intracranial pressure due to the lesion itself or the chosen head position and continuous use of brain retractors during the surgical procedure. In this case report, we trust that the surgical principles we applied with the aid of two cotton pads, gravity assist, and lateral horizontal head position, and without continuous use of brain retractors in the third ventricular lesion in the transcallosal interhemispheric approach are safe and secure in preventing perioperative brain edema or early postoperative neurological complications. |
2,329,282 | The Prevalence, Location, and Dimensions Of Interthalamic Adhesions and Their Clinical Significance: Corpse Brain Analysis. | <b>Background</b>  Interthalamic adhesion (ITA) or massa intermedia is a midline rod-like neural structure interconnecting the medial surfaces of two thalami. Its absence is considered as a midline defect associated with schizophrenia spectrum disorder. The present study aimed to determine the prevalence, location, and dimensions of the ITA in South Asian brains. <b>Materials and Methods</b>  One hundred midsagittal sections of adult cadaveric brains were examined for the presence or absence of ITAs, their location about the lateral wall of the third ventricle, and their dimensions. <b>Results</b>  ITA was found in 86 sections. In two cases, it was double. There was no significant relationship between the incidence of ITAs and sex ( <i>p</i>  > 0.05). The ITA was most commonly located in the anterosuperior quadrant. The horizontal diameter was 4.61 ± 1.17 mm, and the vertical diameter was 3.10 ± 0.78 mm. In all cases, the horizontal diameter was longer than the vertical. The average area of the ITA was significantly larger in females (17.56 ± 5.26 mm <sup>2</sup> ) than in males (13.62 ± 5.22 mm <sup>2</sup> ) ( <i>p</i>  = 0.025). <b>Conclusion</b>  Presence of ITA is common in South Asian brains, with usual location in the anterosuperior quadrant of the lateral wall of the third ventricle. The cross-sectional area of the ITA was significantly larger in females than in males. No correlation was found between the surface area of the ITA and the length of the third ventricle. |
2,329,283 | Erythropoietin administration exerted neuroprotective effects against cardiac ischemia/reperfusion injury.<Pagination><StartPage>100124</StartPage><MedlinePgn>100124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.crphar.2022.100124</ELocationID><Abstract><AbstractText>Acute myocardial infarction (AMI) leads to cardiac dysfunction and also causes brain dysfunction and pathology. The neuroprotective effects of erythropoietin (EPO), the hormone controlling the production of red blood cells, have been shown in case of cerebral ischemic/reperfusion (I/R) injury. However, the effects of EPO on the brain pathologies induced by cardiac I/R injury have not been investigated. We hypothesized that the administration of EPO attenuates brain damage caused by cardiac I/R injury through decreasing peripheral and brain oxidative stress, preserving microglial morphology, attenuating hippocampal necroptosis, and decreasing hippocampal apoptosis, and hippocampal dysplasticity. Male Wistar rats (n ​= ​38) were divided into two groups, sham (n ​= ​6) and cardiac I/R (n ​= ​32). All rats being subjected to the cardiac I/R operation were randomly divided into 4 subgroups (n ​= ​8/group): vehicle, EPO pretreatment, EPO given during ischemia, and EPO given at the onset of reperfusion. The EPO was given at a dosage of 5000 units/kg via intravenous injection. Left ventricle function, oxidative stress, brain mitochondrial function, microglial morphology, hippocampal necroptosis, hippocampal apoptosis, and hippocampal plasticity were measured. EPO administration exerted beneficial anti-oxidative, anti-inflammatory, and anti-apoptotic effects on the brain against cardiac I/R. Giving EPO before cardiac ischemia conferred the greatest neuroprotection against cardiac I/R injury through the attenuation of LV dysfunction, decrease in peripheral and brain oxidative stress, and the attenuation of microglial activation, brain mitochondrial dysfunction, apoptosis, and necroptosis, leading to the improvement of hippocampal dysplasticity under cardiac I/R conditions. EPO pretreatment provided the greatest benefits on brain pathology induced by cardiac I/R.</AbstractText><CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chunchai</LastName><ForeName>Titikorn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apaijai</LastName><ForeName>Nattayaporn</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjanuwattra</LastName><ForeName>Juthipong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pintana</LastName><ForeName>Hiranya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhanat</LastName><ForeName>Kodchanan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arunsak</LastName><ForeName>Busarin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattipakorn</LastName><ForeName>Nipon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattipakorn</LastName><ForeName>Siriporn C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Res Pharmacol Drug Discov</MedlineTA><NlmUniqueID>9918300982506676</NlmUniqueID><ISSNLinking>2590-2571</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Erythropoietin</Keyword><Keyword MajorTopicYN="N">Ischemic/reperfusion injury</Keyword><Keyword MajorTopicYN="N">Microglial function</Keyword><Keyword MajorTopicYN="N">Mitochondrial function</Keyword><Keyword MajorTopicYN="N">Necroptosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36568264</ArticleId><ArticleId IdType="pmc">PMC9780068</ArticleId><ArticleId IdType="doi">10.1016/j.crphar.2022.100124</ArticleId><ArticleId IdType="pii">S2590-2571(22)00044-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apaijai N., Moisescu D.M., Palee S., McSweeney C.M., Saiyasit N., Maneechote C., Boonnag C., Chattipakorn N., Chattipakorn S.C. Pretreatment with pcsk9 inhibitor protects the brain against cardiac ischemia/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation. J. Am. Heart Assoc. 2019;8(2) e010838-e010838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497363</ArticleId><ArticleId IdType="pubmed">30636486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahcekapili N., Uzüm G., Gökkusu C., Kuru A., Ziylan Y.Z. The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sci. 2007;80(14):1245–1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">17300815</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjanuwattra J., Apaijai N., Chunchai T., Kerdphoo S., Jaiwongkam T., Arunsak B., Wongsuchai S., Chattipakorn N., Chattipakorn S.C. Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. Biochim. Biophys. Acta, Mol. Basis Dis. 2020;1866(10)</Citation><ArticleIdList><ArticleId IdType="pubmed">32621957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond W.S., Rex T.S. Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front. Immunol. 2014;5:523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205853</ArticleId><ArticleId IdType="pubmed">25374571</ArticleId></ArticleIdList></Reference><Reference><Citation>Calapai G., Marciano M.C., Corica F., Allegra A., Parisi A., Frisina N., Caputi A.P., Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 2000;401(3):349–356.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarelli C., Angeletti A., Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 2019;19(9):2407–2414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6711804</ArticleId><ArticleId IdType="pubmed">30903735</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.H., Koh R.Y., Lim C.L., Leong C.O. Receptor-interacting protein kinase 1 (ripk1) as a potential therapeutic target: an overview of its possible role in the pathogenesis of alzheimer's disease. Curr. Alzheimer Res. 2019;16(10):907–918.</Citation><ArticleIdList><ArticleId IdType="pubmed">31642777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunchai T., Apaijai N., Keawtep P., Mantor D., Arinno A., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Testosterone deprivation intensifies cognitive decline in obese male rats via glial hyperactivity, increased oxidative stress, and apoptosis in both hippocampus and cortex. Acta Physiol. 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30506942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunchai T., Thunapong W., Yasom S., Wanchai K., Eaimworawuthikul S., Metzler G., Lungkaphin A., Pongchaidecha A., Sirilun S., Chaiyasut C., Pratchayasakul W., Thiennimitr P., Chattipakorn N., Chattipakorn S.C. Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats. J. Neuroinflammation. 2018;15(1):11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761137</ArticleId><ArticleId IdType="pubmed">29316965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekelof S.V., Halladin N.L., Jensen S.E., Zaremba T., Aaroe J., Kjaergaard B., Simonsen C.W., Rosenberg J., Gogenur I. Effects of intracoronary melatonin on ischemia-reperfusion injury in st-elevation myocardial infarction. Heart Ves. 2016;31(1):88–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25319673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003;228(1):1–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick T., Springe D., Grandgirard D., Leib S.L., Haenggi M. An improved simple rat model for global cerebral ischaemia by induced cardiac arrest. Neurol. Res. 2016;38(4):373–380.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344664</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunnet L.G., Aikin R., Tonnesen M.F., Paraskevas S., Blaabjerg L., Storling J., Rosenberg L., Billestrup N., Maysinger D., Mandrup-Poulsen T. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009;58(8):1807–1815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712790</ArticleId><ArticleId IdType="pubmed">19470609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013;123(1):92–100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533275</ArticleId><ArticleId IdType="pubmed">23281415</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M., Stetler R.A., Xing J., Hu X., Gao Y., Zhang W., Chen J., Cao G. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke. 2010;41(5):1032–1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919308</ArticleId><ArticleId IdType="pubmed">20360553</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul S.E., Stallings S.A., Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained cns injury. Pediatr. Res. 1999;46(5):543–547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10541316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellert B.A., McPherson R.J., Juul S.E. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr. Res. 2007;61(4):451–455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515870</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaksari M., Mehrjerdi F.Z., Rezvani M.E., Safari F., Mirgalili A., Niknazar S. The role of erythropoietin in remote renal preconditioning on hippocampus ischemia/reperfusion injury. J. Physiol. Sci. 2017;67(1):163–171.</Citation><ArticleIdList><ArticleId IdType="pubmed">27099131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumfu S., Charununtakorn S.T., Jaiwongkam T., Chattipakorn N., Chattipakorn S.C. Humanin exerts neuroprotection during cardiac ischemia-reperfusion injury. J Alzheimers Dis. 2018;61(4):1343–1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">29376862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y., Chung K., Chung J.M. Involvement of reactive oxygen species in long-term potentiation in the spinal cord dorsal horn. J. Neurophysiol. 2010;103(1):382–391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807226</ArticleId><ArticleId IdType="pubmed">19906875</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liang X., Duan J., Chen Y., Tian X., Wang J., Zhang H., Liu Q., Yang J. Ros-responsive epo nanoparticles ameliorate ionizing radiation-induced hematopoietic injury. Biomater. Sci. 2021;9(19):6474–6485.</Citation><ArticleIdList><ArticleId IdType="pubmed">34582522</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K., Sun T., Wang P., Liu Y.-h., Zhang L.-w., Xue Y.-x. Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats. J. Mol. Neurosci. 2013;49(2):369–379.</Citation><ArticleIdList><ArticleId IdType="pubmed">23001813</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 1996;8(4):666–676.</Citation><ArticleIdList><ArticleId IdType="pubmed">9081618</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 1994;269(30):19488–19493.</Citation><ArticleIdList><ArticleId IdType="pubmed">8034718</ArticleId></ArticleIdList></Reference><Reference><Citation>Menger M.M., Nalbach L., Roma L.P., Laschke M.W., Menger M.D., Ampofo E. Erythropoietin exposure of isolated pancreatic islets accelerates their revascularization after transplantation. Acta Diabetol. 2021;58(12):1637–1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542558</ArticleId><ArticleId IdType="pubmed">34254190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nairz M., Haschka D., Dichtl S., Sonnweber T., Schroll A., Asshoff M., Mindur J.E., Moser P.L., Wolf D., Swirski F.K., Theurl I., Cerami A., Brines M., Weiss G. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci. Rep. 2017;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638901</ArticleId><ArticleId IdType="pubmed">29026145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nairz M., Schroll A., Moschen A.R., Sonnweber T., Theurl M., Theurl I., Taub N., Jamnig C., Neurauter D., Huber L.A., Tilg H., Moser P.L., Weiss G. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappab-inducible immune pathways. Immunity. 2011;34(1):61–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032045</ArticleId><ArticleId IdType="pubmed">21256055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongnok B., Khuanjing T., Chunchai T., Kerdphoo S., Jaiwongkam T., Chattipakorn N., Chattipakorn S.C. Donepezil provides neuroprotective effects against brain injury and alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury. Biochim. Biophys. Acta, Mol. Basis Dis. 2021;1867(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">32956775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Yang X.H., Guo L.L., Gu Y.H., Qiao Q.Y., Jin H.M. Erythropoietin reduces insulin resistance via regulation of its receptor-mediated signaling pathways in db/db mice skeletal muscle. Int. J. Biol. Sci. 2017;13(10):1329–1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666531</ArticleId><ArticleId IdType="pubmed">29104499</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Min J.S., Kim B., Chae U.B., Yun J.W., Choi M.S., Kong I.K., Chang K.T., Lee D.S. Mitochondrial ros govern the lps-induced pro-inflammatory response in microglia cells by regulating mapk and nf-kappab pathways. Neurosci. Lett. 2015;584:191–196.</Citation><ArticleIdList><ArticleId IdType="pubmed">25459294</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng B., Kong G., Yang C., Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997384</ArticleId><ArticleId IdType="pubmed">32015330</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintana H., Apaijai N., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012;91(11–12):409–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">22925597</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Georges-Chaumet Y., Edeas M. Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction. Pathog Dis. 2016;74(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">26500226</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva I., Alipio C., Pinto R., Mateus V. Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: a systematic review. Biomed. Pharmacother. 2021;139</Citation><ArticleIdList><ArticleId IdType="pubmed">33894624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirén A.L., Knerlich F., Poser W., Gleiter C.H., Brück W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001;101(3):271–276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307627</ArticleId></ArticleIdList></Reference><Reference><Citation>Souvenir R., Doycheva D., Zhang J.H., Tang J. Erythropoietin in stroke therapy: friend or foe. Curr. Med. Chem. 2015;22(10):1205–1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497368</ArticleId><ArticleId IdType="pubmed">25620101</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi N., Nakayama S., Tanaka M. Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice. Neurosci. Res. 2016;111:56–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27184295</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng R., Calvert J.W., Sibmooh N., Piknova B., Suzuki N., Sun J., Martinez K., Yamamoto M., Schechter A.N., Lefer D.J., Noguchi C.T. Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Res. Cardiol. 2011;106(3):343–354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601033</ArticleId><ArticleId IdType="pubmed">21347618</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P.T., Ohab J.J., Kertesz N., Groszer M., Matter C., Gao J., Liu X., Wu H., Carmichael S.T. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J. Neurosci. 2006;26(4):1269–1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674578</ArticleId><ArticleId IdType="pubmed">16436614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhang Z.G., Zhang R.L., Jiao Z.X., Wang Y., Pourabdollah-Nejad D.S., LeTourneau Y., Gregg S.R., Chopp M. Neurogenin 1 mediates erythropoietin enhanced differentiation of adult neural progenitor cells. J. Cerebr. Blood Flow Metabol. 2006;26(4):556–564.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhao H., Li J., Duan Y., Fan Z., Tao Z., Ju F., Yan F., Luo Y. Erythropoietin attenuates axonal injury after middle cerebral artery occlusion in mice. Neurol. Res. 2017;39(6):545–551.</Citation><ArticleIdList><ArticleId IdType="pubmed">28413924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Zhang C., Li J., Niyazi S., Zheng L., Xu M., Rong R., Yang C., Zhu T. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. Cell Death Dis. 2017;8(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477572</ArticleId><ArticleId IdType="pubmed">28383559</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M., Lundgren T., Saito Y., Cerami A., Brines M., Ostenson C.G., Kumagai-Braesch M. A nonhematopoietic erythropoietin analogue, ara 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation. 2016;100(3):554–562.</Citation><ArticleIdList><ArticleId IdType="pubmed">26683514</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber A., Dzietko M., Berns M., Felderhoff-Mueser U., Heinemann U., Maier R.F., Obladen M., Ikonomidou C., Bührer C. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol. Dis. 2005;20(2):594–600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X.C., Johns E.J., Richards N.T. Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin. Sci. (Lond.) 1999;97(4):413–419.</Citation><ArticleIdList><ArticleId IdType="pubmed">10491341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S.J., Cho B., Lee D., Son G., Lee Y.B., Soo Han H., Kim E., Moon C., Moon C. The erythropoietin-derived peptide mk-x and erythropoietin have neuroprotective effects against ischemic brain damage. Cell Death Dis. 2017;8(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596568</ArticleId><ArticleId IdType="pubmed">28817120</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Lin C.S., Costantini F., Noguchi C.T. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001;98(2):475–477.</Citation><ArticleIdList><ArticleId IdType="pubmed">11435319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Zhang X., Bo Y., Li W., Zhang H., Jiang Q. The effects of electroacupuncture treatment on the postoperative cognitive function in aged rats with acute myocardial ischemia-reperfusion. Brain Res. 2014;1593:19–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S.-J., Wang R.-L., Zhao H.-P., Tao Z., Li J.-C., Ju F., Han Z.-P., Ma Q.-F., Liu P., Ma S.-B., Cao G.-D., Luo Y.-M. Mepo promotes neurogenesis and angiogenesis but suppresses gliogenesis in mice with acute ischemic stroke. Eur. J. Pharmacol. 2019;849:1–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30716313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">30422584</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK532991</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2023</Year><Month>01</Month></PubDate><BeginningDate><Year>2023</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-27660">Premature Ventricular Contraction | Acute myocardial infarction (AMI) leads to cardiac dysfunction and also causes brain dysfunction and pathology. The neuroprotective effects of erythropoietin (EPO), the hormone controlling the production of red blood cells, have been shown in case of cerebral ischemic/reperfusion (I/R) injury. However, the effects of EPO on the brain pathologies induced by cardiac I/R injury have not been investigated. We hypothesized that the administration of EPO attenuates brain damage caused by cardiac I/R injury through decreasing peripheral and brain oxidative stress, preserving microglial morphology, attenuating hippocampal necroptosis, and decreasing hippocampal apoptosis, and hippocampal dysplasticity. Male Wistar rats (n ​= ​38) were divided into two groups, sham (n ​= ​6) and cardiac I/R (n ​= ​32). All rats being subjected to the cardiac I/R operation were randomly divided into 4 subgroups (n ​= ​8/group): vehicle, EPO pretreatment, EPO given during ischemia, and EPO given at the onset of reperfusion. The EPO was given at a dosage of 5000 units/kg via intravenous injection. Left ventricle function, oxidative stress, brain mitochondrial function, microglial morphology, hippocampal necroptosis, hippocampal apoptosis, and hippocampal plasticity were measured. EPO administration exerted beneficial anti-oxidative, anti-inflammatory, and anti-apoptotic effects on the brain against cardiac I/R. Giving EPO before cardiac ischemia conferred the greatest neuroprotection against cardiac I/R injury through the attenuation of LV dysfunction, decrease in peripheral and brain oxidative stress, and the attenuation of microglial activation, brain mitochondrial dysfunction, apoptosis, and necroptosis, leading to the improvement of hippocampal dysplasticity under cardiac I/R conditions. EPO pretreatment provided the greatest benefits on brain pathology induced by cardiac I/R.<CopyrightInformation>© 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chunchai</LastName><ForeName>Titikorn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apaijai</LastName><ForeName>Nattayaporn</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjanuwattra</LastName><ForeName>Juthipong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pintana</LastName><ForeName>Hiranya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhanat</LastName><ForeName>Kodchanan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arunsak</LastName><ForeName>Busarin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattipakorn</LastName><ForeName>Nipon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattipakorn</LastName><ForeName>Siriporn C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai, 50200, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Res Pharmacol Drug Discov</MedlineTA><NlmUniqueID>9918300982506676</NlmUniqueID><ISSNLinking>2590-2571</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Erythropoietin</Keyword><Keyword MajorTopicYN="N">Ischemic/reperfusion injury</Keyword><Keyword MajorTopicYN="N">Microglial function</Keyword><Keyword MajorTopicYN="N">Mitochondrial function</Keyword><Keyword MajorTopicYN="N">Necroptosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36568264</ArticleId><ArticleId IdType="pmc">PMC9780068</ArticleId><ArticleId IdType="doi">10.1016/j.crphar.2022.100124</ArticleId><ArticleId IdType="pii">S2590-2571(22)00044-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apaijai N., Moisescu D.M., Palee S., McSweeney C.M., Saiyasit N., Maneechote C., Boonnag C., Chattipakorn N., Chattipakorn S.C. Pretreatment with pcsk9 inhibitor protects the brain against cardiac ischemia/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation. J. Am. Heart Assoc. 2019;8(2) e010838-e010838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497363</ArticleId><ArticleId IdType="pubmed">30636486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahcekapili N., Uzüm G., Gökkusu C., Kuru A., Ziylan Y.Z. The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sci. 2007;80(14):1245–1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">17300815</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjanuwattra J., Apaijai N., Chunchai T., Kerdphoo S., Jaiwongkam T., Arunsak B., Wongsuchai S., Chattipakorn N., Chattipakorn S.C. Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. Biochim. Biophys. Acta, Mol. Basis Dis. 2020;1866(10)</Citation><ArticleIdList><ArticleId IdType="pubmed">32621957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond W.S., Rex T.S. Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front. Immunol. 2014;5:523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205853</ArticleId><ArticleId IdType="pubmed">25374571</ArticleId></ArticleIdList></Reference><Reference><Citation>Calapai G., Marciano M.C., Corica F., Allegra A., Parisi A., Frisina N., Caputi A.P., Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 2000;401(3):349–356.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarelli C., Angeletti A., Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 2019;19(9):2407–2414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6711804</ArticleId><ArticleId IdType="pubmed">30903735</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.H., Koh R.Y., Lim C.L., Leong C.O. Receptor-interacting protein kinase 1 (ripk1) as a potential therapeutic target: an overview of its possible role in the pathogenesis of alzheimer's disease. Curr. Alzheimer Res. 2019;16(10):907–918.</Citation><ArticleIdList><ArticleId IdType="pubmed">31642777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunchai T., Apaijai N., Keawtep P., Mantor D., Arinno A., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Testosterone deprivation intensifies cognitive decline in obese male rats via glial hyperactivity, increased oxidative stress, and apoptosis in both hippocampus and cortex. Acta Physiol. 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30506942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chunchai T., Thunapong W., Yasom S., Wanchai K., Eaimworawuthikul S., Metzler G., Lungkaphin A., Pongchaidecha A., Sirilun S., Chaiyasut C., Pratchayasakul W., Thiennimitr P., Chattipakorn N., Chattipakorn S.C. Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats. J. Neuroinflammation. 2018;15(1):11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761137</ArticleId><ArticleId IdType="pubmed">29316965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekelof S.V., Halladin N.L., Jensen S.E., Zaremba T., Aaroe J., Kjaergaard B., Simonsen C.W., Rosenberg J., Gogenur I. Effects of intracoronary melatonin on ischemia-reperfusion injury in st-elevation myocardial infarction. Heart Ves. 2016;31(1):88–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25319673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003;228(1):1–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick T., Springe D., Grandgirard D., Leib S.L., Haenggi M. An improved simple rat model for global cerebral ischaemia by induced cardiac arrest. Neurol. Res. 2016;38(4):373–380.</Citation><ArticleIdList><ArticleId IdType="pubmed">26344664</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunnet L.G., Aikin R., Tonnesen M.F., Paraskevas S., Blaabjerg L., Storling J., Rosenberg L., Billestrup N., Maysinger D., Mandrup-Poulsen T. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009;58(8):1807–1815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712790</ArticleId><ArticleId IdType="pubmed">19470609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013;123(1):92–100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533275</ArticleId><ArticleId IdType="pubmed">23281415</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M., Stetler R.A., Xing J., Hu X., Gao Y., Zhang W., Chen J., Cao G. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke. 2010;41(5):1032–1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919308</ArticleId><ArticleId IdType="pubmed">20360553</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul S.E., Stallings S.A., Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained cns injury. Pediatr. Res. 1999;46(5):543–547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10541316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellert B.A., McPherson R.J., Juul S.E. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr. Res. 2007;61(4):451–455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515870</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaksari M., Mehrjerdi F.Z., Rezvani M.E., Safari F., Mirgalili A., Niknazar S. The role of erythropoietin in remote renal preconditioning on hippocampus ischemia/reperfusion injury. J. Physiol. Sci. 2017;67(1):163–171.</Citation><ArticleIdList><ArticleId IdType="pubmed">27099131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumfu S., Charununtakorn S.T., Jaiwongkam T., Chattipakorn N., Chattipakorn S.C. Humanin exerts neuroprotection during cardiac ischemia-reperfusion injury. J Alzheimers Dis. 2018;61(4):1343–1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">29376862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y., Chung K., Chung J.M. Involvement of reactive oxygen species in long-term potentiation in the spinal cord dorsal horn. J. Neurophysiol. 2010;103(1):382–391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807226</ArticleId><ArticleId IdType="pubmed">19906875</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liang X., Duan J., Chen Y., Tian X., Wang J., Zhang H., Liu Q., Yang J. Ros-responsive epo nanoparticles ameliorate ionizing radiation-induced hematopoietic injury. Biomater. Sci. 2021;9(19):6474–6485.</Citation><ArticleIdList><ArticleId IdType="pubmed">34582522</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K., Sun T., Wang P., Liu Y.-h., Zhang L.-w., Xue Y.-x. Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats. J. Mol. Neurosci. 2013;49(2):369–379.</Citation><ArticleIdList><ArticleId IdType="pubmed">23001813</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 1996;8(4):666–676.</Citation><ArticleIdList><ArticleId IdType="pubmed">9081618</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 1994;269(30):19488–19493.</Citation><ArticleIdList><ArticleId IdType="pubmed">8034718</ArticleId></ArticleIdList></Reference><Reference><Citation>Menger M.M., Nalbach L., Roma L.P., Laschke M.W., Menger M.D., Ampofo E. Erythropoietin exposure of isolated pancreatic islets accelerates their revascularization after transplantation. Acta Diabetol. 2021;58(12):1637–1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542558</ArticleId><ArticleId IdType="pubmed">34254190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nairz M., Haschka D., Dichtl S., Sonnweber T., Schroll A., Asshoff M., Mindur J.E., Moser P.L., Wolf D., Swirski F.K., Theurl I., Cerami A., Brines M., Weiss G. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci. Rep. 2017;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638901</ArticleId><ArticleId IdType="pubmed">29026145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nairz M., Schroll A., Moschen A.R., Sonnweber T., Theurl M., Theurl I., Taub N., Jamnig C., Neurauter D., Huber L.A., Tilg H., Moser P.L., Weiss G. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappab-inducible immune pathways. Immunity. 2011;34(1):61–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032045</ArticleId><ArticleId IdType="pubmed">21256055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongnok B., Khuanjing T., Chunchai T., Kerdphoo S., Jaiwongkam T., Chattipakorn N., Chattipakorn S.C. Donepezil provides neuroprotective effects against brain injury and alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury. Biochim. Biophys. Acta, Mol. Basis Dis. 2021;1867(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">32956775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Yang X.H., Guo L.L., Gu Y.H., Qiao Q.Y., Jin H.M. Erythropoietin reduces insulin resistance via regulation of its receptor-mediated signaling pathways in db/db mice skeletal muscle. Int. J. Biol. Sci. 2017;13(10):1329–1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666531</ArticleId><ArticleId IdType="pubmed">29104499</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Min J.S., Kim B., Chae U.B., Yun J.W., Choi M.S., Kong I.K., Chang K.T., Lee D.S. Mitochondrial ros govern the lps-induced pro-inflammatory response in microglia cells by regulating mapk and nf-kappab pathways. Neurosci. Lett. 2015;584:191–196.</Citation><ArticleIdList><ArticleId IdType="pubmed">25459294</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng B., Kong G., Yang C., Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997384</ArticleId><ArticleId IdType="pubmed">32015330</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintana H., Apaijai N., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012;91(11–12):409–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">22925597</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Georges-Chaumet Y., Edeas M. Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction. Pathog Dis. 2016;74(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">26500226</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva I., Alipio C., Pinto R., Mateus V. Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: a systematic review. Biomed. Pharmacother. 2021;139</Citation><ArticleIdList><ArticleId IdType="pubmed">33894624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirén A.L., Knerlich F., Poser W., Gleiter C.H., Brück W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001;101(3):271–276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307627</ArticleId></ArticleIdList></Reference><Reference><Citation>Souvenir R., Doycheva D., Zhang J.H., Tang J. Erythropoietin in stroke therapy: friend or foe. Curr. Med. Chem. 2015;22(10):1205–1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497368</ArticleId><ArticleId IdType="pubmed">25620101</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi N., Nakayama S., Tanaka M. Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice. Neurosci. Res. 2016;111:56–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27184295</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng R., Calvert J.W., Sibmooh N., Piknova B., Suzuki N., Sun J., Martinez K., Yamamoto M., Schechter A.N., Lefer D.J., Noguchi C.T. Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Res. Cardiol. 2011;106(3):343–354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601033</ArticleId><ArticleId IdType="pubmed">21347618</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P.T., Ohab J.J., Kertesz N., Groszer M., Matter C., Gao J., Liu X., Wu H., Carmichael S.T. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J. Neurosci. 2006;26(4):1269–1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674578</ArticleId><ArticleId IdType="pubmed">16436614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhang Z.G., Zhang R.L., Jiao Z.X., Wang Y., Pourabdollah-Nejad D.S., LeTourneau Y., Gregg S.R., Chopp M. Neurogenin 1 mediates erythropoietin enhanced differentiation of adult neural progenitor cells. J. Cerebr. Blood Flow Metabol. 2006;26(4):556–564.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhao H., Li J., Duan Y., Fan Z., Tao Z., Ju F., Yan F., Luo Y. Erythropoietin attenuates axonal injury after middle cerebral artery occlusion in mice. Neurol. Res. 2017;39(6):545–551.</Citation><ArticleIdList><ArticleId IdType="pubmed">28413924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Zhang C., Li J., Niyazi S., Zheng L., Xu M., Rong R., Yang C., Zhu T. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. Cell Death Dis. 2017;8(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477572</ArticleId><ArticleId IdType="pubmed">28383559</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M., Lundgren T., Saito Y., Cerami A., Brines M., Ostenson C.G., Kumagai-Braesch M. A nonhematopoietic erythropoietin analogue, ara 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation. 2016;100(3):554–562.</Citation><ArticleIdList><ArticleId IdType="pubmed">26683514</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber A., Dzietko M., Berns M., Felderhoff-Mueser U., Heinemann U., Maier R.F., Obladen M., Ikonomidou C., Bührer C. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol. Dis. 2005;20(2):594–600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X.C., Johns E.J., Richards N.T. Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin. Sci. (Lond.) 1999;97(4):413–419.</Citation><ArticleIdList><ArticleId IdType="pubmed">10491341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S.J., Cho B., Lee D., Son G., Lee Y.B., Soo Han H., Kim E., Moon C., Moon C. The erythropoietin-derived peptide mk-x and erythropoietin have neuroprotective effects against ischemic brain damage. Cell Death Dis. 2017;8(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5596568</ArticleId><ArticleId IdType="pubmed">28817120</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Lin C.S., Costantini F., Noguchi C.T. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001;98(2):475–477.</Citation><ArticleIdList><ArticleId IdType="pubmed">11435319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Zhang X., Bo Y., Li W., Zhang H., Jiang Q. The effects of electroacupuncture treatment on the postoperative cognitive function in aged rats with acute myocardial ischemia-reperfusion. Brain Res. 2014;1593:19–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S.-J., Wang R.-L., Zhao H.-P., Tao Z., Li J.-C., Ju F., Han Z.-P., Ma Q.-F., Liu P., Ma S.-B., Cao G.-D., Luo Y.-M. Mepo promotes neurogenesis and angiogenesis but suppresses gliogenesis in mice with acute ischemic stroke. Eur. J. Pharmacol. 2019;849:1–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30716313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">30422584</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK532991</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2023</Year><Month>01</Month></PubDate><BeginningDate><Year>2023</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-27660">Premature Ventricular Contraction</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Farzam</LastName><ForeName>Khashayar</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>John R.</ForeName><Initials>JR</Initials></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract>The heart has an electrical system that allows it to contract and pump blood through the body in a coordinated rhythm. Regular heartbeats occur when specialized cells in the right atrium of the heart, called the sinoatrial (SA) node, conduct an electrical signal down to the atrioventricular (AV) node which is another set of specialized cells. This electrical signal then works its way down the bundle of His and Purkinje fibers to the heart ventricles. The result is the contraction of the ventricles and pumping of blood from the heart out to the body's arteries. During a premature ventricular contraction (PVC), the heartbeat is initiated by the Purkinje fibers rather than the SA node. Given that a PVC occurs before a regular heartbeat, there is a pause before the next regular heartbeat. PVCs can occur in isolation or in repeated patterns. Two consecutive PVCs are termed doublets while three consecutive PVCs are named triplets. It is important to note that three or more consecutive PVCs are classified as ventricular tachycardia. If the PVCs continuously alternate with a regular sinus beat, the patient is in bigeminy. Likewise, if every third heartbeat is a PVC, then it is named trigeminy.  PVCs present as heart palpitations in most patients. They are usually benign and do not require treatment. |
2,329,284 | Ultrasonic Diagnosis and Management of Posthemorrhagic Ventricular Dilatation in Premature Infants: A Narrative Review. | The survival rate of preterm infants is increasing as a result of technological advances. The incidence of intraventricular hemorrhages (IVH) in preterm infants ranges from 25% to 30%, of which 30% to 50% are severe IVH (Volpe III-IV, Volpe III is defined as intraventricular bleeding occupying more than 50% of the ventricular width and acute lateral ventricle dilatation, Volpe IV is defined as intraventricular hemorrhage combined with venous infarction) and probably lead to posthemorrhagic ventricular dilatation (PHVD). Severe IVH and subsequent PHVD have become the leading causes of brain injury and neurodevelopmental dysplasia in preterm infants. This review aims to review the literature on the diagnosis and therapeutic strategies for PHVD and provide some recommendations for management to improve the neurological outcomes. |
2,329,285 | Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model While Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels. | Parkinson's disease (PD) is due to the oxidation of alpha synuclein (αSyn) contributing to motor impairment. We developed a transgenic mouse model of PD that overexpresses the mutated human αSyn gene (A53T) crossed to a mouse expressing the human MPO gene. This model exhibits increased oxidation and chlorination of αSyn leading to greater motor impairment. In the current study, the hMPO-A53T mice were treated with thiocyanate (SCN<sup>-</sup>) which is a favored substrate of MPO as compared to chlorine. We show that hMPO-A53T mice treated with SCN<sup>-</sup> have less chlorination in the brain and show an improvement in motor skills compared to the nontreated hMPO-A53T mice. Interestingly, in the hMPO-A53T mice we found a possible link between MPO-related disease and the glymphatic system which clears waste including αSyn from the brain. The untreated hMPO-A53T mice exhibited an increase in the size of periventricular glymphatic vessels expressing the glymphatic marker LYVE1 and aquaporin 4 (AQP4). These vessels also exhibited an increase in MPO and HOCl-modified epitopes in the glymphatic vessels correlating with loss of ependymal cells lining the ventricles. These findings suggest that MPO may significantly promote the impairment of the glymphatic waste removal system thus contributing to neurodegeneration in PD. Moreover, the inhibition of MPO chlorination/oxidation by SCN<sup>-</sup> may provide a potential therapeutic approach to this disease. |
2,329,286 | Disseminated Human Subarachnoid Coenurosis. | Background: Traditionally, human coenurosis has been ascribed to Taenia multiceps while neurocysticercosis has been attributed solely to Taenia solium infection. Historically, however, the identification and differentiation of cestodal infection was primarily based on inaccurate morphological criteria. With the increasing availability of molecular methods, the accuracy of identification of the larval cestode species has improved, and cestodal species not typically associated with central nervous system (CNS) infection are now being identified as aetiological agents. Case report: We present a case of a 5-year-old male patient who presented with acute hydrocephalus. Initial MRI revealed multiple cysts in the cerebrospinal fluid (CSF) spaces with a predominance of clumped grape-like cysts in the basal cisterns with resultant acute obstructive hydrocephalus. The child underwent an emergency ventriculo-peritoneal (VP) shunt. A presumptive diagnosis of neurocysticercosis racemosus was made and the child was started on empiric albendazole (15 mg/kg/day) and praziquantel (30 mg/kg/day) treatment, along with concomitant prednisone (1 mg/kg) treatment. Despite prolonged anti-helminthic therapy, the child continued to deteriorate, and endoscopic removal of the 4th ventricular cysts was required. Post-operative MRI revealed radiological improvements, with a reduction in the number and size of cysts, especially in the basal cisterns, with no cysts visualized in the fourth ventricle. DNA was extracted from CSF and cyst tissue using the QiAMP DNA mini kit (Qiagen). The PCR performed on the extracted DNA displayed a band of 275 bp on an agarose gel. The consensus sequence had 97.68% similarity to Taenia serialis 12S ribosomal RNA gene. The child, unfortunately, continued to do poorly, requiring multiple VP shunt revisions for repeated blockage of the VP shunt system, and ultimately demised, despite the ‘successful’ surgical intervention and continued maximal medical management. Discussion and conclusions: There have been approximately 40 reported cases of human CNS coenurosis, with the assumed etiological agent being confined to T. multiceps. In 2020, the first case of human CNS coenurosis caused by T. serialis was reported. This case involved a single parenchymal lesion in the occipital lobe, which, following complete surgical excision, was confirmed to be T. serialis by mitochondrial gene sequencing. The case we present is the first case of disseminated subarachnoid coenurosis caused by T. serialis. It appears that T. serialis infection can mimic either of the two basic pathological forms of neurocysticercosis, namely, cysticercosis cellulosae or cysticercosis racemosus. We postulate that the term coenurosis racemosus is applicable if CNS T. serialis infection presents with extensive, multiple grape-like bladders proliferating within the subarachnoid space. |
2,329,287 | Localization of TRPV3/4 and PIEZO1/2 sensory receptors in murine and human larynges.<Pagination><StartPage>1963</StartPage><EndPage>1972</EndPage><MedlinePgn>1963-1972</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/lio2.968</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The primary aim of this study was to identify expression of TRPV3 and TRPV4 chemoreceptors across perinatal and adult stages using a murine model with direct comparisons to human laryngeal mucosa. Our secondary aim was to establish novel cell expression patterns of mechanoreceptors PIEZO1 and PIEZO2 in human tissue samples.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="UNASSIGNED">In vivo<i>.</i></AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We harvested murine laryngeal tissue to localize and describe TRPV3/4 endogenous protein expression patterns via immunofluorescence analyses across two developmental (E16.5, P0) and adult (6 weeks) timepoints. Additionally, we obtained a 60-year-old female larynx including the proximal trachea and esophagus to investigate TRPV3/4 and PIEZO1/2 protein expression patterns via immunofluorescence analyses for comparison to murine adult tissue.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Murine TRPV3/4 expression was noted at E16.5 with epithelial cell colocalization to supraglottic regions of the arytenoids, aryepiglottic folds and epiglottis through to birth (P0), extending to the adult timepoint. Human TRPV3/4 protein expression was most evident to epithelium of the arytenoid region, with additional expression of TRPV3 and TRPV4 to proximal esophageal and tracheal epithelium, respectively. Human PIEZO1 expression was selective to differentiated, stratified squamous epithelia of the true vocal fold and esophagus, while PIEZO2 expression exhibited selectivity for intermediate and respiratory epithelia of the false vocal fold, ventricles, subglottis, arytenoid, and trachea.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Results exhibited expression of TRPV3/4 chemoreceptors in utero, suggesting their importance during fetal/neonatal stages. TRPV3/4 and PIEZO1/2 were noted to adult murine and human laryngeal epithelium. Data indicates conservation of chemosensory receptors across species given similar regional expression in both the murine and human larynx.</AbstractText><CopyrightInformation>© 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC. on behalf of The Triological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foote</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-3676-4091</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery University of Wisconsin - Madison Madison Wisconsin USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tibbetts</LastName><ForeName>Julianna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery University of Wisconsin - Madison Madison Wisconsin USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartley</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery University of Wisconsin - Madison Madison Wisconsin USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibeault</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-9046-4356</Identifier><AffiliationInfo><Affiliation>Division of Otolaryngology - Head and Neck Surgery University of Wisconsin - Madison Madison Wisconsin USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Laryngoscope Investig Otolaryngol</MedlineTA><NlmUniqueID>101684963</NlmUniqueID><ISSNLinking>2378-8038</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">development</Keyword><Keyword MajorTopicYN="N">larynx</Keyword><Keyword MajorTopicYN="N">sensory receptors</Keyword><Keyword MajorTopicYN="N">somatosensation</Keyword><Keyword MajorTopicYN="N">vocal fold</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non‐financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>2</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36544955</ArticleId><ArticleId IdType="pmc">PMC9764771</ArticleId><ArticleId IdType="doi">10.1002/lio2.968</ArticleId><ArticleId IdType="pii">LIO2968</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henriquez VM, Schulz GM, Bielamowicz S, Ludlow CL. Laryngeal reflex responses are not modulated during human voice and respiratory tasks. J Physiol. 2007;585:779‐789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375523</ArticleId><ArticleId IdType="pubmed">17962327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludlow CL. Laryngeal reflexes: physiology, technique, and clinical use. J Clin Neurophysiol. 2015;32:284‐293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527097</ArticleId><ArticleId IdType="pubmed">26241237</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkmeier JM, Bielamowicz S, Takeda N, Ludlow CL. Modulation of laryngeal responses to superior laryngeal nerve stimulation by volitional swallowing in awake humans. J Neurophysiol. 2000;83:1264‐1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10712454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair CF, Tellez MJ, Tapia OR, Ulkatan S. Contralateral R1 and R2 components of the laryngeal adductor reflex in humans under general anesthesia. Laryngoscope. 2017;127:E443‐E448.</Citation><ArticleIdList><ArticleId IdType="pubmed">28776686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair CF, Tellez MJ, Ulkatan S. Human laryngeal sensory receptor mapping illuminates the mechanisms of laryngeal adductor reflex control. Laryngoscope. 2018;128:E365‐E370.</Citation><ArticleIdList><ArticleId IdType="pubmed">30194722</ArticleId></ArticleIdList></Reference><Reference><Citation>Foote AG, Thibeault SL. Sensory innervation of the larynx and the search for mucosal mechanoreceptors. J Speech Lang Hear Res. 2021;64(2):371‐391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632506</ArticleId><ArticleId IdType="pubmed">33465318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak S, Slovarp L, Clary MS, Jette ME. Laryngeal Chemoreflex in health and disease: a review. Chem Senses. 2020;45:823‐831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7718607</ArticleId><ArticleId IdType="pubmed">33247587</ArticleId></ArticleIdList></Reference><Reference><Citation>Thach BT. Maturation and transformation of reflexes that protect the laryngeal airway from liquid aspiration from fetal to adult life. Am J Med. 2001;111:69‐77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11749929</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMantia A‐S, Moody SA, Maynard TM, et al. Hard to swallow: developmental biological insights into pediatric dysphagia. Dev Biol. 2016;409:329‐342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724484</ArticleId><ArticleId IdType="pubmed">26554723</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard TM, Zohn IE, Moody SA, LaMantia AS. Suckling, feeding, and swallowing: behaviors, circuits, and targets for neurodevelopmental pathology. Annu Rev Neurosci. 2020;43:315‐336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359496</ArticleId><ArticleId IdType="pubmed">32101484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Lee H, Caterina MJ. Warm temperatures activate TRPV4 in mouse 308 keratinocytes. J Biol Chem. 2003;278:32037‐32046.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessac BF, Jordt SE. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. Physiology (Bethesda). 2008;23:360‐370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735846</ArticleId><ArticleId IdType="pubmed">19074743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamoto T, Takumida M, Hirakawa K, Tatsukawa T, Ishibashi T. Localization of transient receptor potential vanilloid (TRPV) in the human larynx. Acta Otolaryngol. 2009;129:560‐568.</Citation><ArticleIdList><ArticleId IdType="pubmed">18629672</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung SY, Niimi A, Williams AS, et al. Inhibition of citric acid‐ and capsaicin‐induced cough by novel TRPV‐1 antagonist, V112220, in Guinea‐pig. Cough. 2007;3:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2262090</ArticleId><ArticleId IdType="pubmed">18154688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamoto T, Takumida M, Hirakawa K, Takeno S, Tatsukawa T. Localization of transient receptor potential channel vanilloid subfamilies in the mouse larynx. Acta Otolaryngol. 2008;128:685‐693.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568506</ArticleId></ArticleIdList></Reference><Reference><Citation>Altier C. Spicing up the sensation of stretch: TRPV1 controls mechanosensitive piezo channels. Sci Signal. 2015;8:fs3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25670201</ArticleId></ArticleIdList></Reference><Reference><Citation>Borbiro I, Badheka D, Rohacs T. Activation of TRPV1 channels inhibits mechanosensitive piezo channel activity by depleting membrane phosphoinositides. Sci Signal. 2015;8:ra15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527171</ArticleId><ArticleId IdType="pubmed">25670203</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Romac JM, Shahid RA, et al. TRPV4 channel opening mediates pressure‐induced pancreatitis initiated by Piezo1 activation. J Clin Invest. 2020;130:2527‐2541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190979</ArticleId><ArticleId IdType="pubmed">31999644</ArticleId></ArticleIdList></Reference><Reference><Citation>Du G, Li L, Zhang X, et al. Roles of TRPV4 and piezo channels in stretch‐evoked Ca(2+) response in chondrocytes. Exp Biol Med (Maywood). 2019;245:180‐189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7045327</ArticleId><ArticleId IdType="pubmed">31791130</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Conor CJ, Leddy HA, Benefield HC, Liedtke WB, Guilak F. TRPV4‐mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading. Proc Natl Acad Sci U S A. 2014;111:1316‐1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910592</ArticleId><ArticleId IdType="pubmed">24474754</ArticleId></ArticleIdList></Reference><Reference><Citation>Servin‐Vences MR, Moroni M, Lewin GR, Poole K. Direct measurement of TRPV4 and PIEZO1 activity reveals multiple mechanotransduction pathways in chondrocytes. Elife. 2017;6:e21074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5279942</ArticleId><ArticleId IdType="pubmed">28135189</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen AP, Corey DP. TRP channels in mechanosensation: direct or indirect activation? Nat Rev Neurosci. 2007;8:510‐521.</Citation><ArticleIdList><ArticleId IdType="pubmed">17585304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jetté ME, Clary MS, Prager JD, Finger TE. Chemical receptors of the arytenoid: a comparison of human and mouse. Laryngoscope. 2020;130:423‐430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6761039</ArticleId><ArticleId IdType="pubmed">30908677</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott SL, Umans BD, Williams EK, Brust RD, Liberles SD. An airway protection program revealed by sweeping genetic control of vagal afferents. Cell. 2020;181:574‐589.e514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197391</ArticleId><ArticleId IdType="pubmed">32259485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lungova V, Griffin KV, Lunga T, Thibeault SL. Drainage of amniotic fluid delays vocal fold separation and induces load‐related vocal fold mucosa remodeling. Dev Biol. 2020;466:47‐58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494656</ArticleId><ArticleId IdType="pubmed">32777221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JC, Lee CH. TRP channels in skin: from physiological implications to clinical significances. Biophysics (Nagoya‐Shi). 2015;11:17‐24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4736792</ArticleId><ArticleId IdType="pubmed">27493510</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Romac JM, Vigna SR, Liddle RA. Piezo1‐mediated stellate cell activation causes pressure‐induced pancreatic fibrosis in mice. JCI Insight. 2022;7:e158288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9089793</ArticleId><ArticleId IdType="pubmed">35451372</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neil RG, Brown RC. The vanilloid receptor family of calcium‐permeable channels: molecular integrators of microenvironmental stimuli. News Physiol Sci. 2003;18:226‐231.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614154</ArticleId></ArticleIdList></Reference><Reference><Citation>Liedtke W, Kim C. Functionality of the TRPV subfamily of TRP ion channels: add mechano‐TRP and osmo‐TRP to the lexicon! Cell Mol Life Sci. 2005;62:2985‐3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16314934</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Zhao Q, Zhang T, Xiao B. In touch with the mechanosensitive piezo channels: structure, ion permeation, and Mechanotransduction. Curr Top Membr. 2017;79:159‐195.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalghi MG, Clayton DR, Ruiz WG, et al. Expression and distribution of PIEZO1 in the mouse urinary tract. Am J Physiol Renal Physiol. 2019;317:F303‐F321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732449</ArticleId><ArticleId IdType="pubmed">31166705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudipaty SA, Lindblom J, Loftus PD, et al. Mechanical stretch triggers rapid epithelial cell division through Piezo1. Nature. 2017;543:118‐121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334365</ArticleId><ArticleId IdType="pubmed">28199303</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhoffer GT, Loftus PD, Yoshigi M, et al. Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. Nature. 2012;484:546‐549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593481</ArticleId><ArticleId IdType="pubmed">22504183</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesler AT, Szczot M, Bharucha‐Goebel D, et al. The role of PIEZO2 in human Mechanosensation. N Engl J Med. 2016;375:1355‐1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911918</ArticleId><ArticleId IdType="pubmed">27653382</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Nikolaev YA, Gracheva EO, Bagriantsev SN. Piezo2 integrates mechanical and thermal cues in vertebrate mechanoreceptors. Proc Natl Acad Sci U S A. 2019;116:17547‐17555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717272</ArticleId><ArticleId IdType="pubmed">31413193</ArticleId></ArticleIdList></Reference><Reference><Citation>Praud JP. Upper airway reflexes in response to gastric reflux. Paediatr Respir Rev. 2010;11:208‐212.</Citation><ArticleIdList><ArticleId IdType="pubmed">21109178</ArticleId></ArticleIdList></Reference><Reference><Citation>Canning BJ, Mazzone SB, Meeker SN, Mori N, Reynolds SM, Undem BJ. Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetized Guinea‐pigs. J Physiol. 2004;557:543‐558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665106</ArticleId><ArticleId IdType="pubmed">15004208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding P, Campbell‐Malone R, Holman SD, et al. Unilateral superior laryngeal nerve lesion in an animal model of dysphagia and its effect on sucking and swallowing. Dysphagia. 2013;28:404‐412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710536</ArticleId><ArticleId IdType="pubmed">23417250</ArticleId></ArticleIdList></Reference><Reference><Citation>Murry T, Branski RC, Yu K, Cukier‐Blaj S, Duflo S, Aviv JE. Laryngeal sensory deficits in patients with chronic cough and paradoxical vocal fold movement disorder. Laryngoscope. 2010;120:1576‐1581.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564660</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertigan AE, Bone SL, Gibson PG. Laryngeal sensory dysfunction in laryngeal hypersensitivity syndrome. Respirology. 2013;18:948‐956.</Citation><ArticleIdList><ArticleId IdType="pubmed">23617471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lungova V, Verheyden JM, Herriges J, Sun X, Thibeault SL. Ontogeny of the mouse vocal fold epithelium. Dev Biol. 2015;399:263‐282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352410</ArticleId><ArticleId IdType="pubmed">25601450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling C, Li Q, Brown ME, et al. Bioengineered vocal fold mucosa for voice restoration. Sci Transl Med. 2015;7:314ra187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669060</ArticleId><ArticleId IdType="pubmed">26582902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, Tanaka Y, Hirano M, Nakashima T. Sensory innervation of the pharynx and larynx. Am J Med. 2000;108(Suppl 4a):51 S‐61 S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10718453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders I, Mu L. Anatomy of the human internal superior laryngeal nerve. Anat Rec. 1998;252:646‐656.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders I, Wu BL, Mu L, Li Y, Biller HF. The innervation of the human larynx. Arch Otolaryngol Head Neck Surg. 1993;119:934‐939.</Citation><ArticleIdList><ArticleId IdType="pubmed">7689327</ArticleId></ArticleIdList></Reference><Reference><Citation>Jette ME, Clary MS, Prager JD, Finger TE. Chemical receptors of the arytenoid: a comparison of human and mouse. Laryngoscope. 2019;130(2). doi:10.1002/lary.27931</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.27931</ArticleId><ArticleId IdType="pmc">PMC6761039</ArticleId><ArticleId IdType="pubmed">30908677</ArticleId></ArticleIdList></Reference><Reference><Citation>Orvar KB, Gregersen H, Christensen J. Biomechanical characteristics of the human esophagus. Dig Dis Sci. 1993;38:197‐205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregersen H, Villadsen GE, Liao D. Mechanical characteristics of distension‐evoked peristaltic contractions in the esophagus of systemic sclerosis patients. Dig Dis Sci. 2011;56:3559‐3568.</Citation><ArticleIdList><ArticleId IdType="pubmed">21681510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Knutson K, Alcaino C, et al. Mechanosensitive ion channel Piezo2 is important for enterochromaffin cell response to mechanical forces. J Physiol. 2017;595:79‐91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199733</ArticleId><ArticleId IdType="pubmed">27392819</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcaino C, Knutson KR, et al. A population of gut epithelial enterochromaffin cells is mechanosensitive and requires Piezo2 to convert force into serotonin release. Proc Natl Acad Sci U S A. 2018;115:E7632‐E7641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6094143</ArticleId><ArticleId IdType="pubmed">30037999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">31971755</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK553115</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2023</Year><Month>01</Month></PubDate><BeginningDate><Year>2023</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-20486">Heart Failure and Ejection Fraction<Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Hajouli</LastName><ForeName>Said</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Logan Regional Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludhwani</LastName><ForeName>Dipesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rosalind Franklin University</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Heart failure (HF) is a complex clinical syndrome that results from either functional or structural impairment of ventricles resulting in symptomatic left ventricle (LV) dysfunction. The symptoms come from an inadequate cardiac output, failing to keep up with the metabolic demands of the body. It is a leading cause of cardiovascular morbidity and mortality worldwide despite the advances in therapies and prevention. It can result from disorders of the pericardium, myocardium, endocardium, heart valves, great vessels, or some metabolic abnormalities. <b>Definition</b> Three main phenotypes describe HF according to the measurement of the left ventricle ejection fraction (EF), and the differentiation between these types is important due to different demographics, comorbidities, and responses to therapies: Heart failure with reduced ejection fraction (HFrEF): EF less than or equal to 40%. Heart failure with preserved EF (HFpEF): EF is greater than or equal to 50%. Heart failure with mid-range EF (HFmrEF) (other names are: HFpEF-borderline and HFpEF-improved when EF in HFrEF improves to greater than 40%): EF is 41% to 49% per European guidelines and 40 to 49% per the US guidelines. A new class of HF that introduced by the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and management of HF. This class was known as the grey area between the HFpEF and HFrEF and now has its distinct entity by giving it the name HFmrEF. All patients with HFrEF have concomitant diastolic dysfunction; in contrast, diastolic dysfunction may occur in the absence of systolic dysfunction.</AbstractText><CopyrightInformation>Copyright © 2023, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s10">Staging</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s11">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s12">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s13">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s14">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s15">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s19">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>12</Month><Day>23</Day></ContributionDate><ReferenceList><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327.</Citation><ArticleIdList><ArticleId IdType="pubmed">23741058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, Dagenais G, PURE Investigators Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014 Aug 28;371(9):818-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">25162888</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494150</ArticleId><ArticleId IdType="pubmed">28785469</ArticleId></ArticleIdList></Reference><Reference><Citation>Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, Mueller C. Coronary artery disease and outcome in acute congestive heart failure. Heart. 2006 May;92(5):598-602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860938</ArticleId><ArticleId IdType="pubmed">16159982</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips HR, O'Connor CM, Rogers J. Revascularization for heart failure. Am Heart J. 2007 Apr;153(4 Suppl):65-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394905</ArticleId></ArticleIdList></Reference><Reference><Citation>A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2017 Dec 21;377(25):2506.</Citation><ArticleIdList><ArticleId IdType="pubmed">29262284</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee. Stroke Statistics Subcommittee Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):447-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811276</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014 Sep;1(1):4-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">28834669</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee. Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360.</Citation><ArticleIdList><ArticleId IdType="pubmed">26673558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A.</Citation><ArticleIdList><ArticleId IdType="pubmed">8376698</ArticleId></ArticleIdList></Reference><Reference><Citation>Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol. 2013 Apr 09;61(14):1510-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618527</ArticleId><ArticleId IdType="pubmed">23500287</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009 May;11(5):472-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, CHART-2 Investigators Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017 Oct;19(10):1258-1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">28370829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006 Nov 08;296(18):2209-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17090767</ArticleId></ArticleIdList></Reference><Reference><Citation>Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855265</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014 Jul;10(3):377-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084609</ArticleId><ArticleId IdType="pubmed">24975902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015 Dec 15;6(1):187-214.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015 Mar 14;36(11):657-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359359</ArticleId><ArticleId IdType="pubmed">25176939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009 Jul;13(32):1-207, iii.</Citation><ArticleIdList><ArticleId IdType="pubmed">19586584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22104551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimelli A, Lancellotti P, Badano LP, Lombardi M, Gerber B, Plein S, Neglia D, Edvardsen T, Kitsiou A, Scholte AJ, Schröder S, Cosyns B, Gargiulo P, Zamorano JL, Perrone-Filardi P. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J. 2014 Dec 21;35(48):3417-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25416326</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha SA, Kalogeropoulos AP, Shih J, Georgiopoulou VV, Giamouzis G, Anarado P, Mangalat D, Hussain I, Book W, Laskar S, Smith AL, Martin R, Butler J. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009 Sep;15(7):586-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700135</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson I, Mielniczuk LM, O'Meara E, So A, White JA. Imaging heart failure: current and future applications. Can J Cardiol. 2013 Mar;29(3):317-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439018</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J. The emerging role of multi-detector computed tomography in heart failure. J Card Fail. 2007 Apr;13(3):215-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L. [Validity of Framingham criteria as a clinical test for systolic heart failure]. Rev Clin Esp. 2006 Nov;206(10):495-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dassanayaka S, Jones SP. Recent Developments in Heart Failure. Circ Res. 2015 Sep 11;117(7):e58-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574505</ArticleId><ArticleId IdType="pubmed">26358111</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015 Mar 04;350:h910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353288</ArticleId><ArticleId IdType="pubmed">25740799</ArticleId></ArticleIdList></Reference><Reference><Citation>SPRINT Research Group. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan A, Vohra S, Vishwakarma P, Sethi R. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care. 2019 Jun;8(6):1855-1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618209</ArticleId><ArticleId IdType="pubmed">31334145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, Genta FT, Cicoira M, Tavazzi L, Temporelli PL. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract. 2013 Jul;67(7):656-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23758444</ArticleId></ArticleIdList></Reference><Reference><Citation>CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">2883575</ArticleId></ArticleIdList></Reference><Reference><Citation>SOLVD Investigators. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 01;325(5):293-302.</Citation><ArticleIdList><ArticleId IdType="pubmed">2057034</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members. Document Reviewers 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019 Jul 02;8(13):e012272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662364</ArticleId><ArticleId IdType="pubmed">31240976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013 Jan 16;346:f55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546627</ArticleId><ArticleId IdType="pubmed">23325883</ArticleId></ArticleIdList></Reference><Reference><Citation>Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642700</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12390947</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan D, Thavendiranathan P, Collier P, Marwick TH. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart. 2012 Dec;98(23):1693-700.</Citation><ArticleIdList><ArticleId IdType="pubmed">22791658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002 Oct 31;347(18):1403-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12409542</ArticleId></ArticleIdList></Reference><Reference><Citation>Borer JS, Böhm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa E, Swedberg K, SHIFT Investigators Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov;33(22):2813-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498004</ArticleId><ArticleId IdType="pubmed">22927555</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno R, Oppo I, Saetta G, Aveta P, Bruno S. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis. 2018 Jun 07;88(2):950.</Citation><ArticleIdList><ArticleId IdType="pubmed">29877658</ArticleId></ArticleIdList></Reference><Reference><Citation>Girouard C, Grégoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore) 2017 Mar;96(9):e6239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340463</ArticleId><ArticleId IdType="pubmed">28248890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">21294599</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, PALLAS Investigators Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">22082198</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J, International Society of Heart and Lung Transplantation The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct;33(10):996-1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">25242124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007 Jul 31;116(5):497-505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638928</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009 Apr 23;360(17):1705-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265934</ArticleId><ArticleId IdType="pubmed">19329820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.</Citation><ArticleIdList><ArticleId IdType="pubmed">23747642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002 Jul-Aug;31(4):262-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12122390</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Coordinators Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008 Jul 29;52(5):347-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18652942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail. 2014 Oct;2(5):429-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25194294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 Jan;27(1):65-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219658</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao YF. Cardiac arrhythmia and heart failure: From bench to bedside. J Geriatr Cardiol. 2011 Sep;8(3):131-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390068</ArticleId><ArticleId IdType="pubmed">22783298</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke. 2011 Oct;42(10):2977-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21903953</ArticleId></ArticleIdList></Reference><Reference><Citation>Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail. 2009 Feb;15(1):11-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19181288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke. 2018 Jan;20(1):33-45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836579</ArticleId><ArticleId IdType="pubmed">29402070</ArticleId></ArticleIdList></Reference><Reference><Citation>Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006 Sep 15;98(6):793-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, Scherbakov N, Cramer L, Rauchhaus M, Grosse-Herrenthey A, Krueger M, von Haehling S, Doehner W, Anker SD, Bauditz J. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014 Sep 16;64(11):1092-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212642</ArticleId></ArticleIdList></Reference><Reference><Citation>Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010 Aug;28(3):453-65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904358</ArticleId><ArticleId IdType="pubmed">20621250</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWalt DA, Schillinger D, Ruo B, Bibbins-Domingo K, Baker DW, Holmes GM, Weinberger M, Macabasco-O'Connell A, Broucksou K, Hawk V, Grady KL, Erman B, Sueta CA, Chang PP, Cene CW, Wu JR, Jones CD, Pignone M. Multisite randomized trial of a single-session versus multisession literacy-sensitive self-care intervention for patients with heart failure. Circulation. 2012 Jun 12;125(23):2854-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400336</ArticleId><ArticleId IdType="pubmed">22572916</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31971755</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedBookArticle><BookDocument><PMID Version="1">29262119</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK470446</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2023</Year><Month>01</Month></PubDate><BeginningDate><Year>2023</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-24165">Left Ventricular Outflow Tract Obstruction | Heart failure (HF) is a complex clinical syndrome that results from either functional or structural impairment of ventricles resulting in symptomatic left ventricle (LV) dysfunction. The symptoms come from an inadequate cardiac output, failing to keep up with the metabolic demands of the body. It is a leading cause of cardiovascular morbidity and mortality worldwide despite the advances in therapies and prevention. It can result from disorders of the pericardium, myocardium, endocardium, heart valves, great vessels, or some metabolic abnormalities. <b>Definition</b> Three main phenotypes describe HF according to the measurement of the left ventricle ejection fraction (EF), and the differentiation between these types is important due to different demographics, comorbidities, and responses to therapies: Heart failure with reduced ejection fraction (HFrEF): EF less than or equal to 40%. Heart failure with preserved EF (HFpEF): EF is greater than or equal to 50%. Heart failure with mid-range EF (HFmrEF) (other names are: HFpEF-borderline and HFpEF-improved when EF in HFrEF improves to greater than 40%): EF is 41% to 49% per European guidelines and 40 to 49% per the US guidelines. A new class of HF that introduced by the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and management of HF. This class was known as the grey area between the HFpEF and HFrEF and now has its distinct entity by giving it the name HFmrEF. All patients with HFrEF have concomitant diastolic dysfunction; in contrast, diastolic dysfunction may occur in the absence of systolic dysfunction.<CopyrightInformation>Copyright © 2023, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s10">Staging</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s11">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s12">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s13">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s14">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s15">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-20486" sec="article-20486.s19">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>12</Month><Day>23</Day></ContributionDate><ReferenceList><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId></ArticleIdList></Reference><Reference><Citation>WRITING COMMITTEE MEMBERS. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327.</Citation><ArticleIdList><ArticleId IdType="pubmed">23741058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, Dagenais G, PURE Investigators Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014 Aug 28;371(9):818-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">25162888</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494150</ArticleId><ArticleId IdType="pubmed">28785469</ArticleId></ArticleIdList></Reference><Reference><Citation>Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, Mueller C. Coronary artery disease and outcome in acute congestive heart failure. Heart. 2006 May;92(5):598-602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860938</ArticleId><ArticleId IdType="pubmed">16159982</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips HR, O'Connor CM, Rogers J. Revascularization for heart failure. Am Heart J. 2007 Apr;153(4 Suppl):65-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394905</ArticleId></ArticleIdList></Reference><Reference><Citation>A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2017 Dec 21;377(25):2506.</Citation><ArticleIdList><ArticleId IdType="pubmed">29262284</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee. Stroke Statistics Subcommittee Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):447-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811276</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014 Sep;1(1):4-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">28834669</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee. Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360.</Citation><ArticleIdList><ArticleId IdType="pubmed">26673558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A.</Citation><ArticleIdList><ArticleId IdType="pubmed">8376698</ArticleId></ArticleIdList></Reference><Reference><Citation>Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol. 2013 Apr 09;61(14):1510-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618527</ArticleId><ArticleId IdType="pubmed">23500287</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009 May;11(5):472-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H, CHART-2 Investigators Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017 Oct;19(10):1258-1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">28370829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006 Nov 08;296(18):2209-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17090767</ArticleId></ArticleIdList></Reference><Reference><Citation>Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855265</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014 Jul;10(3):377-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084609</ArticleId><ArticleId IdType="pubmed">24975902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015 Dec 15;6(1):187-214.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015 Mar 14;36(11):657-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359359</ArticleId><ArticleId IdType="pubmed">25176939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009 Jul;13(32):1-207, iii.</Citation><ArticleIdList><ArticleId IdType="pubmed">19586584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22104551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimelli A, Lancellotti P, Badano LP, Lombardi M, Gerber B, Plein S, Neglia D, Edvardsen T, Kitsiou A, Scholte AJ, Schröder S, Cosyns B, Gargiulo P, Zamorano JL, Perrone-Filardi P. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J. 2014 Dec 21;35(48):3417-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25416326</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha SA, Kalogeropoulos AP, Shih J, Georgiopoulou VV, Giamouzis G, Anarado P, Mangalat D, Hussain I, Book W, Laskar S, Smith AL, Martin R, Butler J. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009 Sep;15(7):586-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700135</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson I, Mielniczuk LM, O'Meara E, So A, White JA. Imaging heart failure: current and future applications. Can J Cardiol. 2013 Mar;29(3):317-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439018</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J. The emerging role of multi-detector computed tomography in heart failure. J Card Fail. 2007 Apr;13(3):215-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L. [Validity of Framingham criteria as a clinical test for systolic heart failure]. Rev Clin Esp. 2006 Nov;206(10):495-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dassanayaka S, Jones SP. Recent Developments in Heart Failure. Circ Res. 2015 Sep 11;117(7):e58-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574505</ArticleId><ArticleId IdType="pubmed">26358111</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015 Mar 04;350:h910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353288</ArticleId><ArticleId IdType="pubmed">25740799</ArticleId></ArticleIdList></Reference><Reference><Citation>SPRINT Research Group. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan A, Vohra S, Vishwakarma P, Sethi R. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care. 2019 Jun;8(6):1855-1862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618209</ArticleId><ArticleId IdType="pubmed">31334145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, Genta FT, Cicoira M, Tavazzi L, Temporelli PL. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract. 2013 Jul;67(7):656-64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23758444</ArticleId></ArticleIdList></Reference><Reference><Citation>CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">2883575</ArticleId></ArticleIdList></Reference><Reference><Citation>SOLVD Investigators. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 01;325(5):293-302.</Citation><ArticleIdList><ArticleId IdType="pubmed">2057034</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members. Document Reviewers 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019 Jul 02;8(13):e012272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662364</ArticleId><ArticleId IdType="pubmed">31240976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013 Jan 16;346:f55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546627</ArticleId><ArticleId IdType="pubmed">23325883</ArticleId></ArticleIdList></Reference><Reference><Citation>Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642700</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12390947</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan D, Thavendiranathan P, Collier P, Marwick TH. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart. 2012 Dec;98(23):1693-700.</Citation><ArticleIdList><ArticleId IdType="pubmed">22791658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002 Oct 31;347(18):1403-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12409542</ArticleId></ArticleIdList></Reference><Reference><Citation>Borer JS, Böhm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa E, Swedberg K, SHIFT Investigators Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov;33(22):2813-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498004</ArticleId><ArticleId IdType="pubmed">22927555</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno R, Oppo I, Saetta G, Aveta P, Bruno S. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis. 2018 Jun 07;88(2):950.</Citation><ArticleIdList><ArticleId IdType="pubmed">29877658</ArticleId></ArticleIdList></Reference><Reference><Citation>Girouard C, Grégoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore) 2017 Mar;96(9):e6239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340463</ArticleId><ArticleId IdType="pubmed">28248890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">21294599</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, PALLAS Investigators Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">22082198</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J, International Society of Heart and Lung Transplantation The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct;33(10):996-1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">25242124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007 Jul 31;116(5):497-505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638928</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009 Apr 23;360(17):1705-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265934</ArticleId><ArticleId IdType="pubmed">19329820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.</Citation><ArticleIdList><ArticleId IdType="pubmed">23747642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002 Jul-Aug;31(4):262-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12122390</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Coordinators Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008 Jul 29;52(5):347-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18652942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail. 2014 Oct;2(5):429-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25194294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 Jan;27(1):65-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219658</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao YF. Cardiac arrhythmia and heart failure: From bench to bedside. J Geriatr Cardiol. 2011 Sep;8(3):131-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390068</ArticleId><ArticleId IdType="pubmed">22783298</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke. 2011 Oct;42(10):2977-82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21903953</ArticleId></ArticleIdList></Reference><Reference><Citation>Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail. 2009 Feb;15(1):11-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19181288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke. 2018 Jan;20(1):33-45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836579</ArticleId><ArticleId IdType="pubmed">29402070</ArticleId></ArticleIdList></Reference><Reference><Citation>Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006 Sep 15;98(6):793-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, Scherbakov N, Cramer L, Rauchhaus M, Grosse-Herrenthey A, Krueger M, von Haehling S, Doehner W, Anker SD, Bauditz J. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014 Sep 16;64(11):1092-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212642</ArticleId></ArticleIdList></Reference><Reference><Citation>Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010 Aug;28(3):453-65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904358</ArticleId><ArticleId IdType="pubmed">20621250</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWalt DA, Schillinger D, Ruo B, Bibbins-Domingo K, Baker DW, Holmes GM, Weinberger M, Macabasco-O'Connell A, Broucksou K, Hawk V, Grady KL, Erman B, Sueta CA, Chang PP, Cene CW, Wu JR, Jones CD, Pignone M. Multisite randomized trial of a single-session versus multisession literacy-sensitive self-care intervention for patients with heart failure. Circulation. 2012 Jun 12;125(23):2854-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400336</ArticleId><ArticleId IdType="pubmed">22572916</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31971755</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedBookArticle><BookDocument><PMID Version="1">29262119</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK470446</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2023</Year><Month>01</Month></PubDate><BeginningDate><Year>2023</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-24165">Left Ventricular Outflow Tract Obstruction</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilcant</LastName><ForeName>Viliane</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nassau University Medical Center</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hai</LastName><ForeName>Ofek</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nassau University Medical Center</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract>Left ventricular outflow tract obstruction (LVOTO) refers to the limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. It can include anatomic stenotic lesions anywhere from left ventricle (LV) outflow to descending aorta. Hemodynamically, LVOTO has been defined as a peak instantaneous gradient at LV outflow of at least 30 mmHg, either at rest or on provocation. While traditionally defined in patients with hypertrophic cardiomyopathy, LVOTO is known to have several causes.  LVOTO constitutes 6% of congenital heart diseases, and in most cases, the cause of LVOTO is congenital. It can occur in isolation or accompany other congenital heart diseases. Dynamic LVOTO can also be seen in critically ill patients, whereby the use of inotropes in patients with intravascular volume depletion results in hypovolemia. In general, there is an obstruction to forward flow, which increases afterload and, if untreated, can result in hypertrophy, dilatation, and eventual failure of the left ventricle. |
2,329,288 | Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.<Pagination><StartPage>405</StartPage><EndPage>406</EndPage><MedlinePgn>405-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000206806</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Jannis</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1394-8231</Identifier><AffiliationInfo><Affiliation>From the Neurologic Clinic and Polyclinic (J.M., C.G.), Translational Imaging in Neurology (ThINk) and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland; and MS Center Amsterdam (S.N., M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noteboom</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4796-8636</Identifier><AffiliationInfo><Affiliation>From the Neurologic Clinic and Polyclinic (J.M., C.G.), Translational Imaging in Neurology (ThINk) and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland; and MS Center Amsterdam (S.N., M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granziera</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4917-8761</Identifier><AffiliationInfo><Affiliation>From the Neurologic Clinic and Polyclinic (J.M., C.G.), Translational Imaging in Neurology (ThINk) and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland; and MS Center Amsterdam (S.N., M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoonheim</LastName><ForeName>Menno M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-2504-6959</Identifier><AffiliationInfo><Affiliation>From the Neurologic Clinic and Polyclinic (J.M., C.G.), Translational Imaging in Neurology (ThINk) and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland; and MS Center Amsterdam (S.N., M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc, the Netherlands. m.schoonheim@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2023 Feb 28;100(9):e911-e920</RefSource><PMID Version="1">36543575</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="Y">Choroid Plexus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36543568</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000206806</ArticleId><ArticleId IdType="pii">WNL.0000000000206806</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36543519</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-201X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Heart (British Cardiac Society)</Title><ISOAbbreviation>Heart</ISOAbbreviation></Journal>Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. | Heart failure with preserved ejection fraction (HFpEF) is often complicated by pulmonary hypertension (PH), which is mainly characterised by postcapillary PH and occasionally accompanied by a precapillary component of PH. Haemodynamic changes in worsening heart failure (HF) can modify the characteristics of PH. However, the clinical features of PH after HF treatment in HFpEF remain unclear. We investigated the prevalence and clinical significance of the precapillary component of PH after HF treatment in HFpEF, using data from the Prospective Multicentre Observational Study of Patients with HFpEF (PURSUIT-HFpEF).</AbstractText>From the PURSUIT-HFpEF registry, 219 patients hospitalised with acute HF who underwent right heart catheterisation after initial HF treatment were divided into four groups according to the 2015 and 2018 PH definitions: non-PH, isolated postcapillary pulmonary hypertension (Ipc-PH), precapillary PH and combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). The latter two were combined as PH with the precapillary component.</AbstractText>Using the 2015 definition, we found that the prevalence of PH after HF treatment was 27% (Ipc-PH: 20%, precapillary PH: 3%, Cpc-PH: 4%). Applying the 2018 definition resulted in a doubled frequency of precapillary PH (6%). PH with a precapillary component according to the 2015 definition was associated with poor clinical outcomes and characterised by small left ventricular dimension and high early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity.</AbstractText>After initial HF treatment, 7% of hospitalised patients with HFpEF had precapillary component of PH according to the 2015 definition. Echocardiographic parameters of the left ventricle can contribute to the risk stratification of patients with HFpEF with a precapillary component of PH.</AbstractText>© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation> |
2,329,289 | TRPV1 and GABA<sub>B1</sub> in the Cerebrospinal Fluid-Contacting Nucleus are Jointly Involved in Chronic Inflammatory Pain in Rats. | To assess the receptors of TRPV1 and GABAB1</sub> receptors that were colocalized in cerebrospinal fluid contacting nucleus (CSF-contact nucleus) of chronic inflammatory pain (CIP) rats bringing inspiration for reducing chronic pain.</AbstractText>A rat model of CIP was constructed by plantar injection of complete Freund's adjuvant (CFA), and the paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL) were measured 1, 3, 5, 7, 10, and 14 days after plantar injection. In the first part of the experiment, rats with CIP were divided into the immunofluorescence group and the coimmunoprecipitation (Co-IP) group (n = 6). Rats in the immunofluorescence group were injected with the retrograde tracer CB conjugated with Alexa Fluor 594 into the lateral ventricle two days before the injection of CFA into the plantar surface of the left paw. Three days later, rats that exhibited hyperalgesia were perfused, and their brains were extracted and used for double immunofluorescence staining of the CSF-contacting nucleus. Rats in the Co-IP group were anesthetized and dissected 3 days after CFA injection, and fresh brain segments containing the CSF-contacting nucleus were collected for Co-IP to assess the colocalization of TRPV1 and GABAB1</sub> in the CSF-contacting nucleus (n = 6). In the second part of the experiment, SD rats were divided into the normal saline group (control group) and the CFA group. Fresh CSF-contacting nucleus-containing tissues were collected for Western blot analysis 3 days after plantar injection to observe the changes in TRPV1 and GABAB1</sub> expression in the CSF-contacting nucleus.</AbstractText>TRPV1 and GABAB1</sub> were co-expressed in the CSF-contacting nucleus in rats with CIP, and their expression was upregulated.</AbstractText>TRPV1 and GABAB1</sub> in the CSF-contacting nucleus are jointly involved in CIP in rats, and there is a direct or indirect link between TRPV1 and GABAB1</sub>.</AbstractText>© 2022 Xu et al.</CopyrightInformation> |
2,329,290 | Prognostic value of feature-tracking right ventricular longitudinal strain in heart transplant recipients.<Pagination><StartPage>3878</StartPage><EndPage>3888</EndPage><MedlinePgn>3878-3888</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-022-09327-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The prognostic value of cardiac magnetic resonance feature tracking (CMR-FT)-derived right ventricular longitudinal strain (RVLS) post-heart transplantation has not been studied. This study aimed to evaluate the prognostic significance of CMR-FT-derived RVLS, in patients post- heart transplantation and to directly compare its value with that of conventional RV ejection fraction (RVEF).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a cohort of consecutive heart transplantation recipients who underwent CMR for surveillance, RVLS from the free wall was measured by CMR-FT. The composite endpoint was all-cause death or major adverse cardiac events. The Cox regression model was used to examine the independent association between RVLS and the endpoint.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 96 heart transplantation recipients were retrospectively included. Over a median follow-up of 41 months, 20 recipients reached the composite endpoint. The multivariate Cox analysis showed that the model with RVLS (hazard ratio [HR]:1.334; 95% confidence interval [CI]:1.148 to 1.549; p < 0.001; Akaike information criterion [AIC] = 140, C-index = 0.831) was better in predicting adverse events than the model with RVEF (HR:0.928; 95% CI: 0.868 to 0.993; p = 0.030; AIC = 149, C-index = 0.751). Furthermore, receiver operating characteristic curves revealed that the accuracy for predicting adverse events was greater for RVLS than RVEF (area under the curve: 0.85 vs 0.76, p = 0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CMR-FT-derived RVLS is an independent predictor of adverse events in post-heart transplantation, and its predictive value was better than RVEF. Therefore, our study highlighted the importance of evaluating RVLS for risk stratification after heart transplantation.</AbstractText><AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">• CMR-RVLS is an independent predictor of adverse events post-heart transplantation and provides greater predictive value. • CMR-RVLS may help clinicians to risk stratification in heart transplantation recipients.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to European Society of Radiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yating</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Xuehua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Nianguo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guohua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuman</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. xiehelb@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China. lvqing1987@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China. lvqing1987@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China. lvqing1987@hust.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China. zli429@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China. zli429@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China. zli429@hust.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Mingxing</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4984-1567</Identifier><AffiliationInfo><Affiliation>Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, 430022, China. xiemx@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China. xiemx@hust.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China. xiemx@hust.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81727805</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81922033</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>5003530082</GrantID><Agency>Fundamental Research Funds for the Central Universities</Agency><Country/></Grant><Grant><GrantID>SGDX20190917094601717</GrantID><Agency>the Shenzhen Science and Technology under Grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Radiol</MedlineTA><NlmUniqueID>9114774</NlmUniqueID><ISSNLinking>0938-7994</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="Y">Heart Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016278" MajorTopicYN="N">Ventricular Function, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="Y">Ventricular Dysfunction, Right</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019028" MajorTopicYN="N">Magnetic Resonance Imaging, Cine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac magnetic resonance</Keyword><Keyword MajorTopicYN="N">Heart transplantation</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Right ventricular longitudinal strain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36538069</ArticleId><ArticleId IdType="doi">10.1007/s00330-022-09327-9</ArticleId><ArticleId IdType="pii">10.1007/s00330-022-09327-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khush KK, Cherikh WS, Chambers DC et al (2019) International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. J Heart Lung Transplant 38(10):1056–1066</Citation><ArticleIdList><ArticleId IdType="pubmed">31548031</ArticleId><ArticleId IdType="pmc">6816343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK (2018) Honoring 50 years of clinical heart transplantation in circulation: in-depth state-of-the-art review. Circulation 137(1):71–87</Citation><ArticleIdList><ArticleId IdType="pubmed">29279339</ArticleId></ArticleIdList></Reference><Reference><Citation>Badano LP, Miglioranza MH, Edvardsen T et al (2015) European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. Eur Heart J Cardiovasc Imaging 16(9):919–948</Citation><ArticleIdList><ArticleId IdType="pubmed">26139361</ArticleId></ArticleIdList></Reference><Reference><Citation>Stobierska-Dzierzek B, Awad H, Michler RE (2001) The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38(4):923–931</Citation><ArticleIdList><ArticleId IdType="pubmed">11583860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskote A, Carter C, Rees P, Elliott M, Burch M, Brown K (2010) Acute right ventricular failure after pediatric cardiac transplant: predictors and long-term outcome in current era of transplantation medicine. J Thorac Cardiovasc Surg 139(1):146–153</Citation><ArticleIdList><ArticleId IdType="pubmed">19910002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Q, Sun W, Wang J et al (2020) Evaluation of biventricular functions in transplanted hearts using 3-Dimensional speckle-tracking echocardiography. J Am Heart Assoc 9(10):e015742</Citation><ArticleIdList><ArticleId IdType="pubmed">32370590</ArticleId><ArticleId IdType="pmc">7660853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingvarsson A, Werther Evaldsson A, Waktare J et al (2018) Normal reference ranges for transthoracic echocardiography following heart transplantation. J Am Soc Echocardiogr 31(3):349–360</Citation><ArticleIdList><ArticleId IdType="pubmed">29275986</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemmensen TS, Eiskjaer H, Løgstrup BB, Andersen MJ, Mellemkjaer S, Poulsen SH (2016) Echocardiographic assessment of right heart function in heart transplant recipients and the relation to exercise hemodynamics. Transpl Int 29(8):909–920</Citation><ArticleIdList><ArticleId IdType="pubmed">27159372</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea A, Riegler L, Nunziata L et al (2013) Right heart morphology and function in heart transplantation recipients. J Cardiovasc Med (Hagerstown) 14(9):648–658</Citation><ArticleIdList><ArticleId IdType="pubmed">23442808</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S, Dell'atti D, Judd RM et al (2021) Prognostic value of feature-tracking right ventricular longitudinal strain in severe functional tricuspid regurgitation: a multicenter study. J Am Coll Cardiol Img 14(8):1561–1568</Citation></Reference><Reference><Citation>Carluccio E, Biagioli P, Lauciello R et al (2019) Superior prognostic value of right ventricular free wall compared to global longitudinal strain in patients with heart failure. J Am Soc Echocardiogr 32(7):836–844.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">30979539</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y, Wu VC, Kado Y et al (2017) Prognostic value of right ventricular ejection fraction assessed by transthoracic 3D echocardiography. Circ Cardiovasc Imaging 10(2):e005384</Citation><ArticleIdList><ArticleId IdType="pubmed">28174197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sun W, Wu C et al (2021) Prognostic value of right ventricular ejection fraction assessed by 3D echocardiography in COVID-19 patients. Front Cardiovasc Med 8:641088</Citation><ArticleIdList><ArticleId IdType="pubmed">33634177</ArticleId><ArticleId IdType="pmc">7902006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Li H, Zhu S et al (2020) Prognostic value of right ventricular longitudinal strain in patients with COVID-19. J Am Coll Cardiol Img 13(11):2287–2299</Citation></Reference><Reference><Citation>Tian F, Zhang L, Xie Y et al (2021) 3-Dimensional Versus 2-Dimensional STE for right ventricular myocardial fibrosis in patients with end-stage heart failure. J Am Coll Cardiol Img 14(7):1309–1320</Citation></Reference><Reference><Citation>Longobardo L, Suma V, Jain R et al (2017) Role of two-dimensional speckle-tracking echocardiography strain in the assessment of right ventricular systolic function and comparison with conventional parameters. J Am Soc Echocardiogr 30(10):937–946.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">28803684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WT, Tsai WC, Liu YW et al (2014) Changes in right ventricular free wall strain in patients with coronary artery disease involving the right coronary artery. J Am Soc Echocardiogr 27(3):230–238</Citation><ArticleIdList><ArticleId IdType="pubmed">24332357</ArticleId></ArticleIdList></Reference><Reference><Citation>Keramida K, Farmakis D, Bingcang J et al (2019) Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail 21(4):529–535</Citation><ArticleIdList><ArticleId IdType="pubmed">30811091</ArticleId></ArticleIdList></Reference><Reference><Citation>Avesani M, Borrelli N, Krupickova S et al (2020) Echocardiography and cardiac magnetic resonance in children with repaired tetralogy of Fallot: new insights in cardiac mechanics and exercise capacity. Int J Cardiol 321:144–149</Citation><ArticleIdList><ArticleId IdType="pubmed">32702408</ArticleId></ArticleIdList></Reference><Reference><Citation>Badano LP, Muraru D (2016) Subclinical right ventricular dysfunction by strain analysis: refining the Targets of Echocardiographic Imaging in Systemic Sclerosis. Circ Cardiovasc Imaging 9(6):e005009</Citation><ArticleIdList><ArticleId IdType="pubmed">27266600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz-Menger J, Bluemke DA, Bremerich J et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson 22(1):19</Citation><ArticleIdList><ArticleId IdType="pubmed">32160925</ArticleId><ArticleId IdType="pmc">7066763</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wan X, Xiao Q et al (2020) Value of 3D versus 2D speckle-tracking echocardiography for RV strain measurement: validation with cardiac magnetic resonance. JACC Cardiovasc Imaging 13(9):2056–2058</Citation><ArticleIdList><ArticleId IdType="pubmed">32563636</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ascenzi F, Anselmi F, Piu P et al (2019) Cardiac magnetic resonance normal reference values of biventricular size and function in male athlete’s heart. JACC Cardiovasc Imaging 12(9):1755–1765</Citation><ArticleIdList><ArticleId IdType="pubmed">30553678</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno M (2018) Feature tracking by CMR: a “double feature”? J Am Coll Cardiol Img 11(2 Pt 1):206–208</Citation></Reference><Reference><Citation>Wan K, Lin J, Guo X et al (2020) Prognostic value of right ventricular dysfunction in patients with AL amyloidosis: comparison of different techniques by cardiac magnetic resonance. J Magn Reson Imaging 52(5):1441–1448</Citation><ArticleIdList><ArticleId IdType="pubmed">32691470</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid J, Kamml C, Zweiker D et al (2021) Cardiac magnetic resonance imaging right ventricular longitudinal strain predicts mortality in patients undergoing TAVI. Front Cardiovasc Med 8:644500</Citation><ArticleIdList><ArticleId IdType="pubmed">34026866</ArticleId><ArticleId IdType="pmc">8137844</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiermaier T, Lange T, Chiribiri A et al (2018) Right ventricular strain assessment by cardiovascular magnetic resonance myocardial feature tracking allows optimized risk stratification in Takotsubo syndrome. PLoS One 13(8):e0202146</Citation><ArticleIdList><ArticleId IdType="pubmed">30157266</ArticleId><ArticleId IdType="pmc">6114723</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Yuan Y, Yang M et al (2020) Cardiovascular magnetic resonance-derived myocardial strain in asymptomatic heart transplanted patients and its correlation with late gadolinium enhancement. Eur Radiol 30(8):4337–4346</Citation><ArticleIdList><ArticleId IdType="pubmed">32232791</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S, Winters GL, Fishbein MC et al (2005) Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24(11):1710–1720</Citation><ArticleIdList><ArticleId IdType="pubmed">16297770</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Crespo-Leiro MG, Dipchand A et al (2010) International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 29(7):717–727</Citation><ArticleIdList><ArticleId IdType="pubmed">20620917</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254</Citation></Reference><Reference><Citation>Schulz-Menger J, Bluemke DA, Bremerich J et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 15(1):35</Citation><ArticleIdList><ArticleId IdType="pubmed">23634753</ArticleId><ArticleId IdType="pmc">3695769</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina A, Vaidya A, Gertz ZM, Chambers S, Forfia PR (2013) Marked changes in right ventricular contractile pattern after cardiothoracic surgery: implications for post-surgical assessment of right ventricular function. J Heart Lung Transplant 32(8):777–783</Citation><ArticleIdList><ArticleId IdType="pubmed">23773508</ArticleId></ArticleIdList></Reference><Reference><Citation>Unsworth B, Casula RP, Kyriacou AA et al (2010) The right ventricular annular velocity reduction caused by coronary artery bypass graft surgery occurs at the moment of pericardial incision. Am Heart J 159(2):314–322</Citation><ArticleIdList><ArticleId IdType="pubmed">20152232</ArticleId><ArticleId IdType="pmc">2822903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanobini M, Loardi C, Poggio P et al (2018) The impact of pericardial approach and myocardial protection onto postoperative right ventricle function reduction. J Cardiothorac Surg 13(1):55</Citation><ArticleIdList><ArticleId IdType="pubmed">29866151</ArticleId><ArticleId IdType="pmc">5987597</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldt J, Kling D, Dapper F, Hempelmann G (1990) Myocardial temperature during cardiac operations: influence on right ventricular function. J Thorac Cardiovasc Surg 100(4):562–568</Citation><ArticleIdList><ArticleId IdType="pubmed">2214832</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraj AT, Ghanta RK, Umakanthan R et al (2008) Real-time visualization and quantification of retrograde cardioplegia delivery using near infrared fluorescent imaging. J Card Surg 23(6):701–708</Citation><ArticleIdList><ArticleId IdType="pubmed">19016995</ArticleId><ArticleId IdType="pmc">2767372</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingo-Santos S, Moñivas-Palomero V, Garcia-Lunar I et al (2015) Usefulness of two-dimensional strain parameters to diagnose acute rejection after heart transplantation. J Am Soc Echocardiogr 28(10):1149–1156</Citation><ArticleIdList><ArticleId IdType="pubmed">26165446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada-Harimura Y, Seo Y, Ishizu T et al (2018) Incremental prognostic value of right ventricular strain in patients with acute decompensated heart failure. Circ Cardiovasc Imaging 11(10):e007249</Citation><ArticleIdList><ArticleId IdType="pubmed">30354477</ArticleId></ArticleIdList></Reference><Reference><Citation>Prihadi EA, van der Bijl P, Dietz M et al (2019) Prognostic implications of right ventricular free wall longitudinal strain in patients with significant functional tricuspid regurgitation. Circ Cardiovasc Imaging 12(3):e008666</Citation><ArticleIdList><ArticleId IdType="pubmed">30879327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisi M, Cameli M, Righini FM et al (2015) RV longitudinal deformation correlates with myocardial fibrosis in patients with end-stage heart failure. J Am Coll Cardiol Img 8(5):514–522</Citation></Reference><Reference><Citation>Barakat AF, Sperry BW, Starling RC et al (2017) Prognostic utility of right ventricular free wall strain in low risk patients after orthotopic heart transplantation. Am J Cardiol 119(11):1890–1896</Citation><ArticleIdList><ArticleId IdType="pubmed">28390683</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Dardeer AM, Moody WE et al (2018) Normal values for myocardial deformation within the right heart measured by feature-tracking cardiovascular magnetic resonance imaging. Int J Cardiol 252:220–223</Citation><ArticleIdList><ArticleId IdType="pubmed">29133275</ArticleId><ArticleId IdType="pmc">5761715</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi HM, Boubertakh R, Miquel ME, Petersen SE (2017) Myocardial deformation assessment using cardiovascular magnetic resonance-feature tracking technique. Br J Radiol 90(1080):20170072</Citation><ArticleIdList><ArticleId IdType="pubmed">28830199</ArticleId><ArticleId IdType="pmc">6047663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36537282</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1467-1107</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Cardiology in the young</Title><ISOAbbreviation>Cardiol Young</ISOAbbreviation></Journal>The effect of clinical and haemodynamic variables on post-operative length of stay immediately upon admission after biventricular repair with Yasui operation following an earlier Norwood operation. | The prognostic value of cardiac magnetic resonance feature tracking (CMR-FT)-derived right ventricular longitudinal strain (RVLS) post-heart transplantation has not been studied. This study aimed to evaluate the prognostic significance of CMR-FT-derived RVLS, in patients post- heart transplantation and to directly compare its value with that of conventional RV ejection fraction (RVEF).</AbstractText>In a cohort of consecutive heart transplantation recipients who underwent CMR for surveillance, RVLS from the free wall was measured by CMR-FT. The composite endpoint was all-cause death or major adverse cardiac events. The Cox regression model was used to examine the independent association between RVLS and the endpoint.</AbstractText>A total of 96 heart transplantation recipients were retrospectively included. Over a median follow-up of 41 months, 20 recipients reached the composite endpoint. The multivariate Cox analysis showed that the model with RVLS (hazard ratio [HR]:1.334; 95% confidence interval [CI]:1.148 to 1.549; p < 0.001; Akaike information criterion [AIC] = 140, C-index = 0.831) was better in predicting adverse events than the model with RVEF (HR:0.928; 95% CI: 0.868 to 0.993; p = 0.030; AIC = 149, C-index = 0.751). Furthermore, receiver operating characteristic curves revealed that the accuracy for predicting adverse events was greater for RVLS than RVEF (area under the curve: 0.85 vs 0.76, p = 0.03).</AbstractText>CMR-FT-derived RVLS is an independent predictor of adverse events in post-heart transplantation, and its predictive value was better than RVEF. Therefore, our study highlighted the importance of evaluating RVLS for risk stratification after heart transplantation.</AbstractText>• CMR-RVLS is an independent predictor of adverse events post-heart transplantation and provides greater predictive value. • CMR-RVLS may help clinicians to risk stratification in heart transplantation recipients.</AbstractText>© 2022. The Author(s), under exclusive licence to European Society of Radiology.</CopyrightInformation> |
2,329,291 | Delineation of intermammillary relationships using magnetic resonance imaging.<Pagination><StartPage>29</StartPage><EndPage>34</EndPage><MedlinePgn>29-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00276-022-03063-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">No study has investigated intermammillary relationships using neuroimaging modalities. This study aimed to explore them using magnetic resonance imaging (MRI).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We enrolled 72 patients who underwent conventional MRI examinations, followed by constructive interference steady-state sequence in the coronal plane. The intermammillary distances (IMDs) were measured at the uppermost level of the intermammillary gap (IMD<sub>upp</sub>) and the lowest level (IMD<sub>low</sub>) of the mammillary bodies (MBs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MBs with varying morphologies were consistently delineated. The appearance of both MBs could be classified into four patterns based on the size and relative levels, with the symmetrical type being the most common. Intermammillary relationships exhibited five patterns. In 69%, the IMD<sub>upp</sub> was discernible and measured 0.7 ± 0.4 mm, while it was not discernible in 31% due to the presence of intermammillary connection and adhesion. The age distribution did not differ between populations with and without discernible IMD<sub>upp</sub>. The IMD<sub>low</sub> was measured 4.4 ± 0.9 mm. Although the IMD<sub>low</sub> was not significantly different between both sexes; it was longer in subjects in their 70s.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intermammillary relationships show variable morphologies with gaps formed between both MBs. The IMD<sub>low</sub> may become more evident in association with age-related increase in the width of the third ventricle and atrophy of the MBs.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsutsumi</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan. shotaro@juntendo-urayasu.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Natsuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueno</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Surg Radiol Anat</MedlineTA><NlmUniqueID>8608029</NlmUniqueID><ISSNLinking>0930-1038</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020542" MajorTopicYN="Y">Third Ventricle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008326" MajorTopicYN="N">Mammillary Bodies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Constructive interference steady-state sequence</Keyword><Keyword MajorTopicYN="N">Intermammillary</Keyword><Keyword MajorTopicYN="N">Mammillary bodies</Keyword><Keyword MajorTopicYN="N">Relationships</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36536181</ArticleId><ArticleId IdType="doi">10.1007/s00276-022-03063-x</ArticleId><ArticleId IdType="pii">10.1007/s00276-022-03063-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Vincenzo J, Keiner D, Gaab MR, Schroeder HW, Oertel JM (2014) Endoscopic third ventriculostomy: preoperative considerations and intraoperative strategy based on 300 procedures. J Neurol Surg A Eur Neurosurg 75:20–30. https://doi.org/10.1055/s-0032-1328953</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1328953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaderi Niri S, Khalaf AM, Massoud TF (2020) The mammillothalamic tracts: age-related conspicuity and normative morphometry on brain magnetic resonance imaging. Clin Anat 33:911–919. https://doi.org/10.1022/ca.23595</Citation><ArticleIdList><ArticleId IdType="doi">10.1022/ca.23595</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino C, Tedeschi E, Rapanà A, Massarelli I, Belfiore G, Quarantelli M, Bellotti A (2009) Is the distance between mammillary bodies predictive of a thickened third ventricle floor? J Neurosurg 110:852–857. https://doi.org/10.3171/2008.4.17539</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2008.4.17539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita F, Kinoshita T, Toyoshima H, Shinohara Y (2019) Ipsilateral atrophy of the mammillary body and fornix after thalamic stroke: evaluation by MRI. Acta Radiol 60:1512–1522. https://doi.org/10.1177/0284185119839166</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0284185119839166</ArticleId></ArticleIdList></Reference><Reference><Citation>Meys KME, de Vries LS, Groenendaal F, Vann SD, Lequin MH (2022) The mammillary bodies: a review of cases of injury in infants and children. AJNR Am J Neuroradiol 43:802–812. https://doi.org/10.3174/ajnr.A7463</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A7463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk A, Yousem DM, Mahmood A, El Sayed S (2008) Prevalence of asymmetry of mammillary body and fornix size on MR imaging. AJNR Am J Neuroradiol 29:384–387. https://doi.org/10.3174/ajnr.A0801</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A0801</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Le S, Foster BL, Bourgeois B, Riviello JJ, Prenger E, Saper C, Kerrigan JF (2011) Gelastic epilepsy and hypothalamic hamartomas: neuroanatomical analysis of brain lesions in 100 patients. Brain 134:2960–2968. https://doi.org/10.1093/brain/awr235</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr235</ArticleId></ArticleIdList></Reference><Reference><Citation>Preul C, Hund-Georgiadis M, Forstmann BU, Lohmann G (2006) Characterization of cortical thickness and ventricular width in normal aging: a morphometric study at 3 Testa. J Magn Reson Imaging 24:513–519. https://doi.org/10.1002/jmri.20665</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.20665</ArticleId></ArticleIdList></Reference><Reference><Citation>Quester R, Schröder R (1997) The shrinkage of the human brain stem during formalin fixation and embedding in paraffin. J Neurosci Methods 75:81–89. https://doi.org/10.1016/s0165-0270(97)00050-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-0270(97)00050-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Torres IJ, Acker JD (1992) Age-related shrinkage of the mammillary bodies: in vivo MRI evidence. NeuroReport 3:713–716. https://doi.org/10.1097/00001756-199208000-00016</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199208000-00016</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero Adel C, Aguiar PH, Borchartt TB, Conci A (2011) Quantitative ventricular neuroendoscopy performed on the third ventriculostomy: anatomic study. Neurosurgery 68:347–354. https://doi.org/10.1227/NEU.0b013e318211449a</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/NEU.0b013e318211449a</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz G, Crooijmans HJ, Germann M, Scheffler K, Müller-Gerbl M, Müller B (2011) Three-dimensional strain fields in human brain resulting from formalin fixation. J Neurosci Methods 202:17–27. https://doi.org/10.1016/j.jneumeth.2011.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2011.08.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Jhawar SS, Goel A (2012) Analysis of the anatomy of the Papez circuit and adjoining limbic system by fiber dissection techniques. J Clin Neurosci 19:289–298. https://doi.org/10.1016/j.jocn.2011.04.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2011.04.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagliamonte M, Sestieri C, Romani GL, Gallucci M, Caulo M (2015) MRI anatomical variants of mammillary bodies. Brain Struct Funct 220:85–90. https://doi.org/10.1007/s00429-013-00639-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-013-00639-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubbs RS, Hattab EM, Loukas M, Chern JJ, Wellons M, Wellons JC 3rd, Iskandar BJ, Cohen-Gadol AA (2012) Histological analysis of the third ventricle floor in hydrocephalic and nonhydrocephalic brains: application to neuroendocrine complications following third ventriculostomy procedures. J Neurosurg Pediatr 9:178–181. https://doi.org/10.3171/2011.11.PEDS11290</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2011.11.PEDS11290</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Shrier DA, Rubio A, Yoshiura T, Iwanaga S, Shibata DK, Patel U, Numaguchi Y (1998) MR imaging of the mammillothalamic tract. Radiology 207:593–598. https://doi.org/10.1148/radiology.207.3.9609878</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.207.3.9609878</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36535876</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">0219-3108</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Asian journal of surgery</Title><ISOAbbreviation>Asian J Surg</ISOAbbreviation></Journal>Survival and analysis of prognostic factors for primary diffuse large B-cell lymphoma of the brain. | No study has investigated intermammillary relationships using neuroimaging modalities. This study aimed to explore them using magnetic resonance imaging (MRI).</AbstractText>We enrolled 72 patients who underwent conventional MRI examinations, followed by constructive interference steady-state sequence in the coronal plane. The intermammillary distances (IMDs) were measured at the uppermost level of the intermammillary gap (IMDupp</sub>) and the lowest level (IMDlow</sub>) of the mammillary bodies (MBs).</AbstractText>MBs with varying morphologies were consistently delineated. The appearance of both MBs could be classified into four patterns based on the size and relative levels, with the symmetrical type being the most common. Intermammillary relationships exhibited five patterns. In 69%, the IMDupp</sub> was discernible and measured 0.7 ± 0.4 mm, while it was not discernible in 31% due to the presence of intermammillary connection and adhesion. The age distribution did not differ between populations with and without discernible IMDupp</sub>. The IMDlow</sub> was measured 4.4 ± 0.9 mm. Although the IMDlow</sub> was not significantly different between both sexes; it was longer in subjects in their 70s.</AbstractText>Intermammillary relationships show variable morphologies with gaps formed between both MBs. The IMDlow</sub> may become more evident in association with age-related increase in the width of the third ventricle and atrophy of the MBs.</AbstractText>© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.</CopyrightInformation> |
2,329,292 | [Metallic foreign bodies of brain ventricles]. | Head injuries are often associated with intracranial foreign bodies that require decision making on the need for certain surgical treatment. Intraventricular foreign bodies are rare, so the question of surgical tactics is still open.</AbstractText>To summarize the experience of treating the wounded with intraventricular foreign bodies.</AbstractText>Treatment outcomes in victims with foreign bodies in lateral ventricles are presented. Searching in the e-Library, PubMed, Google Scholar databases included the following keywords: «penetrating wounds», «foreign bodies», «cerebral ventricles», «gunshot injury», «ventricular foreign bodies». We analyzed data on the treatment of victims with intraventricular foreign bodies.</AbstractText>Three victims underwent surgery, and foreign bodies were removed from the occipital horn of the lateral ventricle, third ventricle and temporal horn of the lateral ventricle. Conservative approach was preferred in 1 case. Follow-up ranged from 1 month to 7 years, GOS score - 3-4 points. Disability was due to severe injury and not associated with surgical treatment per se. We found 16 publications matching the searching criteria. Treatment methods varied from standard surgical approaches to stereotactic management. The indication for removal of foreign bodies was their migration through the ventricular system and occlusive hydrocephalus. None patient had neurological aggravation.</AbstractText>Intraventricular foreign bodies are rare and present certain difficulties in choosing the method and timing of treatment. Indications for their removal are migration, occlusive hydrocephalus and infectious complications. The method of removal is determined depending on location, magnetic properties, nature of injury, surgical preferences and other factors.</AbstractText> |
2,329,293 | Cat-Ear-Line: A Sonographic Sign of Cortical Development?<Pagination><StartPage>1445</StartPage><EndPage>1457</EndPage><MedlinePgn>1445-1457</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jum.16153</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Diagonal echogenic lines outside the lateral ventricle have often been observed in the anterior coronal planes of the normal fetal brain by neurosonography. We have observed abnormal shapes of these echogenic lines in cases of malformation of cortical development (MCD). We named the ultrasound finding "cat-ear-line" (CEL). This study aimed to examine how and when CEL develops in normal cases compared with MCD cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively examined the fetal brain volume dataset acquired through transvaginal 3D neurosonography of 575 control cases and 39 MCD cases from 2014 to 2020. We defined CEL as the hyperechogenic continuous lines through subplate (SP) and intermediate zone (IZ), pre-CEL as the lines that existed only within the SP, and abnormal CEL as a mass-like or mosaic shadow-like structure that existed across the SP and IZ. All fetuses in the MCD group had some neurosonographic abnormalities and were ultimately diagnosed with MCD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CEL was detected in 97.9% (369/377) of the control group from 19 to 30 weeks. The CEL visualization rate of the MCD group in the same period was 40.0% (14/35) which was significantly lower than that of the control group (P < .001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From this study, it appears that the CEL is an ultrasound finding observed at and beyond 19 weeks in a normally developing fetus. In some MCD cases, pre-CEL at and beyond 19 weeks or abnormal CEL was observed. Maldeveloped CEL at mid-trimester may help identify cases at-risk of subsequent MCD.</AbstractText><CopyrightInformation>© 2022 The Authors. Journal of Ultrasound in Medicine published by Wiley Periodicals LLC on behalf of American Institute of Ultrasound in Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsuzawa</LastName><ForeName>Nana</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9654-662X</Identifier><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Liona C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-3944-4130</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machida</LastName><ForeName>Megumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Takako</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uenishi</LastName><ForeName>Kohtaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wah</LastName><ForeName>Yi Man</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moungmaithong</LastName><ForeName>Sakita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itakura</LastName><ForeName>Atsuo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4554-164X</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiyo</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pooh</LastName><ForeName>Ritsuko K</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-1527-4595</Identifier><AffiliationInfo><Affiliation>Fetal Brain Center, CRIFM Prenatal Medical Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Ultrasound Med</MedlineTA><NlmUniqueID>8211547</NlmUniqueID><ISSNLinking>0278-4297</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016216" MajorTopicYN="Y">Ultrasonography, Prenatal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="Y">Fetus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cat-Ear-Line</Keyword><Keyword MajorTopicYN="N">fetal brain</Keyword><Keyword MajorTopicYN="N">fetal ultrasound</Keyword><Keyword MajorTopicYN="N">malformations of cortical development</Keyword><Keyword MajorTopicYN="N">medullary vein</Keyword><Keyword MajorTopicYN="N">transvaginal neurosonography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36534508</ArticleId><ArticleId IdType="doi">10.1002/jum.16153</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Pooh RK. Imaging of the normal fetal central nervous system. In: Pooh RK, Maeda K, Pooh KH (eds). An Atlas of Fetal Central Nervous System Disease. New York, London: The Parthenon Publishing Group; 2003:23-42.</Citation></Reference><Reference><Citation>Barkovich AJ, Kuzniecky RI, Dobyns WB, Jackson GD, Becker LE, Evrard P. A classification scheme for malformations of cortical development. Neuropediatrics 1996; 27:59-63. https://doi.org/10.1055/s-2007-973750.</Citation></Reference><Reference><Citation>Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic classification for malformations of cortical development. Neurology 2005; 65:1873-1887. https://doi.org/10.1212/01.wnl.0000183747.05269.2d.</Citation></Reference><Reference><Citation>Kostović I, Sedmak G, Judaš M. Neural histology and neurogenesis of the human fetal and infant brain. Neuroimage 2019; 188:743-773. https://doi.org/10.1016/j.neuroimage.2018.12.043.</Citation></Reference><Reference><Citation>Severino M, Geraldo AF, Utz N, et al. Definitions and classification of malformations of cortical development: practical guidelines. Brain 2020; 143:2874-2894. https://doi.org/10.1093/brain/awaa174.</Citation></Reference><Reference><Citation>Desikan RS, Barkovich AJ. Malformations of cortical development. Ann Neurol 2016; 80:797-810. https://doi.org/10.1002/ana.24793.</Citation></Reference><Reference><Citation>Juric-Sekhar G, Hevner RF. Malformations of cerebral cortex development: molecules and mechanisms. Annu Rev Pathol 2019; 24:293-318. https://doi.org/10.1146/annurev-pathmechdis-012418-012927.</Citation></Reference><Reference><Citation>Parrini E, Conti V, Dobyns WB, Guerrini R. Genetic basis of brain malformations. Mol Syndromol 2016; 7:220-233. https://doi.org/10.1159/000448639.</Citation></Reference><Reference><Citation>Renzo Guerrini MD, William B, Dobyns M. Malformations of cortical development: clinical features and genetic causes. Lancet Neurol 2014; 13:710-726. https://doi.org/10.1016/S1474-4422(14)70040-7.</Citation></Reference><Reference><Citation>Volpe N, Dall'Asta A, Di Pasquo E, Frusca T, Ghi T. First-trimester fetal neurosonography: technique and diagnostic potential. Ultrasound Obstet Gynecol 2021; 57:204-214. https://doi.org/10.1002/uog.23149.</Citation></Reference><Reference><Citation>Malinger G, Paladini D, Haratz KK, Monteagudo A, Pilu GL, Timor-Tritsch IE. ISUOG practice guidelines (updated): sonographic examination of the fetal central nervous system. Part 1: performance of screening examination and indications for targeted neurosonography. Ultrasound Obstet Gynecol 2020; 56:476-484. https://doi.org/10.1002/uog.22145.</Citation></Reference><Reference><Citation>Paladini D, Malinger G, Birnbaum R, et al. ISUOG practice guidelines (updated): sonographic examination of the fetal central nervous system. Part 2: performance of targeted neurosonography. Ultrasound Obstet Gynecol 2021; 57:661-671. https://doi.org/10.1002/uog.23616.</Citation></Reference><Reference><Citation>Malinger G, Kidron D, Schreiber L, et al. Prenatal diagnosis of malformations of cortical development by dedicated neurosonography. Ultrasound Obstet Gyneco 2007; 29:178-191. https://doi.org/10.1002/uog.3906.</Citation></Reference><Reference><Citation>Lerman-Sagie T, Pogledic I, Leibovitz Z, Malinger G. A practical approach to prenatal diagnosis of malformations of cortical development. Eur J Paediatr Neurol 2021; 34:50-61. https://doi.org/10.1016/j.ejpn.2021.08.001.</Citation></Reference><Reference><Citation>Pooh RK, Kurjak A. 3D and 4D sonography and magnetic resonance in the assessment of normal and abnormal CNS development: alternative or complementary. J Perinat Med 2011; 39:3-13. https://doi.org/10.1515/JPM.2010.118.</Citation></Reference><Reference><Citation>Pooh RK, Machida M, Nakamura T, et al. Increased Sylvian fissure angle as early sonographic sign of malformation of cortical development. Ultrasound Obstet Gynecol 2019; 54:199-206. https://doi.org/10.1002/uog.20171.</Citation></Reference><Reference><Citation>Poon LC, Sahota DS, Chaemsaithong P, et al. Transvaginal three-dimensional ultrasound assessment of Sylvian fissures at 18-30 weeks' gestation. Ultrasound Obstet Gynecol 2019; 54:190-198. https://doi.org/10.1002/uog.20172.</Citation></Reference><Reference><Citation>Pooh RK, Machida M, Imoto I, et al. Fetal megalencephaly with cortical dysplasia at 18 gestational weeks related to paternal upd mosaicism with pten mutation. Genes (Basel) 2021; 12:1-9. https://doi.org/10.3390/genes12030358.</Citation></Reference><Reference><Citation>Pugash D, Hendson G, Dunham CP, Dewar K, Money DM, Prayer D. Sonographic assessment of normal and abnormal patterns of fetal cerebral lamination. Ultrasound Obstet Gynecol 2012; 40:642-651. https://doi.org/10.1002/uog.11164.</Citation></Reference><Reference><Citation>Pogledic I, Schwartz E, Bobić-Rasonja M, et al. 3T MRI signal intensity profiles and thicknesses of transient zones in human fetal brain at mid-gestation. Eur J Paediatr Neurol 2021; 35:67-73. https://doi.org/10.1016/j.ejpn.2021.09.014.</Citation></Reference><Reference><Citation>Kostović I, Išasegi IŽ, Krsnik Ž. Sublaminar organization of the human subplate: developmental changes in the distribution of neurons, glia, growing axons and extracellular matrix. J Anat 2019; 235:481-506. https://doi.org/10.1111/joa.12920.</Citation></Reference><Reference><Citation>Prayer D, Kasprian G, Krampl E, et al. MRI of normal fetal brain development. Eur J Radiol 2006; 57:199-216. https://doi.org/10.1016/j.ejrad.2005.11.020.</Citation></Reference><Reference><Citation>Radoš M, Judaš M, Kostović I. In vitro MRI of brain development. Eur J Radiol 2006; 57:187-198. https://doi.org/10.1016/j.ejrad.2005.11.019.</Citation></Reference><Reference><Citation>Glenn OA. Normal development of the fetal brain by MRI. Semin Perinatol 2009; 33:208-219. https://doi.org/10.1053/j.semperi.2009.04.009.</Citation></Reference><Reference><Citation>Okudera T, Huang YP, Fukusumi A, Nakamura Y, Hatazawa J, Uemura K. Micro-angiographical studies of the medullary venous system of the cerebral hemisphere. Neuropathology 1999; 19:93-111.</Citation></Reference><Reference><Citation>Burger IM, Filly RA, Bowie J, Barkovich AJ. The grand unifying theory of bright echoes in the fetal and neonatal brain. J Ultrasound Med 2012; 31:1665-1673. https://doi.org/10.7863/jum.2012.31.10.1665.</Citation></Reference><Reference><Citation>Kolasinski J, Takahashi E, Stevens AA, et al. Radial and tangential neuronal migration pathways in the human fetal brain. Anatomically distinct patterns of diffusion MRI coherence. Neuroimage 2013; 1:412-422. https://doi.org/10.1016/j.neuroimage.2013.04.125.</Citation></Reference><Reference><Citation>Cuo J, Anton ES. Decision making during interneuron migration in the developing cerebral cortex. Trends Cell Biol 2014; 24:342-351. https://doi.org/10.1016/j.tcb.2013.12.001.</Citation></Reference><Reference><Citation>Faux C, Rakic S, Andrews W, Britto JM. Neurons on the move: migration and lamination of cortical interneurons. NeuroSignals 2012; 20:168-189. https://doi.org/10.1159/000334489.</Citation></Reference><Reference><Citation>Barber M, Pierani A. Tangential migration of glutamatergic neurons and cortical patterning during development: lessons from Cajal-Retzius cells. Dev Neurobiol 2016; 76:847-881. https://doi.org/10.1002/dneu.22363.</Citation></Reference><Reference><Citation>Hatanaka Y, Zhu Y, Torigoe M, Kita Y, Murakami F. From migration to settlement: the pathways, migration modes and dynamics of neurons in the developing brain. Proc Japan Acad Ser B Phys Biol Sci 2016; 92:1-19. https://doi.org/10.2183/pjab.92.1.</Citation></Reference><Reference><Citation>López-Bendito G, Sánchez-Alcañiz JA, Pla R, et al. Chemokine signaling controls intracortical migration and final distribution of GABAergic interneurons. J Neurosci 2008; 28:1613-1624. https://doi.org/10.1523/JNEUROSCI.4651-07.2008.</Citation></Reference><Reference><Citation>Noctor SC, Martinez-Cerdeño V, Ivic L, Kriegstein AR. Cortical neurons arise in symmetric and asymmetric division zones and migrate through specific phases. Nat Neurosci 2004; 7:136-144. https://doi.org/10.1038/nn1172.</Citation></Reference><Reference><Citation>Tabata H, Nakajima K. Multipolar migration: the third mode of radial neuronal migration in the developing cerebral cortex. J Neurosci 2003; 23:9996-10001. https://doi.org/10.1523/jneurosci.23-31-09996.2003.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36533630</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-2586</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of magnetic resonance imaging : JMRI</Title><ISOAbbreviation>J Magn Reson Imaging</ISOAbbreviation></Journal>Cine MRI-Derived Radiomics Features of the Cardiac Blood Pool: Periodicity, Specificity, and Reproducibility. | Diagonal echogenic lines outside the lateral ventricle have often been observed in the anterior coronal planes of the normal fetal brain by neurosonography. We have observed abnormal shapes of these echogenic lines in cases of malformation of cortical development (MCD). We named the ultrasound finding "cat-ear-line" (CEL). This study aimed to examine how and when CEL develops in normal cases compared with MCD cases.</AbstractText>We retrospectively examined the fetal brain volume dataset acquired through transvaginal 3D neurosonography of 575 control cases and 39 MCD cases from 2014 to 2020. We defined CEL as the hyperechogenic continuous lines through subplate (SP) and intermediate zone (IZ), pre-CEL as the lines that existed only within the SP, and abnormal CEL as a mass-like or mosaic shadow-like structure that existed across the SP and IZ. All fetuses in the MCD group had some neurosonographic abnormalities and were ultimately diagnosed with MCD.</AbstractText>The CEL was detected in 97.9% (369/377) of the control group from 19 to 30 weeks. The CEL visualization rate of the MCD group in the same period was 40.0% (14/35) which was significantly lower than that of the control group (P < .001).</AbstractText>From this study, it appears that the CEL is an ultrasound finding observed at and beyond 19 weeks in a normally developing fetus. In some MCD cases, pre-CEL at and beyond 19 weeks or abnormal CEL was observed. Maldeveloped CEL at mid-trimester may help identify cases at-risk of subsequent MCD.</AbstractText>© 2022 The Authors. Journal of Ultrasound in Medicine published by Wiley Periodicals LLC on behalf of American Institute of Ultrasound in Medicine.</CopyrightInformation> |
2,329,294 | Case report: Active clinical manifestation of endocardial fibroelastosis in adolescence in a patient with mitral and aortic obstruction-histologic presence of endothelial-to-mesenchymal transformation. | This is the first description of active clinical manifestation of endocardial fibroelastosis (EFE) and remodeling of the endocardium <i>via</i> endothelial-to-mesenchymal transformation (EndMT) in an adolescent with Shone's variant hypoplastic left heart complex (HLHC) and a genetic heterozygous ABL1 variant. While EFE has not been typically associated HLHC or Shone's syndrome, in this patient flow alterations in the left ventricle (LV), combined with genetic alterations of intrinsic EndMT pathways led to active clinical manifestation of EFE in adolescence. This case emphasizes that new therapies for EFE might need to focus on molecular factors influenced by intrinsic and extrinsic stimuli of EndMT. |
2,329,295 | Development of the brain ventricular system from a comparative perspective. | The brain ventricular system (BVS) consists of brain ventricles and channels filled with cerebrospinal fluid (CSF). Disturbance of CSF flow has been linked to scoliosis and neurodegenerative diseases, including hydrocephalus. This could be due to defects of CSF production by the choroid plexus or impaired CSF movement over the ependyma dependent on motile cilia. Most vertebrates have horizontal body posture. They retain additional evolutionary innovations assisting CSF flow, such as the Reissner fiber. The causes of hydrocephalus have been studied using animal models including rodents (mice, rats, hamsters) and zebrafish. However, the horizontal body posture reduces the effect of gravity on CSF flow, which limits the use of mammalian models for scoliosis. In contrast, fish swim against the current and experience a forward-to-backward mechanical force akin to that caused by gravity in humans. This explains the increased popularity of the zebrafish model for studies of scoliosis. "Slit-ventricle" syndrome is another side of the spectrum of BVS anomalies. It develops because of insufficient inflation of the BVS. Recent advances in zebrafish functional genetics have revealed genes that could regulate the development of the BVS and CSF circulation. This review will describe the BVS of zebrafish, a typical teleost, and vertebrates in general, in comparative perspective. It will illustrate the usefulness of the zebrafish model for developmental studies of the choroid plexus (CP), CSF flow and the BVS. |
2,329,296 | A Randomized Trial of an Exclusive Human Milk Diet in Neonates with Single Ventricle Physiology. | To determine whether weight gain velocity (g/kg/day) 30 days after the initiation of feeds after cardiac surgery and other clinical outcomes improve in infants with single ventricle physiology fed an exclusive human milk diet compared with a mixed human and bovine diet.</AbstractText>In this multicenter, randomized, single blinded, controlled trial, term neonates 7 days of age or younger with single ventricle physiology and anticipated cardiac surgical palliation within 30 days of birth were enrolled at 10 US centers. Both groups received human milk if fed preoperatively. During the 30 days after feeds were started postoperatively, infants in the intervention group received human milk fortified once enteral intake reached 60 mL/kg/day with a human milk-based fortifier designed for term neonates. The control group received standard fortification with formula once enteral intake reached 100 mL/kg/day. Perioperative feeding and parenteral nutrition study algorithms were followed.</AbstractText>We enrolled 107 neonates (exclusive human milk = 55, control = 52). Baseline demographics and characteristics were similar between the groups. The median weight gain velocity at study completion was higher in exclusive human milk vs control group (12 g/day [IQR, 5-18 g/day] vs 8 g/day [IQR, 0.4-14 g/day], respectively; P = .03). Other growth measures were similar between groups. Necrotizing enterocolitis of all Bell stages was higher in the control group (15.4 % vs 3.6%, respectively; P = .04). The incidence of other major morbidities, surgical complications, length of hospital stay, and hospital mortality were similar between the groups.</AbstractText>Neonates with single ventricle physiology have improved short-term growth and decreased risk of NEC when receiving an exclusive human milk diet after stage 1 surgical palliation.</AbstractText>This trial is registered with ClinicalTrials.gov (www.</AbstractText>gov, Trial ID: NCT02860702).</AbstractText>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation> |
2,329,297 | What has single-cell transcriptomics taught us about long non-coding RNAs in the ventricular-subventricular zone? | Long non-coding RNA (lncRNA) function is mediated by the process of transcription or through transcript-dependent associations with proteins or nucleic acids to control gene regulatory networks. Many lncRNAs are transcribed in the ventricular-subventricular zone (V-SVZ), a postnatal neural stem cell niche. lncRNAs in the V-SVZ are implicated in neurodevelopmental disorders, cancer, and brain disease, but their functions are poorly understood. V-SVZ neurogenesis capacity declines with age due to stem cell depletion and resistance to neural stem cell activation. Here we analyzed V-SVZ transcriptomics by pooling current single-cell RNA-seq data. They showed consistent lncRNA expression during stem cell activation, lineage progression, and aging. In conjunction with epigenetic and genetic data, we predicted V-SVZ lncRNAs that regulate stem cell activation and differentiation. Some of the lncRNAs validate known epigenetic mechanisms, but most remain uninvestigated. Our analysis points to several lncRNAs that likely participate in key aspects of V-SVZ stem cell activation and neurogenesis in health and disease. |
2,329,298 | Added value of hemodynamic forces for left ventricle function evaluation.<Pagination><StartPage>104409</StartPage><MedlinePgn>104409</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2022.104409</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(22)00591-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monosilio</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancone</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. Electronic address: massimo.mancone@uniroma1.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maestrini</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="Y">Heart Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36525722</ArticleId><ArticleId IdType="pmc">PMC9772577</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104409</ArticleId><ArticleId IdType="pii">S2352-3964(22)00591-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dal Ferro M., Stolfo D., De Paris V., et al. Cardiac fluid dynamics meets deformation imaging. Cardiovasc Ultrasound. 2018;16(1):1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819081</ArticleId><ArticleId IdType="pubmed">29458381</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvidsson P.M., Töger J., Carlsson M., et al. Left and right ventricular hemodynamic forces in healthy volunteers and elite athletes assessed with 4D flow magnetic resonance imaging. Am J Physiol Hear Circ Physiol. 2017;312(2):H314–H328.</Citation><ArticleIdList><ArticleId IdType="pubmed">27770000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrizzetti G. On the computation of hemodynamic forces in the heart chambers. J Biomech. 2019;95(xxxx)</Citation><ArticleIdList><ArticleId IdType="pubmed">31492418</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrizzetti G., Arvidsson P.M., Töger J., et al. On estimating intraventricular hemodynamic forces from endocardial dynamics: a comparative study with 4D flow MRI. J Biomech. 2017;60(October):203–210.</Citation><ArticleIdList><ArticleId IdType="pubmed">28711164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara F., Capuano F., Cocchia R., et al. Reference ranges of left ventricular hemodynamic forces in healthy adults: a speckle-tracking echocardiographic study. J Clin Med. 2021;10(24):1–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8707005</ArticleId><ArticleId IdType="pubmed">34945231</ArticleId></ArticleIdList></Reference><Reference><Citation>Airale L., Vallelonga F., Forni T., et al. A novel approach to left ventricular filling pressure assessment: the role of hemodynamic forces analysis. Front Cardiovasc Med. 2021;8(September):1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455914</ArticleId><ArticleId IdType="pubmed">34568448</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvidsson P.M., Nelsson A., Magnusson M., Smith J.G., Carlsson M., Arheden H. Hemodynamic force analysis is not ready for clinical trials on HFpEF. Sci Rep. 2022;12(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901629</ArticleId><ArticleId IdType="pubmed">35256713</ArticleId></ArticleIdList></Reference><Reference><Citation>Monosilio S., Filomena D., Luongo F., et al. Cardiac and vascular remodeling after 6 months of therapy with sacubitril/valsartan: mechanistic insights from advanced echocardiographic analysis. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9157573</ArticleId><ArticleId IdType="pubmed">35665260</ArticleId></ArticleIdList></Reference><Reference><Citation>Backaus S., Uzun H., Rösel S., et al. Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: a case-control substudy from the HFpEF stress trial. EBioMedicine. 2022;86 doi: 10.1016/j.ebiom.2022.104334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104334</ArticleId><ArticleId IdType="pmc">PMC9691873</ArticleId><ArticleId IdType="pubmed">36423376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapinskas T., Pedrizzetti G., Stoiber L., et al. The intraventricular hemodynamic forces estimated using routine CMR cine images: a new marker of the failing heart. JACC Cardiovasc Imaging. 2019;12(2):377–379.</Citation><ArticleIdList><ArticleId IdType="pubmed">30343088</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36525386</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal>Continuous mechanical aspiration thrombectomy performs equally well in main versus branch pulmonary emboli: A subgroup analysis of the EXTRACT-PE trial. | The EXTRACT-PE trial evaluated the safety and performance of the Indigo Aspiration System (Penumbra Inc.) with an 8F continuous mechanical aspiration thrombectomy system for the treatment of pulmonary embolism (PE). This subgroup analysis evaluates performance outcomes of patients with main pulmonary artery (PA) emboli versus discrete unilateral or bilateral PA emboli without main PA involvement.</AbstractText>The EXTRACT-PE trial was a prospective, single-arm, multicenter trial that enrolled 119 patients with acute submassive PE. Emboli location was collected at the time of enrollment, CT obstruction was measured and assessed by a Core Lab, and patients were grouped on whether emboli involved the main PA (with or without branch vessels) or not (branch vessels alone). Procedural device time, changes in the right ventricle to left ventricle (RV/LV) ratio, and systolic PA pressure from pre-and posttreatment were compared between the two groups.</AbstractText>Out of the 119 patients enrolled, 118 had core lab-assessed clot locations. Forty-five (38.1%) had emboli that involved the main PA and 73 (61.9%) had only branch emboli. No significant difference was observed between these groups for 30-day mortality, procedural device time, changes in RV/LV ratio, reduction in CT Obstruction Index, or for systolic PA pressure from pre-and posttreatment. The mean absolute reduction in clot burden was significant in both groups.</AbstractText>Continuous mechanical aspiration thrombectomy with the 8F Indigo Aspiration System was effective at improving clinical outcomes for submassive PE patients regardless of emboli location, and clot burden was significantly reduced in both groups.</AbstractText>© 2022 Wiley Periodicals LLC.</CopyrightInformation> |
2,329,299 | Activin A rescues preterm brain injury through a novel Noggin/BMP4/Id2 signaling pathway. | Activin A (Act A) has been reported to promote oligodendrocyte progenitor cell (OPC) differentiation in vitro and improve neurological outcomes in adult mice. However, the roles and mechanisms of action of Act A in preterm brain injury are unknown. In the present study, P5 rats were subjected to hypoxia‑ischemia to establish a neonatal white matter injury (WMI) model and Act A was injected via the lateral ventricle. Pathological characteristics, OPC differentiation, myelination, and neurological performance were analyzed. Further, the involvement of the Noggin/BMP4/Id2 signaling pathway in the roles of Act A in WMI was explored. Act A attenuated pathological damage, promoted OPC differentiation, enhanced myelin sheath and myelinated axon formation, and improved neurological performance of WMI rats. Moreover, Act A enhanced noggin expression, which, in turn, inhibited the expression of bone morphogenetic protein 4 (BMP4) and inhibitor of DNA binding 2 (Id2). Furthermore, upregulation of Id2 completely abolished the rescue effects of Act A in WMI rats. In conclusion, the present findings suggested that Act A rescues preterm brain injury via targeting a novel Noggin/BMP4/Id2 signaling pathway. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.